var title_f10_13_10448="Anterior and lateral defib pad placement";
var content_f10_13_10448=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior and lateral defib pad placement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hands free defibrillator patches placed in the anterior (white lead) and lateral (red lead) positions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Taylor C, Lillis C, LeMone P, Lynn P. Fundamentals of Nursing, The Art And Science Of Nursing Care, 6th Ed. Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_13_10448=[""].join("\n");
var outline_f10_13_10448=null;
var title_f10_13_10449="Schistosomiasis on colonoscopy";
var content_f10_13_10449=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Schistosomiasis on colonoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric Libby, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_13_10449=[""].join("\n");
var outline_f10_13_10449=null;
var title_f10_13_10450="Ultrasound of embedded IUD";
var content_f10_13_10450=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Ultrasound of embedded IUD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    It is important when assessing the position of an intrauterine contraceptive device (IUD) to assess not just the shaft of the IUD (which is in good position in this image), but also the cross bars. In this case, the cross bar extends into the myometrium anteriorly (arrow) instead of in the expected location in the endometrial cavity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_13_10450=[""].join("\n");
var outline_f10_13_10450=null;
var title_f10_13_10451="Patient information: Tests to monitor HIV (The Basics)";
var content_f10_13_10451=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/31/18931\">",
"         Patient information: Blood or body fluid exposure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/25/21907\">",
"         Patient information: HIV/AIDS (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/35/31282\">",
"         Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/44/22210\">",
"         Patient information: Starting treatment for HIV (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/41/36498\">",
"         Patient information: Vaccines for people with HIV (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/29/7635\">",
"         Patient information: HIV and pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/31/15861\">",
"         Patient information: Initial treatment of HIV (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/0/7170\">",
"         Patient information: Symptoms of HIV infection (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/60/1986\">",
"         Patient information: Testing for HIV (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/56/2946\">",
"         Patient information: Tips for taking HIV medications (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Tests to monitor HIV (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/tests-to-monitor-hiv-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H105340674\">",
"      <span class=\"h1\">",
"       How do doctors monitor people with HIV?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors monitor people with HIV by doing regular exams and talking to them, and by doing tests. Among the tests doctors use, 2 are especially important in keeping track of whether HIV treatment is working. These are called the &ldquo;viral load test&rdquo; and the &ldquo;CD4 cell count.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H105340681\">",
"      <span class=\"h1\">",
"       What is viral load?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Viral load is the amount of virus in your blood. If you have HIV, it&rsquo;s important to have your viral load tested often. This test helps your doctors check on your infection. It can also show whether your treatment is working. &nbsp;",
"     </p>",
"     <p>",
"      The goal of treatment is to get your viral load below &ldquo;detectable levels.&rdquo; That means there is so little virus in your blood that the test cannot even pick it up.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H105340688\">",
"      <span class=\"h1\">",
"       What are CD4 cell counts?",
"      </span>",
"      &nbsp;&mdash;&nbsp;HIV attacks and destroys the cells in your body that fight infection. This virus especially likes to kill a type of cell called &ldquo;CD4+ T&rdquo; cells &mdash; often called &ldquo;CD4 cells&rdquo; or &ldquo;T cells&rdquo; for short. &nbsp;",
"     </p>",
"     <p>",
"      The number of CD4 cells you have has a lot to do with how well you fight infection. In general, people who have CD4 cell counts below 200 have a hard time fighting infections. They can get something called &ldquo;opportunistic&rdquo; infections. Opportunistic infections are caused by germs that healthy people can usually fight off. In people with HIV, though, these germs can cause infection.",
"     </p>",
"     <p>",
"      If your CD4 count gets too low, your doctor will probably want to give you medicines to keep you from getting opportunistic infections. For example, if your CD4 count falls below 200, your doctor might give you antibiotics to prevent a lung infection called &ldquo;PCP pneumonia.&rdquo; When your CD4 counts get back up over 200, you can stop the antibiotics.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H105340695\">",
"      <span class=\"h1\">",
"       How often should I have viral load and CD4 tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;How often you should be tested will depend on how your treatment is going and how recently you were diagnosed with HIV.",
"     </p>",
"     <p>",
"      Some people need to be tested every 2 to 8 weeks. This might include people who:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Were recently diagnosed",
"       </li>",
"       <li>",
"        Recently started treatment",
"       </li>",
"       <li>",
"        Recently changed treatment",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It is very important that you follow your doctor&rsquo;s instructions about getting tested. The results of your viral load tests will tell your doctor whether your HIV treatment is helping. The results of your CD4 tests will tell your doctor how well your immune system is working. &nbsp;",
"     </p>",
"     <p>",
"      People whose HIV seems to be under control and who are not changing medicines or doses might go 3 to 6 months between testing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H105340702\">",
"      <span class=\"h1\">",
"       Can anything besides HIV affect viral load and CD4 test results?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your viral load is mostly affected by your HIV treatment. If your treatment is working right, your viral load should go down below the level that test can even detect.",
"     </p>",
"     <p>",
"      CD4 counts can go down because of a lot of things, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Infections (other than HIV)",
"       </li>",
"       <li>",
"        Alcohol abuse",
"       </li>",
"       <li>",
"        Pregnancy",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H105340746\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=see_link\">",
"       Patient information: HIV/AIDS (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/44/22210?source=see_link\">",
"       Patient information: Starting treatment for HIV (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36498?source=see_link\">",
"       Patient information: Vaccines for people with HIV (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/35/31282?source=see_link\">",
"       Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/31/18931?source=see_link\">",
"       Patient information: Blood or body fluid exposure (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/60/1986?source=see_link\">",
"       Patient information: Testing for HIV (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/31/15861?source=see_link\">",
"       Patient information: Initial treatment of HIV (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/0/7170?source=see_link\">",
"       Patient information: Symptoms of HIV infection (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/56/2946?source=see_link\">",
"       Patient information: Tips for taking HIV medications (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=see_link\">",
"       Patient information: HIV and pregnancy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?10/13/10451?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16937 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E9920BD3B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_13_10451=[""].join("\n");
var outline_f10_13_10451=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105340674\">",
"      How do doctors monitor people with HIV?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105340681\">",
"      What is viral load?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105340688\">",
"      What are CD4 cell counts?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105340695\">",
"      How often should I have viral load and CD4 tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105340702\">",
"      Can anything besides HIV affect viral load and CD4 test results?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105340746\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/31/18931?source=related_link\">",
"      Patient information: Blood or body fluid exposure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=related_link\">",
"      Patient information: HIV and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/31/15861?source=related_link\">",
"      Patient information: Initial treatment of HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/35/31282?source=related_link\">",
"      Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/44/22210?source=related_link\">",
"      Patient information: Starting treatment for HIV (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/0/7170?source=related_link\">",
"      Patient information: Symptoms of HIV infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/60/1986?source=related_link\">",
"      Patient information: Testing for HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/56/2946?source=related_link\">",
"      Patient information: Tips for taking HIV medications (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36498?source=related_link\">",
"      Patient information: Vaccines for people with HIV (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_13_10452="Trimebutine: Patient drug information";
var content_f10_13_10452=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Trimebutine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33458?source=see_link\">",
"     see \"Trimebutine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Modulon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat irritable bowel syndrome.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bowel block after surgery.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703083",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to trimebutine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695830",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 minutes before meals.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12065 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-4554544F47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_13_10452=[""].join("\n");
var outline_f10_13_10452=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231294\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013328\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013327\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013332\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013333\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013335\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013330\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013331\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013336\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013337\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33458?source=related_link\">",
"      Trimebutine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_13_10453="Bronchoscopic cryosurgery: Principles and technique";
var content_f10_13_10453=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bronchoscopic cryosurgery: Principles and technique",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/13/10453/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/13/10453/contributors\">",
"     Henri G Colt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/13/10453/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/13/10453/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/13/10453/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/13/10453/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/13/10453/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopic cryosurgery (also known as cryotherapy) is a technique in which endobronchial tissue is destroyed by repeated freezing and thawing. It is useful for the ablation of endobronchial lesions, such as a malignant mass or benign tracheal stenosis. The principles and technique of bronchoscopic cryosurgery are reviewed here, while the indications, contraindications, and outcomes are discussed separately [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10453/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38292?source=see_link\">",
"     \"Bronchoscopic cryosurgery: Indications, contraindications, and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BASIC PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryosurgery involves the repeated freezing and thawing of target tissue. Freezing should occur quickly because this forces the ice crystals to form intracellularly, where they are most lethal. The core temperature needed for a lesion to be destroyed is between -20&ordm;C and -40&ordm;C. Freezing to -40&ordm;C or below at a rapid rate (-100&ordm;C per minute) results in more than 90 percent cell death. In contrast, the tissue should be thawed slowly. This allows the intracellular ice crystals to increase in size before they melt (rapid thawing leads to immediate melting).",
"   </p>",
"   <p>",
"    Intracellular ice crystals can cause cell death directly by damaging mitochondria or other micro-organelles. However, they may also lead to cellular dehydration and a toxic increase in the concentration of intracellular electrolytes, both of which promote the flow of extracellular fluid into the cell once the permeability increases due to freezing-induced denaturation of lipoproteins complexes in the membranes. The result is cell swelling and rupture.",
"   </p>",
"   <p>",
"    Cryosurgery also induces microvascular changes. These include initial vasoconstriction of arterioles and venules, modification of vascular endothelium, increased permeability of vascular walls, increased blood viscosity, lower intracapillary hydrostatic pressure, decreased blood flow, and formation of platelet plugs. Thrombosis of the feeding vessels causes the microcirculation of the target tissue to cease soon after thawing. This has a hemostatic effect that explains why bleeding is usually minimal as ischemic necrosis occurs. The end result is a clear line of demarcation between previously frozen tissue and unfrozen tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10453/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain tissues are highly sensitive to freezing-induced destruction (ie, cryosensitive), while others are less sensitive (ie, cryoresistant). Examples of cryosensitive tissues include the skin, mucous membrane, and granulation tissue. Examples of cryoresistant tissues include fat, cartilage, fibrous, and connective tissue. Tumor cells are generally more cryosensitive than normal cells. Tissue sensitivity is probably related to the adequacy of the microcirculation, with more vascular tissues being more cryosensitive.",
"   </p>",
"   <p>",
"    The amount of tissue destroyed by cryosurgery appears to be influenced by numerous factors. These include the cooling rate [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10453/abstract/5-7\">",
"     5-7",
"    </a>",
"    ], the thawing rate [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10453/abstract/8\">",
"     8",
"    </a>",
"    ], the minimal temperature achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10453/abstract/9\">",
"     9",
"    </a>",
"    ], the water content of the cells, the number of freezing and thawing cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10453/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], and the sensitivity of the tissue.",
"   </p>",
"   <p>",
"    Cryoadhesion is a related phenomenon. It refers to using a cryoprobe to freeze material, thereby causing the material to adhere to the cryoprobe so that it can be removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5429570\">",
"    <span class=\"h1\">",
"     EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopic cryosurgery requires a bronchoscope, cryosurgery device (ie, cryomachine), and cooling agent (ie, cryogen). Bronchoscopes are described separately, while the cryosurgery device and cooling agents are discussed in this section. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=see_link\">",
"     \"Flexible bronchoscopy: Equipment, procedure, and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37394?source=see_link\">",
"     \"Rigid bronchoscopy: Instrumentation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cryosurgery device",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryosurgery devices have three components: the cryoprobe, transfer line, and console. The cryoprobe is used to freeze the target tissue. The transfer line connects the cryoprobe to both the cooling agent storage container (eg, gas cylinder) and the console. And, the console controls the flow of cooling agent through the transfer line.",
"   </p>",
"   <p>",
"    The cryoprobe may be rigid, semirigid, or flexible. Rigid and semirigid cryoprobes can be used through a rigid bronchoscope only, whereas flexible cryoprobes can be used through either a flexible or a rigid bronchoscope. An important difference between the cryoprobes is that the rigid cryoprobes have a system of reheating that induces a nearly immediate thaw phase, whereas thawing is a passive process with flexible cryoprobes As a result, the freeze-thaw cycle is longer with flexible cryoprobes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5429654\">",
"    <span class=\"h2\">",
"     Cooling agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cooling agents that are used most often for bronchoscopic cryosurgery are liquid nitrogen and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Liquid nitrogen",
"      </strong>",
"      &ndash; Liquid nitrogen (LN2) is stored near its saturation temperature of -196&ordm;C in vacuum-insulated containers. It evaporates as it passes through the transfer line at room temperature, leaving gaseous nitrogen to slowly cool the metal tip of the cryoprobe (the temperature of -196&ordm;C is reached in about one minute). Once the temperature in the transfer line becomes sufficiently low, evaporation is prevented and droplets of LN2 bombard the inner wall of the metal tip of the cryoprobe, cooling the cryoprobe at a more rapid rate [",
"      <a class=\"abstract\" href=\"UTD.htm?10/13/10453/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"       Nitrous oxide",
"      </a>",
"      &ndash; Nitrous oxide (N2O) is the most commonly used cryogen for bronchoscopic cryosurgery [",
"      <a class=\"abstract\" href=\"UTD.htm?10/13/10453/abstract/13\">",
"       13",
"      </a>",
"      ]. It is stored in the liquid state at room temperature in high-pressure bottles. The vapor haze of N2O occurs at the metal tip of the cryoprobe, where it expands as it goes from high pressure to atmospheric pressure. This expansion lowers the temperature of the fluid (via the Joule-Thomson effect) and produces droplets of liquid. The result is an equilibrium temperature of -89&ordm;C in the distal two centimeters of the cryoprobe.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Carbon dioxide (CO2) is an attractive cryogen for treating skin lesions, but it is unsuitable for bronchoscopic cryosurgery because it produces snow when it expands at atmospheric pressure. These solid particles obstruct the instrument channel in the bronchoscope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5429704\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be selected for bronchoscopic cryosurgery only after carefully weighing the indications and contraindications for each patient. The indications and contraindications for bronchoscopic cryosurgery are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38292?source=see_link\">",
"     \"Bronchoscopic cryosurgery: Indications, contraindications, and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The preparation and initiation of bronchoscopic cryosurgery are identical to that for conventional flexible bronchoscopy if a flexible bronchoscope will be used, or to that for conventional rigid bronchoscopy if a rigid bronchoscope will be used. These steps are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=see_link&amp;anchor=H2538548#H2538548\">",
"     \"Flexible bronchoscopy: Equipment, procedure, and complications\", section on 'Preparation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=see_link&amp;anchor=H2538580#H2538580\">",
"     \"Flexible bronchoscopy: Equipment, procedure, and complications\", section on 'Entering the tracheobronchial tree'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7412?source=see_link\">",
"     \"Rigid bronchoscopy: Intubation techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the endobronchial lesion has been identified bronchoscopically, the cryoprobe is inserted into the working channel of the flexible bronchoscope. It is advanced until the metallic tip is completely outside the working channel and then placed adjacent to the target tissue. For polypoid lesions, the metallic tip of the cryoprobe is either placed onto or pushed into the target tissue. This produces circumferential freezing of maximal volume. For infiltrating lesions, the cryoprobe is placed so that it has lateral tangential contact with the target tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10453/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. Three freeze-thaw cycles are then carried out. The probe is then moved 5 to 6 mm and another three freeze-thaw cycles are performed. Each freeze zone should overlap the previous freeze zone. The procedure is continued until the entire endobronchial lesion has been frozen. The frozen areas are larger with liquid nitrogen than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    ; thus, fewer freeze-thaw cycles are necessary and the procedure tends to be shorter when liquid nitrogen is used.",
"   </p>",
"   <p>",
"    Some cryoprobes are equipped with a device that measures impedance. When such cryoprobes are used, reheating is begun when a plateau between 250 and 500 kilo-ohms is reached. Subsequent freezing cycles are commenced when the impedance has fallen to 50 kilo-ohms, but before the probe becomes unstuck. If a cryoprobe is used that does not measure impedance, the freezing and reheating times must be estimated. This is done visually, by watching the halo of ice form around the cryoprobe. When the halo stops growing, freezing should be terminated and the tissue allowed to warm up. Generally speaking, a freezing time of approximately one minute is required for the first freeze-thaw cycle when liquid nitrogen is the cooling agent. The freezing time is shorter during subsequent cycles. In contrast, a freezing time of roughly 30 seconds per freeze-thaw cycle is required when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    is the cooling agent. There is no value in prolonging the freezing beyond this time; instead, greater tissue destruction can be achieved by performing more freeze-thaw cycles.",
"   </p>",
"   <p>",
"    The cryoprobe should be removed from the flexible bronchoscope only after it has completely thawed. Any icicle adherent to the probe may damage the working channel of the bronchoscope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5429767\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeat bronchoscopy (usually flexible bronchoscopy) is generally performed eight to ten days after bronchoscopic cryosurgery. The repeat examination allows the extent of tissue destruction to be assessed. In addition, sloughing material can be removed by forceps, aspiration, or cryoadhesion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10453/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. The latter refers to using a cryoprobe to freeze sloughing material, thereby causing the material to adhere to the cryoprobe so that it can be removed. If necessary, additional bronchoscopic cryotherapy can also be performed during the repeat examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the complications associated with bronchoscopic cryosurgery are related to the bronchoscopy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the sedation. These complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7412?source=see_link&amp;anchor=H7#H7\">",
"     \"Rigid bronchoscopy: Intubation techniques\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=see_link&amp;anchor=H13#H13\">",
"     \"Procedural sedation in adults\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19817?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of anesthesia and anesthetic choices\", section on 'Common anesthesia procedures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=see_link&amp;anchor=H12562876#H12562876\">",
"     \"Flexible bronchoscopy: Equipment, procedure, and complications\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With respect to cryosurgery-specific complications, reactive edema can occur following cryosurgery. It is usually not severe because the cartilaginous armature limits swelling. Corticosteroids are generally not needed, but they are sometimes administered for 24 hours following cryosurgery on a tracheal or subglottic lesion if the risk of airway compromise is judged to be high.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5429555\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchoscopic cryosurgery (also known as cryotherapy) is a technique in which endobronchial tissue is destroyed as a result of freezing. It is useful for the ablation of endobronchial lesions, most often malignancy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The amount of tissue destroyed by cryosurgery appears to be influenced by numerous factors. These include the cooling rate, the thawing rate, the minimal temperature achieved, the water content of the cells, the number of freezing and thawing cycles, and the sensitivity of the tissue.(See",
"      <a class=\"local\" href=\"#H3\">",
"       'Basic principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchoscopic cryosurgery requires a bronchoscope, cryosurgery device (ie, cryomachine), cooling agent (ie, cryogen), and cryoprobe. The cooling agents that are used most commonly for bronchoscopic cryosurgery are liquid nitrogen and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"       nitrous oxide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H5429570\">",
"       'Equipment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the endobronchial lesion has been identified by bronchoscopic airway inspection, the cryoprobe is inserted into the working channel of the bronchoscope. For polypoid lesions, the metallic tip of the cryoprobe is either placed onto or pushed into the target tissue. For infiltrating lesions, the cryoprobe is placed so that it has lateral tangential contact with the target tissue. Three freeze-thaw cycles are then carried out. The probe is then moved 5 to 6 mm and another three freeze-thaw cycles are performed. This is continued until the entire endobronchial lesion has been frozen. Repeat bronchoscopy is generally performed eight to ten days after the initial procedure. (See",
"      <a class=\"local\" href=\"#H5429704\">",
"       'Procedure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5429767\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many of the complications associated with bronchoscopic cryosurgery are related to the bronchoscopy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the sedation. With respect to cryosurgery-specific complications, reactive edema can occur following cryosurgery. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/1\">",
"      Bolliger CT, Mathur PN, Beamis JF, et al. ERS/ATS statement on interventional pulmonology. European Respiratory Society/American Thoracic Society. Eur Respir J 2002; 19:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/2\">",
"      Ernst A, Feller-Kopman D, Becker HD, Mehta AC. Central airway obstruction. Am J Respir Crit Care Med 2004; 169:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/3\">",
"      Ernst A, Silvestri GA, Johnstone D, American College of Chest Physicians. Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. Chest 2003; 123:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/4\">",
"      Benson JW. Combined chemotherapy and cryosurgery for oral cancer. Am J Surg 1975; 130:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/5\">",
"      Gage AA, Guest K, Montes M, et al. Effect of varying freezing and thawing rates in experimental cryosurgery. Cryobiology 1985; 22:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/6\">",
"      Smith JJ, Fraser J. An estimation of tissue damage and thermal history in the cryolesion. Cryobiology 1974; 11:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/7\">",
"      Miller RH, Mazur P. Survival of frozen-thawed human red cells as a function of cooling and warming velocities. Cryobiology 1976; 13:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/8\">",
"      Gage AA, Caruana JA Jr, Montes M. Critical temperature for skin necrosis in experimental cryosurgery. Cryobiology 1982; 19:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/9\">",
"      Rand RW, Rand RP, Eggerding FA, et al. Cryolumpectomy for breast cancer: an experimental study. Cryobiology 1985; 22:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/10\">",
"      Rubinsky, B, Ikeda, M. A cryomicroscope using directional solidification for the controlled freezing of biological tissue. Cryobiology 1985; 22:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/11\">",
"      Gilbert JC, Onik GM, Hoddick WK, Rubinsky B. Real time ultrasonic monitoring of hepatic cryosurgery. Cryobiology 1985; 22:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/12\">",
"      Noppen M, Meysman M, Van Herreweghe R, et al. Bronchoscopic cryotherapy: preliminary experience. Acta Clin Belg 2001; 56:73.",
"     </a>",
"    </li>",
"    <li>",
"     Homasson, JP, Bell, NJ. Cryotherapy in chest medicine, Springer Verlag, Paris 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/14\">",
"      Rodgers BM, Moazam F, Talbert JL. Endotracheal cryotherapy in the treatment of refractory airway strictures. Ann Thorac Surg 1983; 35:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/15\">",
"      Homasson JP. Cryotherapy in pulmonology today and tomorrow. Eur Respir J 1989; 2:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/16\">",
"      Walsh DA, Maiwand MO, Nath AR, et al. Bronchoscopic cryotherapy for advanced bronchial carcinoma. Thorax 1990; 45:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/17\">",
"      Maiwand MO, Homasson JP. Cryotherapy for tracheobronchial disorders. Clin Chest Med 1995; 16:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/18\">",
"      Homasson, JP. Bronchoscopic cryotherapy. J Bronchol 1995; 2:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/19\">",
"      Marasso A, Gallo E, Massaglia GM, et al. Cryosurgery in bronchoscopic treatment of tracheobronchial stenosis. Indications, limits, personal experience. Chest 1993; 103:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/20\">",
"      Homasson JP, Thiery JP, Angebault M, et al. The operation and efficacy of cryosurgical, nitrous oxide-driven cryoprobe. I. Cryoprobe physical characteristics: their effects on cell cryodestruction. Cryobiology 1994; 31:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10453/abstract/21\">",
"      Mathur PN, Wolf KM, Busk MF, et al. Fiberoptic bronchoscopic cryotherapy in the management of tracheobronchial obstruction. Chest 1996; 110:718.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4407 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-99C72D4C66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_13_10453=[""].join("\n");
var outline_f10_13_10453=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5429555\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BASIC PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5429570\">",
"      EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cryosurgery device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5429654\">",
"      Cooling agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5429704\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5429767\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5429555\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38292?source=related_link\">",
"      Bronchoscopic cryosurgery: Indications, contraindications, and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=related_link\">",
"      Flexible bronchoscopy: Equipment, procedure, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37394?source=related_link\">",
"      Rigid bronchoscopy: Instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7412?source=related_link\">",
"      Rigid bronchoscopy: Intubation techniques",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_13_10454="Chest x-rays of K pneumoniae";
var content_f10_13_10454=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Chest x-rays of Klebsiella pneumoniae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 451px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Panels A and B: A 43 year-old diabetic man with alcoholism presented with intermittent fever for five days and dyspnea for one day prior to admission. Mild ketoacidosis was observed. Chest film initially demonstrated bilateral patchy infiltration (Panel A), followed by rapid extensive consolidation, particularly of right upper lobe three hours later (Panel B). Acute respiratory distress syndrome ensued and the patient died within 12 hours of admission despite appropriate antimicrobial therapy and aggressive hemodynamic support in the intensive care unit. Blood and sputum cultures yielded K. pneumoniae.&nbsp;&nbsp;",
"     <br>",
"      <br>",
"       Panels C and D: A 64 year-old woman with K. pneumoniae bacteremia and right upper lobe pneumonia; the patient died of extensive pneumothorax following two weeks in intensive care unit (Panel C). A 52 year-old man with chronic alcoholism presented with K. pneumoniae bacteremia and right upper lobe pneumonia; he developed acute respiratory distress syndrome with profound septic shock and died within 24 hours of admission (Panel D). These radiographs demonstrate the predilection for involvement of the posterior segment of the right upper lobe in K. pneumoniae community-acquired pneumonia as well as the bulging fissure sign, characterized by bowing of the fissure downward due to intense consolidation.",
"      </br>",
"     </br>",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Wen-Liang Yu, MD and Yin-Ching Chuang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_13_10454=[""].join("\n");
var outline_f10_13_10454=null;
var title_f10_13_10455="Dissection isthmus";
var content_f10_13_10455=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Dissection isthmus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 393px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGJAgoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiio4Z4ZnlWGWORon8uQKwJRsA7T6HBBx6EUASUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZ/iDTm1bQ7/T47qezkuYXiS5t3KSQsRgOpHIIOD+FaFFAHL/DnXrjXfDi/wBpqI9bsJGsdSiHGy4j4Yj/AGWGHX/ZcVlTD/hG/ixFNnbp3imDyX9FvoFyp+rw7h/2xFN1/wD4pL4hWevr8uk675emajjpHcg4tpj7HJiJ94/Stb4l6Nca14SuRpo/4m9k6X+nn0uIjvQfRsFT7MaAOporN8NazbeIfD+navZE/Z72BJ0B6ruGdp9weD7itKgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAy/FGiWviPw9qGj34JtryFomK/eQnoy+hBwQfUCsf4ba3daroDWuskDXtKlNhqK9MypjEgH92RSsg9mrrK4DxR/xSvj3TPEqfJpmreXpOq+iOSfs05+jMYyT2kX0oAk8B/8AEi8UeI/Cj/LAkv8Aa2nDt9nnYmRB7JMJPoHWu7rhPiX/AMSW+0HxfGMLpVx9mviO9nOVRyfZH8qT6Ia7ugAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK5nxF450DQbsWNzeG51VhlNOsY2ubpv+2SAsBz1OB70AdNRXCf2h468QZGm6ZZeGLJulxqjC6uiPUQRtsU/wC9IfpTh8Oba/IfxXret+IJCPmiuLowW2faCHYhH+8GoA6S/wDEmh6dKY9Q1nTbWQHBWe6jQg+mCavWd5bX0AmsriG4hJwJIXDqT9RWLp/gjwrp0fl2PhrRbdcYPl2Ma5+vy81lap8NdAllN5oMJ8OauB+7vtIAt2yOm9ANki+quDx6UAdtWb4k0a08Q6Bf6RqKb7S8haGTHUAjqPQg4IPYgVheCfEWoXN/eeHvFEcMPiOwUSloQRFe25OFuIwegz8rLk7W9iK6+gDhvBVw3inwXqGgeKAJtTsvM0fVlPHmnbgSjPaSNlcH/a9qsfCvUbm58L/2bqkm/V9EmfS7xu7tHjZJ/wADjMb/APAqo+JwfCvj3TPEsfy6Zq2zSdVx0RyT9mnP0ZjGSe0i+lLqh/4Rj4pWOpfd03xLGunXJ7JeRhmgc/76b4/qqUAd9RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVHPPFAgaeVI1Jxl2CjP41yXiH4k+GNFvBYm/Ooaq33NO0yNru5Y+myPO3r/FigDsaK86XXPiJrnzaL4Y03QbU8rNrt0ZJWX18iH7p9mcVW8nx7/aKWsPjnw/PqLxSTiz/ALEbytqFVYM4m3Dl19+vXBoA9OorgdB8dXNprJ0Dx9aWui6v5TzwXUc2bK9jTG9onbBUrnJRuQOeRWhP8S/A9vLJHN4u0FXjGWH2+I/15PtQB11FclF8SvA0sYdfGPh0A/3tShU/kWzTE+IOk3w/4pu31HxFzjfpcG+HPp57lYs+2/jvigDsKKy9BvtSvopZNU0htLw2I45LhJXYerbMqv0DGtSgAooooAKKKKACiiigAoorz+6+IM0fjObQodP05fJuo7bZd6oLe7nDKrGWCBkxKgDdnBO04GcAgHoFFcF4f+KGjaloNtqF3BqVnLPLLElqNOupZH2MwJQCLc4AXLFQQucEg1fuPiN4Wgt5Z21J5IIbVL2WSG0mlWOBkLrIxVCACqnr3wOpAoA66iuTX4h+GzA8gu7vzFnW2+zf2fc/aGkZC6hYPL8xgUBYEKRgE5wDWPdfFDSLTxAiz3IOgS6Wt+l3FZzysh850YybVPlou3kuFwepHSgD0Siudn8beHrdXafUkjVLma0fdG42SRRmSTPHChFLbz8uMHPIzSg+IGiXr2y2Fz88lzFA6XkFxauokR2RgrxZIIRsE4U4PzcYIB19FcT4f8d23iLxomm6OWm0ptNe8FzJaTQ+YwlVAY3cBZEIYncuR05rtqACiiigAooooAKKKKACiiigAooooAKKKKACioL+9tdPtJLq/uYLW1iGXmnkCIo9Sx4FcS3j251wmLwDo0+sg8f2lck2tgnv5jDdJ16Rq2fUUAd4SFBJIAHJJrir74iWEt5Lp/hSzuvE+pxkq6afjyIW9JbhsRr9AS3+zUA8B3WunzfH2tTauhOf7MtQbWwX2KA75cf9NGIPoK7axs7bT7SO1sLeG2tohtSGFAiIPQKOBQBxH/CNeKfEh3+LddOm2Tf8wvQXaPI9JLkgSN7hBGPrXUeHPDejeGrQ22habbWMTHL+UmGkPq7dWPuSTWtXLeK/H3h3wvMlrqV+JNSk/wBVp1ohnupT2CxJlufU4HvQB1NQ3l1b2Vs9xeTxW8CDLySuEVR6kngV57/aXxC8VAjSNNtPCGmtwLvVALm9Yf3lgU7EPs7H6VYs/hToc1yl54qnvvFV+h3LJrE3mxIe+yAYjUe22gB9z8WvCIuXtdLvbnXLpDgxaNZy3v8A49GpX9at+HfiFpesa1HpFxZavo2pzI0lvb6tZtbtcKoyxjJyGx3Gc+1dZaW0FnbpBaQRQQIMLHEgVVHsBwK8++Ov9mHwlH9pu3tNdjmFxoskMDzzC7jBdQiIrMQQCrcY2sc0AX/ipYzwaZbeKNKiL6t4ec3iInWe3x/pEH/AkBI/2lWuw0+8g1Cwtr2zkEtrcxLNFIvRkYAqR9QRWN4F8SW/i7wtaanEvlzOvl3dswIa2nAxJE6nkFTkYPbB71i/ConS4NZ8Jy536BdmO3B72kv7yA/grNH/ANszQB1mv6Taa9ol9pWopvtLyFoZAOuGGMg9iOoPYiuF0iG48beAdV8Na7cGPxHpcv2Oe5UYZbiPDwXS/wC8PLkHuSO1ek15/wCL/wDilPGeneLI/l029Eelav2Chn/0ec/7rsUJP8MntQBufD7xBJ4i8ORz3sYg1a1drPUbcf8ALG5jO1x9CfmB7qwNdJXn+vf8Uh4/tNeQ7dH15o9O1IdBFcji3nPsf9U3TrH6V6BQAUUUUAFFFFABRRRQAUUVBfXltp9pLd31xFbW0S7pJZXCqg9STwKAJ6zPEmvab4a0ifU9auktrOLGWIJLE8BVUcsxPAAyTXLeIPGTRaf9t+0W/h7Q2Oz+1tWXY0hwSBDC2DkhTgyY5Awjg1x2mJrfiq9W98JaRA1mikDxB4tRpprgkjD29uMFFwCRgRqcg44oA6jRNb1nx1JI+m6pa6HpiAHbabLu8IJ43SHdDE3H3AJCO5B4qrq2h6Qy3VpFbeI/Euqplf8AS57iSDd3B3PHB9QpBrm/Eema6up/YdU+IV3d3CqD5Gn3P2OQey2ttE8zAe8g+tZp+GzXUMstynjjWIxGSsKXz2UEjY43LcXDSjPsvc8dqAOU1i906KWVbjQvD2kx4aF5pdPtrB/MxnZIshefAGMurDBwBk4FN8MeMJGjutM8ClpIrOBpJ7bw9pskgmx93LbI5h82QSJXY5BBOCT3lj8KdO0OMyto3hHSzhT5b20us3LEsANrzMoDFmUZCEZOOldbpfg+0037fDf6zq1lYwyBQ8M8GnQzEoGJUW6RkAE45JOQaAPDbn/hINQu/K1DRvHE1sweUvrZ8qNoI03ZKtFM4YOQxUMFOBwOo6/wL4Dey129sdR0XxMylYBLHpl3DYwxq7Ox80i78yQd+CemAi9K6a8i+Gs93f2t/qthcFU8u3eXW5dQmYuvzMY2kc43FcAg5K57Ct/QfEujabdXlr4X0HU7u3ZI2VrLTZF8+T5wxeaUIpOAoyzdO/oAY/xP8JaVv+H3h21gW306TWJBtKiYrm2mYkeYGy2ecnPOD2rstJ+HXhXTHRotItpjGuyEXCCVYV44RSMAnAJbG5iMsTXH6foWsweK/Al34muIw0Ms1vZ6ZDgxWiLaSAMzf8tJSF5P3RkhR3PrtAGFJ4O8MSyF5fDmjO56s1jESfx201vBnhd3LP4b0VmPUmwiJP8A47W/RQBX0+xtNOtEtdPtYLS2TO2GCMIi5OThRwOSTViiigAooooAKKK5LVviJ4Y0+7NkmpDUNRzj7FpkbXk+fQpEGK/8CxQB1tFcJ/bvjXWh/wASLw1b6PA3S6164BfHqLeEk/gzrQ3gK71fnxh4o1bVUIw1naN9gtT7FIjvYezO1AHbxXEMzypFLHI8TbZFVgSh64Poa5bVvBEerXzSX+uazNpzXUd4dMd4jB5iMGXBMfmqoZQdocD8CRW3oGg6T4dsfsehabaafbZ3GO2iCBj6nHU+55rzvUj43uvEN41rq+r2VifECWEcMWnwMi2RtldplZ4iTiQkBySoIIIPSgDQ1D4R6LqFjbWl3fX08NpcTT2a3EFpOLYSktIirJAyspJz84ZhgYIrR/4VxpH9hazpQmukt9WsYrCcxLDFtSNGUMipGEUncScLtz0A6VxjeJvHGm6RM1/BrNzO+l6jDatBpBkdr2K5dLeR1SPC7ogjDICNyQOQKS61/wAeRapqUdimq38/2GSS2i/s8w20MogBAkMlsu9t+cbJzkkAqACaAO01zwdpN34lGof2veadrtzKtxbSQSxCRTFE0TeWjowYFJCGBDdQeOKYPhpow0q9sBcah5V5pcmlTOZVLskkjyPJkr/rC0jnPTnpXG6rN4glbTNT8OyeINb1O0s9RMcmsaUbMxzGGLYm0QxAgkHGQcnI3HHHVfCPUfEmoW2pHxLLPKitH9nNzbSwzLlTvB32lsrDIGNqnGSCelAD5fh5Z3/i3xBqOqxRPYahpw06OBJGywZNs0rjACyMqxoCufljHPOBLD8NtONyl1qeqatqt0kkDedeSRZKQrIqREJGo2fvpCeNxJyTXcUUAch4T8C2vhvUYLuLVdVvjbWI022ivHiKQW4ZWCLsjUnG0DLEnHUniuvoooAKKKKACiiigAooooAKKKKACisrxJ4h0nw1p5vdcvobO3ztUyH5pG7KijlmPoATXKpqfi/xYQNGsj4X0hv+X/UYxJeyD1jt/ux/WQk/7FAHU+JPEmj+GrIXWu6jb2ULHCeY3zSH+6ij5nPsoJrmP7f8WeJCU8L6KNGsDx/aeuxkOwz1jtQQ59R5hT6GtXw34G0bQrw6gI5tQ1lxiTVNQk8+5b2DH7g/2UCj2rqKAOJsPh1pr3Ud94oubvxNqaHcsupsGiib/plAAI06dQpPvXagBQAAABwAKR3WNGeRgqKCWZjgAeprgNQ+J1ldXkuneCNPufFepxna4sSFtYT/ANNLlvkH0G4+1AHoNcPr/wAS9GsNQfStGjufEWujg2Gkp5zRnp+9f7kQz13EH2rO/wCEK8R+Kvn+IGvNHZN/zBdEd7eAj+7LN/rJeOoG0V3Gg6Hpfh/T0sdD0+1sLRekVvGEBPqcdT7nmgDhv7D8c+Lvm8S6svhfS3/5huiyb7lh6SXRHB/65gfWuq8J+DfD/hOF49A0yC1eTmWfBeaU+ryNlm/E10FFABRRRQAV5V4qS7j+OWkA3yafFqOjPa2V09uJWSZJS8qRbjtR2RkOSrZEeMV6rXJ/E/whF418I3OmExJeIy3NlNKgdYrhDlGIIOQeVPH3WNAHFaVrI0P4pLdXGo6ZcQeIdtnfR6ZE7Q2l4mBB5kuSC7gtHkhCdsfy8V03iRTonxM8Oa2oxbarG+iXh7b+Zbdj/wACEqZ/6aCuPu7mDxr8PpFvNQl0C6tVNp/ZNpCALXVIHLbztUsyhhGyqMDbknOfl6HVL5/iB8EP7W03aNTazS/hVRzFewESbPUESxlT+NAHpVUdc0q01zRr7S9SiEtneQvBKnqrDBx6Hng9qTQNTh1vQ9O1S1/49723juY+c/K6hh/Or9AHnnhOFvFnw+1Xwr4oYzX9i0ujX8hHzSFQPLnHu0bRyA+p9q2PhlrF1q/hWNNVIOsadK+nahz1niO0t/wIbXHs4qjbr/ZfxmukTCwa5o4uGH96a2lCEj3KToPogp2hL/Z3xZ8T2aD9zqVjaangdBKDJA/HuscX5UAdvRRRQAUUVDe3VvY2kt1ezxW9tCpeSWVgqIo6kk8AUATUV5tqvxOhe/aw0aAibAO+e3mmmwejLaRKZSPd/KB6gkVhax4ity0aeI7DxBq88vMdldvb2Fu57KLXzBLIP9lllPFAHe6n4vhCXC6FCNSaBWaa68zZZ24X7xkmwRkYOVQMw7gdawtSubOw1mJdTebxV4tXElvptqgEVpngOEJKwrz/AK2Vi3UAn7tcna6p8U/F9pFDaeFofC+jgeWEN8baZwOnzeWZI0xjhY1Y9mFap8Ja/o2kxwnUrKys5JDv0/RNIuJTOxBO6acTCVjxyxZc9DnOKAILDRNT8TeNxq+oz6PqOqWlpG62lx5rQaM0hbaFg4MkpUHcX8thgYx0HV6V4bgvbeW88TaneXl2YYjeWvnmGGEhA21o4yN3X/loWyMUaD4bvdD0+S50a2ge9v4Y45YbhksUtUXeyqiQxuMhpXJySST944Fc/cSXEGn3+nal4os9Qv5bRLe7s9N017uQ4j2/P/rSN3OSyYwenUkA9B0GGytLYJo1lHa2ZuJITDDEkSRlCykgL2LJ9eR0q3FeGa/RI3h+zvG5CtuWUujhWwCPujPX1I9a8osbC+u44ZIoPG2oWdzdSSpcLfrZRzRyBpAcRyxPHlmHOzHBwBuBp9t4Ej1bU7qG6sLNbywnDiLU55tUje3liwFZnYNu8xC3Xpxk5yADs/FV+LCfUJZPEmmaWHt4YoPtUyRmBxI5lk+fKklDHjKnBTng15no+n+AJpbnUL/xUNU1GW7uHM3kWl1M6+a+0q6wF9u0KQFOOmBjArt9L8G2tlIq2l74e0slii/2No1vbOWDEHHmGTkHcOnWugk8MwthtR1jW7pycKTqD22T1xiDyx+lAHNaL4k8PaNKq2D+JLlCfKZH0+9cAbc70jEWCcgLwBjJ7Cn+KfH9iNNaJ9P1mCOSSJXe5tvsoMZdd4zKUxlN3Ws7UdHuALZpfh9p0/75U3anq5lXL/IN37uUsMt3HHB7ZEkdve21+tlB4P8ABNk6TRCQQXEkhUvko2PssY6pnqenagCyuu6Vq/ijwZFpmoQ3NwLu7upYBdRTyQq0EudxjZlABcKOTxgV6TXm2jWJi8faVALi0uHVNQ1G4a0j2RxuWhgWMDceciTPuh6dK6fRfEj6nr11Y/YTDbJ53kztLlpTFL5UmUx8o35AOTkDOBxkA6Kiq+oX1ppto91qN1BaWycvNPII0X6seBXGN8SrC/YxeENM1TxNLkqJLCHZbA+9xIVjx/ulvpQB3dR3NxDawPPdTRwwoMtJIwVVHuT0riTbeP8AWyDcX2leGLVhny7OM310PYySBY1P0Rvqaktvhn4fadbjXFvPEV2p3CbWrg3IB/2YjiJf+AoKAEn+JmgyzPb+H1vvEd0h2tHo1ubhAfebiJfxcUz7R8QNa4t7LR/DFswxvu5Df3I9wiFYwf8AgbV28EUcESxQRpHEowqIoAA9gKfQBw3/AAri01Eh/Fusax4iY8mG6uPJts+0EWxCP94NXWaTpWnaNaLa6RYWljar0htoViQfgoAq7RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAUZ9I0641a31O4sbaXUbZGjguXjBkiVuoVjyM+1XqKKACiiigDz+7+HB1/UJbjxvrt7rlp5peHTEH2WyRc5UNGhJlI45djn07V3Gn2NrptnFaafbQWtrENscMCBEQegUcCrFFABRRRQAUVl694g0fw9a/aNd1Sy06Ds1zMse72GTyfYVzX/Cwf7SbZ4T8Oa3reelz5H2O19/3s23I/3Q1AHc1Hc3ENrA891NHDCgy0kjBVUe5PSuJ+wePtZwb7V9K8OW55MWmwm8nx6edKAgOPSM1JbfDLw6Z0udbju/EN4pyJtauGugP92M/u1/4CooASf4m6BJM9voAvvEd0mQY9GtzcKCPWXiJfxcUz7T8QNa4t7LSPDFqy/6y7c39yP+2aFY1P8AwNq7eCKOCJYoI0jiUYVEUAAewFeM6iPEvxB8ReLJNF1zVNL03Qbn+zLCDTZkgNxdqqmWSdmByilgNo6jpznIBijwPd+E/jXYXg1vUdRvdZtLm9jMki263F7EF3RlUARUaNupViADjnkdf8LLh9C8deL/AAffXtpPcGVdbg8kbOLj/XKEydoWQZAznEgrzzx5rWvy6fFo3jKa2tfE3hnULG+XVLQukV3ZTubd5DtKMoBkw4UrkjjFJ471iDwd4p8A+J9Gt7ZNFs7yTTbvUI4VhS/WfDO0ajqiBWPmE/Mx6nBJAO/0HXf+EO+DfiRlGJfDM1/ZQjb12SN5Ax6bXiFclo1vfeB/EPg65mtdYgvrjUY9H166n1D7RBqE08O5XClyQQ5Uhtq4zt5p/wATrnyX8beG7ZWeXXde0gRRRMAxMyR7sE8AkWr8nAGc5rL+M+u6h4Xn8GtrL+IZdMj1y2vRb6gbOWYiBgzCMwnc3BA+c9WHNAHsOon7X8ZNDij/AOYfot5NKfTzpoFQe2fJkP8AwE02zYXnxo1J4/mTTtDggkb0eaaR9v8A3zEp/EetVPDcjeG9C17xv40xZX2pEXVxCfmNrAg2wWw9XAPIHV5GxWp8NdLvrXSrvVtciMWta3cG/uoicmAEBYoc/wCxGqKffd60AdfRRRQAV4P8btSn1X4keFvDNzdzWXhpZBcX00PmB5ZlIZYl8v595BRVwOsoIywXHvFeEfH9I/DfiGx8XT+fHZpaOjyRxySD7SjK0C4DbULPsbcR0h652ggHSeAfDTabcLLb2+sRabe2MdvNp6W8VrBC5y0jtvKzM+6R/mAzj1wK7Sxi0fw9qaabYaXBp6TwPcGeGBY422MqkOw/i+cHnrz6V5jptje3MmtLfW/iTULwxfa9Lt5NduLdLyLzWUuAs2NoQwOysAQZNoUVg38uhvf6LcSeGfDulrJbrqMNzrupLMt3G6su0bopGYr8rHDKQcc8kEA9c1P4haDbXcdrYXsWq3fmbJLbT91zKvysQAsasN2QOGKgDLE8YKNqPi/VQTp+lWOhW/B8/VZPtEwHr5MTBR+Mv1FeUSeI9S0/SQsVxqElnok/nQp4e8Pusf2cKQ8n2iYmIjynkC4wcqDk9auT61q9vrN5o19PH4fstRtvss0OrX82r3ZbaSDHEr4RpFlK4VmGY+F4GQDuIPC9reX+rf8ACdalPrBtikqLdSeTaJAyDkwqQn31kGX3HA61naN4zsdI0e+sPC+l2s1np91Kpu/Ojs9NgSRzJGPM6n5ZEGI0bnj0rn9H8PeKNd1HSNUmsLmW6aDy7+68TqrwiQAMrwWaFMbHDBSwQ4kJOeob438Z+DvhjqUt5rN83ibxzMqqGm25t8Z2ghF2wINzdAXIJ+91oA6yLTtetZtC8PyeI5jcMN88OnQJFHBaJnqzBpM52RqQyk8nBwcVPGHgaNtUtLzTdLv9ahmSOOZZtWkkU7Z0YeZ5sh3JsMoGA2Ceg615bHrA1zVZdStviDqV7qF6ytPa6fY3FtbtgELHGUkjnKLk7T83clfmNW1VtNspLG01S+8PXEpZla48RX1lmVjuJ8q8twuSST8r5bPXoaAO+sPDsiy2jaV4U8E6PNLqMsC3L2Ru3UxiRw2AIiWzHjO/g5I9Bdtr7WZ7Cxu9Y8Vvbz3TTSW9vpWi+a7BHKl1VvOfbhhz2DDnHXyvV9Q8Y+FrG2nvZLQWdrJLdm8h8QqjElHyQkrzFmO8khFJPQcmqFp4v8R6cLE6Z4Y8dXtrZWxtIdQtZsQeV8vEZksQdpKL94A8DrQB6rY+I7uQSi48U+MQy3EkKGPwnIyuFY4wRaHkAEEeqntVRtXsW1rSriTxjrdr5902+7v9BWwjJSCUDM0tsqkj7u0nPJxzXmWoal49sDbJN8SNH0g4DNA8oeZnmk2yEBoUO7LFtoyFwSCOtW9F+FmiXWozS2HjVvFOvzgWtqbSOOSGJcBmmlMjTfu1DL0KcjYMlsUAdZpPxX8NaJruuahGZdVZ47W0SayhEduTukeSRpnKxIGmnfLFhkj6Vm3Pi7xh4u8QwarEsvhe3toBJ9khgM18bVgjmQ7hsIaPzmX5G+aLb94qa9K8OfBzwzpC2QvJNT1tbI7rWLVLnzYIGyTlIQFjHJP8PFdX4o8Nwa4Le4jnlsNWtCWs9Qt8eZAT1GDw6HADI2QR7gEAGLo/w78Ls9vqd2kviK6ZQ8V/q1wb0lTyGQN8ij02KK7ZVCqFUAKBgAdAK8jTWdf8AztFqunxf2SWLFoQwswTyWifBNvnkmKUeXk/LKOleg+GvElv4gjElra3cSMm9ZHVXjYZH3ZY2ZG69mNAG5RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUU13WNGeRgqKCWZjgAepoAdRXF3vxK8OR3ElrpU9xr18h2tbaNA12yn0Zk+Rf+BMKhOo+PdZONO0bTPDtsePP1Wb7VPg9xDCQgP1l/CgDuq5jXfHvhjQ7kWt9rFu18TgWdtm4uCfTyowz/pWZ/wr46l83i7xFrOuZGGtxN9jtT/2yh25Hs7NXT6FoGkeH7b7Poel2Wnw90tYFjB+uBz+NAHM/wDCU+J9XyPDnhCe3iPC3euzi0T6iJd8p+jBKT/hFPE2rnd4k8YXMMR5NpoUAs0HsZWLyn6hlruqKAOZ0HwF4Y0K5+1afo9sb4nJvLjM9wT7yyFn/WumorM8Ta3aeHNBvtX1EuLW0jLsEXcznoFUd2YkAD1IoA06K8q0nR77xlql1/wnN1e4gjSSXSbG5eCzs2cblhkdCGmlCYZsnaNwwuCCeN+JWjeDLLxDoujaA+k2Vyxa8vY5r6WO3uY0A2WszBtq+YWJUsDjyuhzggH0PXgXhDRzq9hql0/iuPQ9M1bxTe3unIoVLh3WUruhkLDJYq+VKuMHGMVV8HfEjwx4W8G+NtQsLvTdLb7RLLpmgG8jd4mSFI9oRWIw8yO2F42nI4NP+G3xE8B6f8Oo/C3i7UtKmgsIhEzGJp4L1WUOWAKnLhmYMvJyMjgigDO+Kml3EPizxlHqmq3GpzQeBmmjnljjiZD9r3Afu1UcNEpH1Ndf4nt7XXPE3gDwjeafcXunLdS6hcPfy/aY5/LtSSp8xi7Ya4j6/L8wxnBA898Pa1ous/8ACzhoGheKZIr7Thotgpsri8MRCSgqW+bylLOhCMRtA7dBL4S8VX/hS/l8XeLvCnjV4dN0SDTxLd2qoscxI85lDuoSMsI1UovIBLDOcgHfXXg/w9P8TdK8OeHli0eLSIG1u6+wsomeZsQwqc5wAu8+2VxjOa5+71LQfEXxKvfEfjO4hFn4Suf7L0nToZTcyXl2PnMgQKGd+UAVR1Xk8ZrqPhxLfWXhXX9S8a+HL3SXvhNqF5qKzJNJKspOFRYS0iCOMIBkDG3PHNT/AAi0G21DWtT8c/2Nbabb6hFFbaNB5CpJHZxqQspwPlaTOcf3QoyaANbTNF1bxdrFnrvi63aw06zfztO0JmDFXH3Z7kjgyDqqDITrkt09AormvFPimLS5YtN0wQ3/AIium8u2sBKAQSCfMk7pGoBJbHsMkgEA6RmCqWYgKBkk9AKw5vGHhmCRo5vEWjRyL1V76IEfhurMg8DWt+UufGU58Q333ilyuLSM+kdvkoAPVtz+rGti4sdM0qyH2bRonUEKkFpapkk8AAcAD3JAHcigDM1Lx3pFvKINN8/W7ryxMYtMCyhEOcM8hZYoxwcb3GccZrnrrxFceNdLvdNtdBhuoyFLiDWrZ5YGDBkfCFgCGUEZyMr+FWtK8I2g8RXeoa94as5JLuVDAYUjkgtkUfIGTAPm5LEuA3XG4KAK9BRVRVVFCqowABgAUAfNsV7rvhaTTdI1WK90q4t5GTT0mjcxMWUjZa3USTAKwGfIljbaQMHCgAt/EQ02YHVda8Q2kVtLMLdrGTTJwizYeSMsVDKd2flMakALgcV754t0O28R+H7zTL22s7mOdMBLuIyRhuzEAg5HUEEH0Iryi3/Zw8KzLA2v6lrurSxDaqzXZWJBnO1F5ZV9ixPvQByE/wATfhhZww6ZqV1411GCJRCLC4kkEYUDAVkV0VxjAwdwpdF+JXhuSwtLfwT4MhjBmW3S+1a8t9NAeImVd5RizbcderdCSSQfS4fh3deDL2yufh0ltLbKTHJperTs0USkE74ZiryRkN1UZUhjwDzVK7GiaXrv234jeANDsJbt9h12BI7y1Lk4HnO0avGSSBuZcHuw6UAebah8QNUu4AvjT4g6fGhupUfTPC00eZolgd0IuE3ON0gSMLweefUV4NQ+GOn3fhjSo10C5s4ZLW51DWXtGklaZRLJLvlYE7S6QDbn/lrjpRoGqyX+pWsninUPE+n6WPO/tEaDblNODgqIYYnswxYcsS7Nn5QMck1sw3nw8SOOxj8Ua9rmqTySiKM63d2rENKFgiIdxziSNScdFZyMA0AWPEa/D7WdH8em3/4RS7ul0iSSxawEBEIxKIljUAFpsruZhgguijIGTlwfDv7D4xbS08YXGlr9mnn1Gz8NiW2tLXaisI/3juGdgS204O1d2B1N7VPhpbNeafolvrN3qniX7UIJxqltDeWiII0lmcK6+YFVJI1B3hizoM9xyXjLRfGPgyPU5fBjxXmm6as51B7GVpLO3V1xKvkz7ikmB8xjkYqM5255AOh8C6FH4B0m0k1jwZo/ibTpNOh1S6vIbVWv7KOXcT5iyZ80Ag8qVOFJxxivaNL8IaDd6bbah4O1HUNItLqMTQPpN0VgZGGQRA4aIcf7FeT/AA88f+KvEtvpj6X4PsbrVNLtGtZUj1SGJlIUIjTxSESKoO48buHOOSa7HwlrF54M0i28EaBol54m1jRoVbUpopI7W1t5Jcy7PMkI/v8ACqDhcdOlAHXy+FtbmaJZvGN+yRNvjk+wWnnIxUqSrGLaDtZhkL/Ee3Fa3hrw1p/h2KYWQnluJzunubiUySynJPJPQZZjtUBQWOAMmuAtfi/eW1ha6l4l8D65p2j3QRor+1ZL2La+AjNsO4BiQBwScj1rvvCvivQ/Fdo9z4f1KG8jjbZIqgrJG3o6MAyn2IFAGxPLHBBJNPIscUal3djgKoGSSfSuPi+JOgzPHFbRazPcyp5sECaTc754+P3iZjAKcj5iQORzyM9VqljDqemXdhdAm3uoXgkAOCVZSpx+Br520jxtPo+o299rVxHc6z4duZdL1MSXoDtaLtWRoLdAV2AGGZnYhmaMr2AAB7bYeNdIudQg0+6+2aZfznbDBqVq9sZj6Rsw2ufZSTTb3wJ4durt7uLTzYXr8tc6bNJZyMfVmiZS3/As1hfEnxB4budFZLjVtFvbe3fzLzTZLyLdcQ7TuC/NkSLkOuMfMoGRnIzvAfxM8NQPeaFqXjDSrtrHD2moTXiD7TbFQyl3JAMqcq3c7QxHJwAdT/wimpwDFh4y1+Je0cy21wv5vCX/APHqd/Y/itD+68V2zevnaUrfltkX+tVZfin4GSQoninS53HUW0wn/wDQM0n/AAs7w0/Fq2sXbdAttot5Jk+gIixn2zQBb/snxa3EnimyVfWLSQrfm0rD9K19Ds9Ss45Rquq/2izEFG+zrDsHcYXrXO/8LDtmyYPDni6UdP8AkCzx5Pp84X8+nvR/wnV2xxD4H8XSnv8A6Pbpj/vuYfpQB2tFcV/wlviKTm3+Huu7T90zXljH/wB9DzyR+Ro/4SLxi5/d+Bdvr52rwr+W0N/SgDtax/GNze2fhbVJ9Kns7fUEgb7PLeOFiWTGF3E8DnHXjNYX9q+P5uIvCug2+ejXGuSNge4W2PP0JrqI7dr/AEeODW7a0kkmhVbqAfvYSxHzKNwG5c5xkDI7UAeP3XivxTpd3Dp0N7fz6q1/p6Paa4tpERFK7qSs1rG6FHZccqHXBPPArdi+KN5Jrt7ZL4Yu5LSzmntZ7qEXDLHLFGWYlvs4iEZYbQ3mbuQSgzx2UHg7wxBplxpsHhzRY9OuGDzWqWMSxSsOhZAuCRjqRT/+ES8N/wBoLf8A/CP6R9uVPLW5+xR+YE27NobbnG35cenHSgDi5/iPrghsXg8MWTtd6RNrarJqzKVt4xESDiA/OTLgAZHAJIycTW3xMmvLpHtNGiOlte22m+dNe7J/tE8SSJiEIcoPMUFt2fvEKQK7v+yNNxGP7Ps8R25tE/cr8sBxmIccIdq5Xp8o44rF8P2vhrV9Qn1Sy0Kyi1DTbiTTVuntIllTyjswjjJCdhyOOwoA8x0bxl4znbwZqNxbWV3NNpep3EkI1N4YrlY2t8PIFgwrrlgoCt948jJrstO+JX26/wBMsYtIZb3UxZz2cTXH+stZ4jI8xO3jywkgI5BIQZG8Y62y8MaBY3Ek9loel288vmb5IbSNGfzMb8kDJ3bVz64GelR2/hnT7fxBb6tChSW1sRp9tAqosVvFuBIRQoIztUdcYUAAc5AOPsPiLq+o2miyWfh2yWbWElltEuNUMa7IgTIXYQttP3doAbIJJ2bTVPTfijJqE8Labp8k82pmxjs7e6u0igR5oZpTmRYyQMQtz8+47doGTXoN74a0K/0yHTb7RdMudOhO6O1mtY3iQ88qhGB1PQd6Lzw1oV9bS297oumXFvKI1kimtY3VxH9wEEYO3Jx6dqAMH4P315qXgSC61OZprtr2/V2MzTABbyZQquQCyqAFHA4A4HSu0qtpun2el2Udnplpb2dpGWKQW8axopJLHCqABkkk+5NWaACiiuZ8T+OvD/hi8NrrV3PDMtv9qcR2c8yxw7ivmO0aMEXIxliAPxoA6avn8aDIdbuU0nRry4v7qS+8y9utEltb628xJcM16xMNwuSqrHg8FT/Dx6zp3jvw9qE8MEF5MtxNdiySGezmhk80xGUAq6AgGMFgxAUjoaSPx54fmntYba4vLqW53lEtdPuJyAkrRMzbIzsUOrDc2Bx1xzQBwfg+bxNDpOkW1vd+JTY2WhefNFNpccEzXURjAtVMkCjBG5QcEkZIYn5hgWnjLxvDa3n9q3Gu2VlJe6bHBdS6Z5lyqyvIs6Ips4t7gKnAifBPBYGvR9d+Idmq2yeHzJdyNqtrYSzSWM4tisl0kMmybaI3Ybjjax5HQgGrF3478HXSSG8uRJFaf6Ujz2ExRzHIqb4GKYlKuyjMZY5I9aALfw4utYvPDry68bp5Ptc620t5bi3nltw5EbyRhV2MR22rxg4Gay/GHxX8L+GNYl0a4uZbrWowpayt1AZAwBG53KxrkEHlh1rsNI1KDVrIXVrHdxxFiu26tJbZ+P8AYlVWx74qpf8AhfQNRu5LrUND0u6upMb5p7SN3bAAGWIyeAB+FAHl9x8S7rVQ+7xX4I8J2oJVt+pRajej/gCsI1P4viqL6t8Kbm4V/E/jGTxZdKQdt7M9xCD1yLeJREB/wA9hmvYrbw7olqUNro+mwlOF8u1Rdv0wK0Yo0hjCRIqIOiqMAfhQB51Y/E/wnb2yW3h/TtbuYEACQ6doN0FHsB5YHTmpx8R7ucAWHgLxnOxxgy2cduv4+ZICPyr0GigDz4eK/HU+DbfDl4we95rVvH+iBzQLr4o3PKaX4PsV9Jr24nb/AMdjUfrXoNFAHn40z4m3X/Hx4m8M2Hr9k0iWXH/fc1IPCnjl8ef8SJkP/Ttotsgz/wAD38f5zXoNFAHn/wDwgOsygC7+Ivipl6/uBawnP1EJ49q8ufw/L438UXOi23iTxNrGiR4SK4u74BFkST95dKIlQMqFdke7IaTcRlUau4+Jniu41nUW8HeFmklnkcQahPbyBWBIybaNv4XK8vJz5SZOCxVa3Yv7B+E/gmW81SeCPao8xokCGeQLhIYUJ6ADaiZOAMk53MQDn/EHw1+G/hbRnu9Q0F76Rn2xQS3E1xNezt91FUud7sfbjGeAMjzG58JaLf6Lb6Dp3hiwj8Y+IJje2l5ZIGgtLSQlXY5AKLEhMZRlBL4I+Y/L6HrWqeItA1O18X+KtD02+uZtlnpelwX7faLR5ODHGhj2ySvxvcMMBcD5QSefsYNRtNd1DQ9Hn02P4k+JGkuNWvYV3Q6HbEbvKTH3n5yAOWZi7cYNAEusaPYa3rulaL4O8GW2s+FPCsrx34VoIVu7rySixqzYDlNxZyT94juOez8Ha9YJ4V1Lw/47Q2sunxzeZZ6xseSWxGSjsQWSYBPlZlLZK84JxT/BXiTQPB2hWXhfUbebSNS0+LZJZiGWfzAD81wjoh3oxO7fxySGAORVXxXf6H8S9a0Dw/pH2LWLWC6TUtSuAiyraQxNlYiSPlkkcBdvB2B8jFAG58EtJGk/DnTf9FNpJetJftCfvIJXLopz3WMov/Aa4/4jLZ/EHxBruiX2rW1j4X8O2Z+2TzShYG1CUEReYcgMsQwxXcPmIB6V7VXi/h/4VeJtJ0y40SDxFpdlplzmO71GysHXUryPe74eRnKBj5rjeFJGeO1AFixsbjxoW0Cx1y91bwjDIBqmpS+Uq3hXGLS3MSqDHx+8bnj5QSS2PX0VUVVRQqqMAAYAFU9E0qz0PR7PS9MhEFlaRLDDGOdqgYHPc+9c54ourvWdfg8LaVcy2qmH7Vql3A22SGAkqkaN/C8jBvmHKqjkYJU0ASeM9Tu5byx8NaHc/Z9W1EM8lwgDNZ2yY8yXB/iO5UXPG588hTXO6R4O0+Txp52gPJp9ho1vNZSzw4aW6uZmjeUtIwLMQqIC5ycuQCCpruNB8N6L4fVxo2l2lm8gAkkiiAkl93f7zn3Yk0eFdMk0jQbW0uDG10N0lw8ZJWSZ2LyOM88szHn1oAt6fp8VgJBBJdOr4yJ7mSbBHoXJIqW8u7axt2nvbiG3gXGZJXCKM9OTxTpIVkkjdi+UOQA5A/EA4P41xuvaXHo/ivw5qmnW4W3kuXs7m2Rf3Y81CVmVeiuGQKWABKyNnPFAHYWd3b3sAntJkmhJIDocg4ODzUGr6paaRai51CRorfcFaURsypwfmcgHYvHLNgDuaTXbx9O0a9vY/s+63iaX/SJPLjAUZJZsHAwDzivBV/aE8Q39vbx6P8MdZmv7lS0aGR2XA6sMRZZffgdeeDQB7TceMvD0E9pANWtZ7i7x5ENq32iSQEgbgke5tvI+bGB3Nb9fMPhvUfjhY2usDSPAOlW82o3Mt2Z5THHJGzsTj5phu29twOPccVs+K/iV8XrHw5iH4cNZXyR4mvlmF2oPALrEnTnnksB7gGgD0i61TxR/wl0t9Y+HNQn0WCB7QwPdwxPPLvBEyRs2NoAIyWUnd0IxXR+Jp7D/AIRe6OvWU81lcQ+TPZpA1w7+Z8vl7Y8kklscfXPeuH0P4vQXmuaTY61o114ftb+GZ0vdQmj8iSRCu2OKRCVYkF85K424wSa9RVgyhlIKkZBHQigDx+636x4ptIfBOiNoHiDT4Y55b3VAbfzrbcV8to1y1wp2kHcV2EqQwbg6HiqHXvsXneNvCfh3xLpEYInWwjeS5iQ9ZEikU7sd1Vt3celbHxKgvIL7w1qujTwWupx332ETzwmWPyp1IKOoZSVMiw9GGCB16HrNHOpGxX+2ks0vMkN9kdmjI7EbgCPp29TQB5jpHw30GS3tvEXwr1240WWaMiGa3kN3ayIcAq0MhOBlFyAVIK+3HOeM7/xZoXh/VtL8XWUcNnqc6Rt4hsFeaxsoeCWNoMuhyDnPDM/LYAFehat4U1HQ9WuNd8BNDFcXD+ZfaPO2y1vj3dSP9TNj+MAhv4getaXhvxrpmu3jaVdQ3Gl64qFpdL1CPy5cdyn8Mqf7SEj6UAfPNzpXiPxtd/21B4zll1S3vLex0e8t9OgtZZpJo/Mbc0TEiJYvnKszNgNlQflrhZvEfibwr8SNX0fxp4qv7fT9TnMWpX9iFPnoh8pnUbDztRk4AII5ztIP0N498K6V4X1aw1TwbcS6Nr5ke5g060tGuLS4ITZI7264WP5WCmVSn3h1JFcdb6Vq/wAQ7Z9JvPDOiyXMetQ6ld3xmaIW65XKm1kQSENGhQDlG65PWgDoIPC0mt6zoulwa/48OnyAX/n3l9DFEbeIqU2RxAMCZDHjeq8BiPu4qlrvgDwrafFeddX1XXEnudKheO5GozG7lmMzIAm35nO1V+UA4C5xwTXW/wDCF6v8P9Um1X4d28eoaZPGsdzoV3cFWVVZmX7LK2dmC7ny2+Xk4wTVPwh448O3fiDXPEPiKf8As/X1ZdPg0i5hb7ba26n5UWIAs7yOxc7AwwUHO2gDiJNH0bwx4kvdP+Icmp+KdNRmkOtw6neTtZJuGEvYUfamNwww4IAOBzi34/8Ahp4S0BrLxfoemWdx4VntzDqpijN6Y4HIIu4dxYFgMgtzgNuAJFenP4pa9l/sHw/oGoWN9fpLNHNe2iQwxAsPMmdC248yZwV+ZmwSPmI46LSm+Hh19vDwN94G06KK31TR7uUyHcY90zwFjgHY8ZMZ4fcwGDigDV+GVlb+EoNM8P6rp1jFpupGW70eUASeUZGaU2bvzudVclXzhwGA+7y74n+B7A6fPLHHHZ6a8ouvtMMQ3aTdrjbdoOnlnAEq9MfNx8xrh7C58NaTeWMGs6hdax8LdRRU0a8muZPJ0udScwTYKkYONjONybQARgkej+EfE15ptnaW/iOK4l0G8laHS9YnO4vEXKxLc8Dazjbtc8MGXdhjggGr8M/Fba3ZXGlatbw2HiXSiIr+zj4Q5+7NF6xOPmB98fXta8Y8d+Frvw3qFjrHh+4Wzkszs0+6k4it1ZgTZXGOtq54Rv8Alk2BkDGPQfAXi618X6S88cT2eo2rmC/0+Y/vbSYdUYencN0I/EAA6aiiigAooooAK534iaJc+JPAuu6LYvDHdX9nJbxNMSEDMuAWIBOPoDXRUUAeTy/CW1ttfudR0Ww0eyK6tp17ZtGhRoIYTH9oVcL8pkCtkDh8jcaoL8NvEL2lnpt2mkzaZp9rqNtEY7+WKW4FzIrqWPkkR4Awcb/xBxXs9FAHi9h8MtXt4dNN/o/hLVre1a5H9kXG2G2XzPL2TZjtQjyjYwJ8leHwMYJMPij4Ta1qsgdJtPltze305sXlRI1Wd1ZHVpLWYB1CkcICM/Kw5B9uooAp6LavY6PYWk0jySQQRxM8knmMxVQCS21dx467Rn0HSrlFFABRRRQAUUUUAFcx4n8Fad4jfVWvpruM6lpp0qXyXUbYtzNuXKnDZY8nI9q6eigDkNa8BWGp6lPqS3+o2eoyXkN9HcW7R7oZY4TCNodGUgozAhg3XtxWWfhRpJsdIs31LU3g0yRpYi6WzSs7TNKzGYw+YhJYj92ycfiT6HRQBxMPw8tIYorVdZ1g6VBex39vp7NAYoJEuFnUK3leYV3LjDOeGI4OCM7SvhDoGkNff2ZK9ulzE8IAsLB2iV2DEB2ty7jgjEjOMHpkAj0eigDD8G+GrTwnoq6ZYSzSwiR5d0oReWOSFWNVRF9FVQB6VuUUUAFFFFAAPeiiigAooooAK8z+JXjS4W4k8NeE5i2tOVS5uIQrtaBwSqICQGncAlVPCgF2IVcmb4l+M7m0eTQvDEmdXIUXV0kfm/YEfhAE/jnfpHH/AMCbCjJg8K+H9I+HXh6TXvEJ8i6UEnfIZ3jaRhkBgMyTyNt3MBlmwo+VVAAJ/Duj6V8MfCc+sa04W4SLEpRjKVyciKPIBd3fBZsbpHOTgbVXhfEV1q+ma0fGnjjw/pWotclLLR9Fk1F2ubUScGKOAQMjzuDljv4HGQBVfxleXGueHLLx7q08E/2lvs2h6HEBJJBJI22N4yMhrsOFYgjChXTrlqzGXV5fE1/dWdub/wAd3kqf2rf6Xbedb+HYSio0UOSVe5KoFJyTx1AFAF+2kvrLxHpGiw3sd38QbotaW7Tv9ptvDVoUaTywcASTmNCMt8zbeTtHzek6L8Pm8O+DILPTpobrXbK7bUYr5kMb3U5LZMzFmJLozRs2ejEgDAA5nwp4W0y98QJo2mxa1odpolqt+Hlbyby6vLhpIzcu3JchI3XJ4/esMcACXxj4h8Q+HdetPDvhHX7nxL4mn2uNOv7SFkt4e8k0sSx7F+uWPHrkgF74jeJrK40jw9qnh8Sv4wkufL0izCjznkyFngmXPyxgAiQk4UqDnIFb3hXSx4B8H6tqviK8+16lMZdV1a6jXh5NvKxr/dVVCqPYdM15z4T1XSfCeu6l9kjm8efEm+LzalPp0aLHbqNuYhKxCRxr8owCSTjIHAHWaD4lvvG1ze+E/FejwafHqmi/2jBJYX3nkW8hCYYlBtfLAg4IOD6GgDmI/jHqs3iPVLRVtUk0rEl5YpYvKkah1V4TdCUDz+SABHs3KVyeDXvNcdZeCN95bz67q0+qR20ouIbXyIreDzQciV0jUb3B5BY4B5AB5rsaAMHxfr50OyhS0g+2aveyfZ7CzDYM0pGck/wooyzN2APU4BXwfoLaHYTNd3H2zVr2T7Tf3ZGPOlIA4H8KKAFVeyqOpyTiaZc2tz8VNXa+mU3lrClhp8JGSqbEmndfTcZIgf8ArmtdZq+pWmkafNe6jMsNtEMsxBJJPAUAcsxOAAMkkgDmgDI0q+urzxzr8HmH+z7G2tYUj7ee3mSSN/3w0Ix/jXR1yHhzw3Fd/btX8QWKtfapN9oa1n+dbdAipGm3JXeEQbmHO4sASAK6q0t0tbWK3iMhjiUIpkcu2B6sSST7nmgCWqurXRsdKvLsbMwQvKPMOF+VSeT2HFJ/aVn/AGv/AGWZ1F/5H2kQkEEx7tu4diAcA46ZGeoz5l8Y/Ea3VlquhWzsNNsLRr3xBcRtjZb4JW1U9pZsbf8AZQk9xQBh6z4rn8RxaKda02S/l1CCO90/whYsGecEBlmvZT8qRg4IQ/KD97eRgVvEUg8LWPnfELxvD4WhuBvXRvDY23EnYM85DTSN2LAKM96drGsH4O/CSfxHfRRT+NteZGkZ14E7LlY8dooUGAo4+XHG6vleXRvEfibUZda1RLzUpbh4555ikj+Yjo77vMVSigCNlxnIKkBflOAD1i/+JfwfWbA8G65rbZJa41S8aRnPr88rfyH6mtTw547+CV/OEOj6z4Suj926tLiaJUJxyDDIeeO6YrzbRfh2tyjxWiPdzKwf7WQpCDyFk2+Ru5wzYJZsYHKjmtnSPAUPkLdx23l2VzGkguL03UdjcIVG9Ay26hiHXcC0ip0wGHJAPa/Fvge71rw7b3cF6PiN4WCO8VvczgX0Kn7z29ymBI4IHyuM8YzziuI+HXivWvhzeabpejXb654P1W+SGCe+Ro/7MzNFG6uM5SRfMIaM4GdrjIYg6/gXQ/Enw00uTxXYGabw7bhZr+0UQmO+tn+9cw+TO6bo1CnO2Pcvqckz/tJeGbZbS11rQ54IbXxNPDaTEMFT7SQXguVORglVeNzn7rbsEqKAPo+6tYLtEW5hjmVJFlUOoO11IKsM9wQCDU1eKeC/iR4gu/Cuh6RqOnTR+LL6b7Fb380O6zudjOJJg6nG5UidjGdpYgYGDkeu61c3tpYPNplgNQuFI/0fzxEWHfazDGfY4HuKAKdzrj2nimz0m7tClvfRM1pdrJkPKgLPEy4+U7PmU5OQr9NvOB8WrXT73QoIryy1eW/Ehk0+60qzknns51GVlDIPkx3yQGGRzVfTdTuvGni6xdNMudLs/Dd1JJcpetGJ3umt2jVAiMwCCO4ZtxPJ27cjJr0GgDwTU7iH4madZaTq1rJY+MI7DytR0LUxJZi+iJjkcwyAHGJIldWXd0IYYJx0nwu8D3HhvVLA2umXel6ZY2k8AW+vo7maUyvE2xfLGBGrI78nO6RsAAmt34yaI2peDLnUrDEeuaGDqenXA+8ksQ3FfdXUFSvQ55rq9A1KPWdC03VIBiG9to7lBnPyuoYc/jQB4DNeapPrb6Z4i8XeJdJ8ZzaxHAtlb3Cx20lo8wUSWy7CrqIzkk5YEHcOKm8U6fr8i+IB4otbfxVpfh25CrqEJWx1i0TyI5hNDIoCNtEn3flJZT1r23xb4Y0nxXpTWGt2omiyHjkUlJIXByHjccqwIHI/lXk+p6br3w9s57XUlk1zwhdalHeXusLvl1CGNXViLhefNXEaoXXkJn5eAKAKHhHxzd+H5Nb1X/S/GWmKqLdXSw+Tq2niNSFiubcgZQHcd6jqzsQc16p4NudJj8C2upXGp6fdWlxm+ub4yL5DTO+923HgBXOADyu0DgiuA8W2mj31mvjFfFMg8STwONKn0Hb8yBvli2gEzLuKKxlO0H/nnnFZGj2LaF438mbSdKh8YxAXkmmI2bTV0YHdc2e7AguR5bgrxnBzwdygGqNMW/8AFHim78GSWt3FqGy5m0e7hK2Grw7FSRkcrjzA+cyLuXLqGHeuXgn0zQtPvZNT07Vda8Exp9jm029uHM2gzjkW8yFtphJYbZOcfLyQAa9TudVtPGmt+H08P6lc2dxb/aJrx4lVbi2jChGt5EkVtjNI8ZwRn92SOgNJ4k+G8Nx9r1TS9Uuodfkh8qS4vZDNb3cQz+5uIuFaMgkcAMM5B4oAzPDfiC38N6xd+Etevvt/h+Wb7PpuoXkqOMNFG5tZSTlgBKoVzkEMqk5xnK8aeHdU8IeIbTxB4caMTRYggllcrHcRHgWV03p0EUx6HCN/CTy3hWey8Hw69aap4cluNNkVNOutNmmVzpM0jHbEzMQPskpdWSYZIwA2dox6L4I1i4stSuvAPjWaLUZ0jSK2ujEWiuUaHcbeQtnMiqG+9y6jdjO4UAdf4I8WWHi/SDeWIkhnhcw3dnONs1pMPvRyL2I/XqK6GvEPFOg6v4F8SRa74XMk0jhYAk0hKX8Y4W0nY9JB0hmOc8RtztLeqeDvE2neLdDi1TSZGMTExyxSLtkglX70Ui9VdT1H49CDQBt0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcD8SPGUmmFtE0KRV1mSLzZ7po/Mj02AnHnOo+85PEcY5dvatTx74nl0O3tbHSIY7vxFqTGKxtnOEGPvzSn+GJByx78AckVzPw18KwuBrF5K15bmY3aXU6gPqNxjm8kHZQOIk6KvzdWG0Af4K8Naf4P0ObxF4iLWy2ySXebtzJJDuGZJ5m/juHH3iPujEa8AlvP/ABdrV7favdeKPE63GnvpCaZqGg6I0x3SCW5lBV4wPmuJEgYAc7A47qTXod3ex+MWl1PVre1/4V1axO5a8lKC9K8/aDHtIeEY+UMQGzvwcJXl0Whalqt3can4djupNcexlOg2165c6JYNnZMzsC/nSkMIkJyoY84U4AK0sWoyeJdS1m5hg0vVZ7sLqmq20fm23huORANiHgNdMNollwQmQSRzj1vwrpWr/DbRYtKs9Jh1vQ4iXFxp+I73nkvLE52yse7KwJ7J2pvhDwF4euPB1k2g3+uW2lajbLM8K37ss3mKCzOr7hubJ3AYBJPFc7NqXiK0udT8AaBqcSafpMMbXPiW4kG/TLMpxEwwA04VTh/7pUt82TQBT8a+NE8S+J7ST4e6g+nXVhbyx63rt1bFLfTrVuTHIsgGZg6gqp5Uhh3bGZ4F0GbVNMS70mw1b/hDL2aR72+gvAdV1p92POmbKskOQ3yI2856cmo9L0OfxTZ6JZ6PDFpfgeLzLrSLe8+catPC6P514MZKSDzCBnPG4g8CtbQ9Ouvibqzaho1jL4U8Ps8sOqXum32G1eQEqyxBBtaPI/1xAYjgY5oAybOVrfUYYPAQs9IvNEhl0jWvEUiRjTEgG3bJ94K1x8sbYH3SSrZAGOh8B+IvAPgrTpk8KWviHXWKKt5qtrptxdeb5YwMybdu0DOAvyjtUfh/SvD+r2F34i1iGC1+HXh15IdG0wDNvIISVku5F/5aszhggbPc4JbNcZ8UPiNa6fLBN4u03+0tSmVZdM8Js2LawiI+SS8A/wBZMwIIjIIUccHmgD1fS/jn4FvWZZtRutP2sELX1lLEgPu+0qv4kV6Pp19aalZx3enXUF3ayDKTQSCRGHsw4NfOzT3xstM1LWdG8O6d4hK2N7psuhI0azW89zHC1pOrffDK/TJHUjG3J9L1j4apYXcur/Du7HhvWSd7Qxg/YLs/3ZoBxz03KAwznmgC/baba2/xmvr5oj9putFj8pyTgbZisxAzjJH2YHj+Ba6OTQbCbWl1W5je4vI/9R50jOlvxgmNCdqMecsBuOSM44rzS28aC+8QaPe6xZtpGv6LcnS9YspGBCQ3W1Vmjb+KIzJb4btk57E+v0AZPivWB4f8O32qND5/2aPcIt23zGJACg4OCSQOla1cN43bVtVENtbaHcPplnf21zdO8iB7hIplfEMYJL4KhjuK5AwAxOK6Cy8QQ3SXtw9reWmnWsQka6vIGtweCWARwHwoAJYgDngnBwAYHiPSo/EHxE0u2mS6W10/TZ5LiSGaSHf58kapFuQjKnyHZlz/AALkc15dq1laQeGvH9np9tBbaVc+LrCw2QoEUKGtFkAA465B+pr1m61zUda1ZbDw6TBp4cxT6qIfOG8LuKxAnbxwC7ZG47QrYYrwFx4em/4Qfx54L026/tG8tsazaXnDS3MrzySBZdvBkE9tIhIA428DmgDlf2xEa71TwbazRGSzRL26ZMsqymNY3ZMqCQSisBjuwJIGTWR4V8FoZRd3ujzGy01zbwPJoEt+jCJ50bcJJd2F342gDmNeMrz654zsv+FlfDnRfEfhlYri/gT7da20pOy4DRtHNauQRtLKzpnIIYdR1rA+Gtj4N8U+HtSvNcGjLdJxf2wgksbiwkbd5izO0pdsk/fJGSCck8AAtaf4OTxpp+katpuoeH7rTrOdpIbWbw49tFIw4BdfNVsDO5Qfl55B4I9O0LwzpOjXD3lhpljZXs6bbhrOLykc8EnaOOo6nn3rNi+IHguCJYo/FGkPHEAm8XqyAYHd8nJ9ST9a2dL8RaJq0Rl0rWNNvYxgF7a6SUDPTlSaAL19bw3dlcW10oa3mjaOQHoVIwR+VeESSvcfsr+G7qU77u2GmtbOequt1EiYPbjjPoTXbfEnxd9ojm8H+EJkvfFeoobfEJ3Lp8bcPPMw4QKCSAeScAA1ieOVsNKbwZ4KtXZdM0SOPWdScDPlWVkuU3/78ir9dpoAb4IUeIPC2qeGNP8AOg1nw1q08sV7JEfs6TrezNGm7q2YwA4A+7L6nA9b02W5nsLeS+tha3TIDLCsgkCN3AYYyPfArxPwB4g8SeBPCGif8JF4cjuINUMt9NLZXLyXZkkJmdniMYUthidiuX2qcA7TXpWh+Jk8Q+KNui3cFxocWmR3TSxjPmyTSMI8HttWF8j1cZxigCr4q0jV4fF2kax4akWBrk/YdUJh80NCAzxyFdy8q2VyDkCU8HAx1V7qNrZXVhbXEm2a+lMFuoUnewjaQ9Og2oxyeOg6kVbrhfiRrGnaNrHg+8v7+2tmh1M7klkClongmjZsHoqs6Et0GPegBfjXe3Np8OdShsG2XeotDpkcn9w3EqxFvwDkj3xW/Nc6N4L8L24vry30/SdPgSBZJ3CqqqoVRk9TgdBya8r/AGlfHNloVp4b0ZYXvby+1G3vPKgIL+VDKj8e7sAo7dT2qPTr3w2PEaav8V/EGmXHieFgYtL8zzLPRM8hOAVEvTdI564xgAEgGt4h+LV+NN+3eG/Dkp013WKDU9XL20U7t90QwKrTzZ7bUHQntWVp/jbxnfX0FpqWt6DoF/cHbb2epaBeQJOeyrLJIoYnpgc+1afxl1GfTdU0HX7OQyW/2C9t7G4iUSiG7kWNo5FHIZ2jSZU9WYD+LB8T+J3xB1Hwd41m0y31OTxd4OvoI5nstYkW5WeN1DEpIFBUc/KR0K5IOKAO31u38WfDbxFN4hg0vR9IjvNsd7c2IaTSrlsnb50ZxJbHLf6xSy5IyOSa1Jb/AMO+K4NEj8RX0q6i15Lea3HM/kT2jR2siR7dpykavKnllSdxZTlmY53PhV4otb+zsNHubiTVPDGuwSHSJ77EkilQfOsJyc7mUZKk/eQHk45zPDng3bq2r6TYJCdf8G3ccui3N18yyWUy+ZHbynqyKRIobqhUFeRyAM0H/hIP7btthex8bQ2jm1l1JAsXiLT1f5BOF5jnQFc/xKWyQQSB2PhC6tvGujyap4n1Eu1nIftmjuv2aCwlTkpMhJZyuM5dihwGCiuJ8Ro/j/X9I1WeW50K9tdRm0u1AlHnadcQ2k8zs+04wzqMjkNHGh43YrRudMT4keALPxho0ATxJ5KR6jZRO0Ueo+S4820nHcEqwUnkZHYkUAWNWgXxxc6z4h02O5SW3spLazt5NNmNvqlopy6zMUAkWQk7AhLKMOMlmFcXp02lQRWen6pHqB8O3mqvcQ3ck8hvba5jtXhFg+CXE8b+X5WOGAGMkc+9aV4s0jUPCC+JIpzHpghaaQyLh4dud6MvUOpBUr6jFeW+LPB8mmeFZdfube48rUUabxLYwE+YoeQyi4ix0mt2bg91THYUAdr4S1O71Kzfwr47sSuqPbMw88IV1C2ztLnYSokAKiRAcBjlcqRXD6zaat8NvGDavpcc99BcKTdW6ks2pwIMkjLc3kSgnP8Ay1QE/eDVcW8PiBY9H1601CfxZp9sLjT9b0rbiaBiPLu4suANxwHTkHocqRXYeHNRTx34budN1+zn03XrFo47+24WS1uAA6TRMCRjOHRgT6diKAOr0TVbHXNJtNT0m4S5sbqMSwyp0ZT/ACPqDyDxV2vDvDOo3Hw48X3FlqOyPQNQuliu0QbY7C7kz5dwg/ht7jByOiSBlyAOfcaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKzfEmt2XhzQ7zVtTkMdpaxl2wMsx6BVHdiSAB3JArSryvxbqY1vxXM/lm50bwtIh8gHAv9WkwIIc9MJvQ+zyLn7tAFXw7od94g1y8m19SNRv0STV1ByLO1+9BpqH3B3y469+HUje8eXd9rFw/hrw/aSXMVusc+r+TcfZ28gnIto37SSAHjKgJ1Zd6mtK6uYvAPgS91G/b7XeRI1zcMvyteXTn7q5/vOVRR2G0dq83vrnxFomk+H7zwz4k0u/v/EuptDK5t2ZTPMCJXGG+ZIfLG0MNyiPaSc4oANUj8P6kjXdrpmqP4a0H5J7O6lnxf3+5Y4LIRyMQwR8A9V3FAMgNXdaVLD4Jj0uLXJ7abWdfvc39z5oVmuHXC7FPLRqQkSgfdG0nua5q30fT38XaT4FtdXlhsfD1oup3JWdVuLu8ldyrMTzkDzJGx3kQ8cV0U+pfDfSYdQsL3WdA824iKXi3eopNcTIAeHZ3MjYGcAk47UAZHiS+1vwA76R4bsU1BNeunXRULgfYbl8vIsi9TCP3koIztwVOBtNcH4l0a5gu7LwJpWL62t7yC98QXd02P7Tvpw8kUUg/55s0a7sdFK9cc9tpE9poVnN478YXuqfYrVXtdDtdRANxFA+3+EAM00pUY3ZcIFDHO81i6b8OfFHibWL/AMQ6jcWvhmPVr2K/MEUHm6jbKiKiqJshUJVckFW2k8c5oAjPh7S/if4sgh0rSrnSvCumSF9XADQJeXgBU2wRSFyoLrJIvXO0Ejk+ueIzHoHgbVW0uGO2jsNOma3iiUIseyMlQoHAAwKu+HtGsvD2i2mlaXF5VnapsjUnJPOSxJ5LEkkk9SSatX9rDf2VxaXSCS3uI2ikQ9GVhgj8jQB4s8UNh4B+F+jvGZdOisRq13Ao/wCPj7NaiYKR3BmZGxg5xXyj4Uh1fx58ULC5m+3XN5qGpxyXU1nnzYw0gLupHKhVyc9FAHSvqGyOqaHf6B4YvBDN4j8NyyLpQvJBFFrmnOhj2JJjAlVdgKnvGOoORo+GPhbMl3fiy0i28F6RfsTeR2d2bi+uVzkwiUfLBETzhCT2ytADfCGg6dJ4ie9tru7v/DnhkfvdSuyrNe3MCMkcabQF8q3RnxtABkYnkgk8tqniay17XZrbXL6J9WSx/tS5jubR7yKzQqsiW0EIdULJE2+R8lzhsei+tX2v+CY9Cu/C1nrOkWcH2d9OWNJQsMRZSgj3D5Q3ONuc/jXzj4u1WPw1rcfiDVtFudS0rUreA3MMbeWbTUoYTbyI0o+aN0OXABAO5SOgYAHR+ILVpdEt9XjQ3UFvaXcqxxTNKk1pDKIr2CKRiWaF0dZ4txOwq2D0x7l4E8TNJ5Gg67cBtXSESWt0w2pqlvgFZ4/VsEb16q2f4SCfJPhbealqvgrw/a+Jkn22mmapMDcLhxYiOOKMsD2O9gpPURk816l8PNGs9e+D3g+21+ziulGl2rr5g+ZCIl2urDlWAx8wIIoA715Ej273Vdx2ruOMn0HvWR41MQ8Ha59ou0soTYzh7l/uwgxsN5+nWudvfh//AKXp93Z+JdbiksJC9ql5Kt5EjMuzOJVLk4JAJbIyfU1l+I7aS11qwt9cm1fxZcqjXsenQi3tbaJY2UCWQMyB23Mu1WZhkZAG3IAOM+GHjm88GfCo6HrtgIPFmmxyNb2F5OEl1EyFpIxEi7pHYlwpwuM5ywIOPRfhXoOoafHqOra0jw3uoFVWGQKHWNXkk3OFJCs8s877QTtDquSQa6rw9rdnr+nC8sTIFDtFLFMhSSGRTho3U8qwPb8RkEGtOgDy7V/D2r+BbvU9a8Haxo1lolzI11e6ZrZaO1ikb70sUq8x57qQVyT04x5Rq8mveJPGFn4zTQ9JuZbOExRTW+kvJZ3W4cNJLdSW4IX+Fkzj1IrvmlvPiZ44l8jyv7C01z9jMyCSJNrtG115Z+WSRnSRIg2VVY2cgllDcVffFix07xhdafpfw8vPElxbSMqapqV9umkCEq8q743EcW4NypCAAH5egANQfEzx2y/NceHbYqMCOE2DLgfXUs/hXEfFm38TeOBpN5rPh+JLO0maWee102WLz0OMq0sLXIHTAYtwW5r1XQ/if4ri8URWPiHQbGaxktzNLDpEU7zWCniMyPIFikDn5RsPOCRkVuXHiRdA1C61RfBlhpiiLzrwyXsEeoG1DjfN5MQcOqZ3Hc4IGe/FAHO/D3xLe3GhvZ/DDwBoenA4WS4Or2zwxOOAZViJmY9eGAP0rppfh1Pb+APGFvLevqfirxBZzLd6gyiPzZDGyxxqP4I1zgL6E+tVvFvhmy8QajLrOiX1rqV9GPMX7DLFDfQDHHkXEeM9zsmDqxOCyitb4deLbq8uhomvzx3F8YTc2N+kRhW/gUhWJQ/6uZG+WSPscEegAILSaz8R/BwXk3n6orQtdJGilJo5VcusPHKNGwEZPGNpPA6YP7O6edfeO9QURIk+qJHth5RykS5mBxz5u4SccfPXR+LPhhomqTXd7HqGpaIk8hub5LKdVt7lgOXlhkVoy2Od23OQCckV5R4A8et4P1TUrfSoJNX8P313Ddx2ctyX1WNZ2SNZyCgV/NZkYRl94VgelAH0zXJ+JLnwn4RS81TUrWyivNQ/dMsdur3N+xGBEqgbpCeBt6euBXNeJDrfj+bTNO0/SfEfh2ygu47i71Ka6+xP5a/eijWKQs7MMjJwq5z1ArrfD3gfw54fvGvNN0yMX7Daby4d7i4x6ebIWfHPTNAHzPZ+E5JvH3kQ2EGlaw91DDFFDGCdPluVeb5ex+z2kXyjgLJJkdqp+O9T1LwTqF7pfha1awvdOubgmY3IdBAmGRREsmwh4WjeRplLO7sP4OPT9WjudO8c+MdUtYpJrzQdYtNadEXMk1nLY/Z5dgPUovmkepTGOa8DvvC3jLT7K4max0ibSLk7n8QyXAeC6UliJWdnIZjvJxt3/wAODypAPoL4W29l4p0HVPDksRi0HV9Js9Zt7aJiBYSzNKsqQk/dVZoN6ehPHpXmHxd8Cajr2mR2ul6TbxeL9AkkbU7WyhEb6nE+3ZfRKo+fOz5gOQxIx6+hfCC8utA8+30zw9qmq6m1pawx2+5IRZ2Mat5RmeQgLJKzyy+WMkBhnGK7wLp3xAvJbTVdP1Tw94p0QrIjpKqXFusoIWSKVCyvG21gQcglSGXgUAfPfwOGo2vwl8UteWtzANH1ix1DTpJYio+1CUI6KSOSQqoR/wBNMd6+hvAz/bfin8RL+AbrVGsNPEgOQ0sUTvIPw85QfeuS8dJqNrqul6MfEV54s8SCQXOn6Q1vDDFHIv3Lq7aNR+7jOGAONzAYHp6b4B8Mx+EvDFvpgna6uSzT3d04+a5uHO6SQ/VifoMDtQBS1/wFpupeIoPENlNcaV4ghxi9tNpMg2snzxuGRztdlDEbgDwRXOaWbr4WXt4mu3LX3hbVL17o6syBZLO6mbLi4VQFETMcq4ACk4YAYNepVFdW8N3bS291FHNbzIY5I5FDK6kYIIPBBHagDzbX9I0vw341ttdvXZPDWpzCS6Rpttrb34K+VcuvT58bSx4DhG6nI19NudT1LVZ/EcOm/adJmgW1tLd5Ak5hBZmnVW+XEhK/KxU7Y0OcnbWI1qnhWVvCHiMteeCNaDWen3ExJNozgj7HIx5Kkf6tzyMbT/Cas6T4l1nRvEsHg3Wfsct4LfzNP1C5maManGpwV4UhZlGNwGc/eAA4ABwptpbS+v8AQPD73dj4k0NJtT8LtPbsnn2jjMtiQ4G9FfKgZ4HlkH5TU0Pivw3ZwaT4l8MXk1zr32ZLrU4nk825vombbJBKg+YypskdcLtTyiPlRudL4k6pfXb6d4vg0tbeHwZqRN5IZt00qHEdykaqPuBG3bmIJ2Y2ik1Oa3+HfxY1HUkgWLR/Gdqogu7eza4MWoRqcL5cY3MJAd2ByzZ9zQB2Hj/SdO8T+GE1i2hTUrVrQ+bHEM/bbGQBnRe+7AWRD13ooBGTVf4Pa9PcafdeG9Wuxd6pouxUu85+3Wbrut7geu5OG6/Mp9apfBC9vNOtL3wlrNtNaXNizXdgs0QiaWxldih2Bm27W3LtJyo2Z5rB8Tg+B/Gdlrafu7TSphBcY4DaVdvjn1EFwCQB0RloA9vooByMjpRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYvjPXU8NeFdU1iRDKbSBnSIdZZOiIPdmKr+Ncj4M8PvY3ejaPeOJ59KhOralLx++1C4Ljdx1x+/OO2Yz2FZPxs8a6RpereHdIvJJ7lYLsatqNvZwmeRLe3VpELKOgMojOWwMKTTtHj+ImprqWpA6R4TsdQmN6812pvLuOMRoqDZlY0wiDOS2CTx1oA2/Fup6LrXjbT/Ct/qccT2wW8e3iuTHcyznIhCBSHIUB5GI+7tQngmqHgjSX1j4havrV9qV5qlnoEj6TpbXWzKSFVNy/yquSCRFuPOEbJPWvOtG0geFfDtz8SfEeiTa54ku1N3a6xJdAMGlO23D252CIENGu1N5GcDA4HvHgbQF8MeE9N0nf5s0EWZ5v+eszEtJJ/wJ2Y/jQB5LNd+Hp/hX4p1TXH0+fUNU1S9uIba4VZpHnSUxW8KpyS22KNdoHQnjGa35bMzWkev+MrK18MeDNFP2220YbNzyL9yW42fKCDjbEufmIySQBXoUPhvQ4dYfVodF0yPVXJLXqWsYmYnrl8bj+dcFGv/CzvGzySfP4L8O3O2NM/JqV+h5Y/3oojwB0ZueQKAJ/Bui33i/XIPG3i+2aFEGdD0mXn7FGek8g6Gdxg/wCwMDr07HxL4q0TwxFE+ualBatKcRRHLyyn0SNQWY/QGuf8TahqfiHxM/hTw9eS6dDbxLPq2pxAeZCr52QQk8CRgCS3O1cHqRhvhDwro3hrx1qqadaASy6fbSi5ndp55G8ycSEyuSx6RZGcUATt8TNCjXzLq18Q2tselxPoV4kR9DuMXAxzzXQeH/Eei+IoGm0LVbLUI1+99nmVynswByp9jVnTZ7y6gla+s/sL7iI1EqyNtxwTgYB9uR7muGt/B9r4nnln8RWOlte2jvAmr6ZLLb3ryK2NxZVQocDlQzrnpxQB13inw1pHirS20/XrKO7tidy7sho2HRkYcqw9QQa841x/EvgTR7/T9Wur7XPCNxBJBHq6KZL/AEsMpUNMo5mRc53j5hg5B4rZ1ez8T+D9OlvLTxfBfafFgLb65ZGWUknCoksJVmYkgAFHYkgcmi31H4pNaRXE3h/wowdAzWo1KdJRkfdJMRUEdDyR70AVfDOv3d34Gs9N03wauoRm2FtG1pcWx0uZcYLh9+4RnnKmPeORtJrW0X4d21ho+lIL++s9YtbKG1uL7TpzF9oMaBQXQ5V8YwC4LAcZrzW90fxDp+tXd5oPhq+8H6lJE11N/ZmtWsllOAfnkeKZAhIyuSApG7n1MNrqXxB1yzWS/fx1LprE5Ol2unWjyAEglZPMLEHsVwCOQTkGgDpvGVna+ddeBfCs1zeeJdeVV1fUZpTNLaWXRnkc8LlSypGMDLkgDPPr1law2VnBa2qCO3gjWKNB0VVGAPyFeS+B/GPgXwktzpK6VrHhi53JLdNq1lJvkLlgJZpxvXBIbDM4HBx0r18OpTeGGzGd2eMetAHk99rutXuhDxI2vXunWN1I/wBjtLJbNEjiDFUaZrhHdnY4+WMcFguD1OGLS8+KGh3cUrwzalaW6wSiVWtVvbWVg4V8bjDPHLAeQGXch4KvgXPFkfgQ6zcW8HiCTzvMaabT7LTY9WSCRzlnCeRKYWY8kDAJ5IzzWz4L8S+A/DNtJZWeo3sM8xEs02p2U9vJLtCoD88SKEUbVAUBFHAAoA6jwPpep2b6zf61HbwXep3a3Bt4JPMEYWGOIbn2qGc+XkkKByB2zXR3iyPaTrAcSlGCHOMHHFYlj428LX+fsXiTRZyOojvoiR7Ebsg89DVi38UaBcXH2e31zS5Z848tLuNmz9Ac0AecfBNj/wAId9h0yVbbUJdGtHhkdARHMkRgkBHcpNExYf7Qz1FZ/gT4fWOj6jquh+Jk3qlrDqUlxFqcyhyZJPmlIEe4qY9wJyF7Y61teLPB+r6H4hPiPwd5s8DTNc3Wmwsqyq7Y814N3ysJAq74mxuKhlZWwauQah4J+IuqzQ30OL+0jETW1zM9pcPGcM0csG5XZA3UOpQ9RnJoAo/8IToOoRR6pYR6lpGkxMLqO6iv7nzpm27RJHFvKruXA3FS7DjA4NdZ4K0V9LgZbe0S0sZMs4ucy3t0x6STyZ64OMHc2MZYcrXNWDWFksqeBPH+hWulSAkWdx5d9FbE94CsyFF9FJZR2AHFV4rHTPCpa88O+O9GsGuYwupS6rIlytzKMn7R/rU2y4LA/wAJXaMYQUAcvqOlaXH8XfCEGoXUMuurqDSzrpsHlQWC+VLJDArKBy5TLFiWYL0VTiuk8aQrpnjOzntNqywa3pt3Hg8r9sMlrOgHoVQSEepLe9U/D8fhDR9bbxDY3GseL9cAmf7XawhrePzDukZHwlvGD6s+cZ561Dr/AMRPBWt+PtMX/hINGh0nR2GoXl0bhAbq4CusESY5kCbnckZAOwdTQB7Drenx6to1/pszskV5byW7svUB1Kkj35rxK/8Ah5c+EzqPjrXJdO1C60LTvOt7ezt3hW6kt4sRPNljgLt3YXvySQqgd0fjJ4BPEPiKG5b+7awSzt+SITVTUvi1oLW3lw6J4m1OG5YW6KmjTKkzOcBMyhV+b0J6UAeYeGr+bxD48udH8Qa9cPfid4hcLrV1bTfK+wyW8UP7lQWwyo4yUKsSQc17X8KtVu9Y8HRXF9di/aO6ubaK+ChftcUUzxxzYHGWVQSRwScivMn06zt4fKvPAHxEj0Lo2mwal59sAe32dLgkr/sD5favSvA/j3wf4iWHTfDOpWolhiASwMZgkjRRjCxsAcLjHAwMUAUvH+i6rZa9Y+M/CluLvVbKE2t7p+7b/aFoTu2KegkRssv1I74qj4JT4Y+ItV/tTQ9L0aLXY33y281qkN3by990TDKvnqwHOOprS1/x1fw+IL/RvCvhm61+702NHvnW5jt4oS67kjDNks5XBwBwCOe1chqmieI/iJaw3994Q+H7wt9yS+nmuZ0AJBXckSlSCMEZGCCCPQA6fxhZzeG9avvEum+KtK0Nb2NBeQaxCJbeUxqVV1xIjK20gYBIOBxmuM8MXPirxHqepXvha5eabU0jiuPFN7Ym3toYI92yOytmJaTmRzvc4J654rldR8Baz4R+0ahc6T4dspImRLO407RFvlllZgsSb7idpImZyq7im0Z+90r2Wz8Ha/eW0T+IPG+tG4KgvDpqQWsKNjkDEZcj0JagDX8FeDtL8I2cqWAlnvblvMvNQun8y4u5O7SOev06DsKiv/HGlRXkljpS3OualGdr2uloJjGfSR8iOM/77LXK6x4ZtdE1GN/FWqaxq/ha42QZv9Rfy7WVm2r5yqVWSNyVXLZ2t1yGyvoS6TZLpC2GnoLG0CjyhYnyAncFdmOPboe+RQByWnav4w8Q6nqNtbRaToMFi6RyPKGv5GdlD7PlaNEYKUJ5cfMOc9Ha7qvizwnYtqF9/ZniCwV442itoWsrkM7qi7dzuj/Mw4JTjvxz0nhvRV0nw1aaZI++VYcXM0bMrSysMySbs7tzMWbOc5PWub8cSWyaHaaLbT3N48F/ZS3IG+4ligjuY5WMjDJA2IeWOSM9TQBcsdX0L4g6XqmhX9ncQzCPy77StQi8qeIN91sZIIyMq6EjIyDkVzunadb67FdfD/4gxm/v9PVbiwv3JWS7twcJcI4wVmQ/K+O+DyGrV+J9qDoUPjHQ2R9V0NDfQSwsCLm2A3TQkg4ZHQHH+0FI6Vb8caRL4i0PT9a8OOg13TiL/SpScCQlfmiY/wByRDtP1B7UAcTqXg7xzo3hTXvCujHTfEGk6tHcxpe39y0N7AZwwZpTtZZsbuCNpOPpXQfFnwzc3Pwma30079W0KOC/sZAOfOtsMCB6kKwH+9XY+EtftfE/h2x1eyDpFcplon4eJwSHjYdmVgVPuK16APGte1iUR+EPihp995+kMY4Lu3kjQGG1umjRxvUAny5BGcNk5Dc12PxN0m2vbC3uL1A1p8+n3vAybW5xG/J6bX8qTPYRmvI/DfhHTxfeOvCWr+Hv7VstNvHWKWO5eaSytrpTJC0Ns3yjblstGQ+QcKSK9Q+GN4fGfwktLXXGaW6a2k0vUVcEP5iZik3AgEMcZOR3oAsfBzVLq+8GJp+qvv1fRJ5NJvT/AHpITtD++5NjZ/2q7ivIPA17PpvxKh+2MMeJtNInI6HUrFvJnwO25effZXr9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFcT8Z7u5sfhrrFxYzXUNwvkhXtZTFLzNGCFcEEEgkZyOvWvPZp9V8L+ILXVNZXUbOxhTVLjT7bUJjqVzbRLbwZ3ssjFwXDMF8w4BxuHYA94or53PxM13W/sEza1o+lW1hrsMM2obB9meKS0mYecIrt02BxjHmkFih+UrtPZ3nj3xDHea3p0VvpEV5osdxPd3N2WhtmibBtCrs+FLqxLEtjMbjIyMAHqtFeLWfxH8Q6ta6eNFu9FeWWDUp5p5tOYx5tRAQkYiunVgfOILrIw44GVILp/ibrem6bPJrMukxSTabp+pWk0Fkxjh+0ySL5UokuEU48v/WGSNRnJHagD2eqWr6rp+jWL3mr31tY2ifemuJVjQfiTXJfDfxJqHjnwFcXks0VhqJnubNbm0RGVSjsiyKpeRDwAcbnXPQkVa0b4eaJY30eo6iLnXNXTlb/VpftEiH/pmD8kf/AFWgCmPHN/rvy+BvD91qUR4GpX5NlZ/VSwMkg/3EIPrR/whuta2N3jHxReSRN10/Rs2FuB3BcEzOP+BgdeK7yuX+KOtnw78OvEeqq+yW2sZTE3pIVKp/48VoA8X+H2h6bd2mpvpVpHb2fi3xJ9lhROQdOs9zMTnn5zE6scnJkHevXPi7cTf8IbLpNkxW912aPR4WH8Hnna7/8AAY/Mb/gNc/8ADDRF0zU9B0naMeHfDkKP6faLp90h+v8Ao+fYP7mtHxoL3VfiV4V0zSpraGfTYLnV5GuYWljHyi3jBVWU5Pmy4OeNucGgDlPEuj6Ze/EXwn4aiiv73VrbUF1O7vdQg+7awR5VYm2rGIzI0a7YwBuU7hnmvbq8l+Hen3g+LviY6hcmc6Lp1tp8H755QonZpmG5/m6JFwxY9PmNeskhQSSABySaAOE+K2sXy2un+F/D03la/wCIJGtopRybWADM1wf91eB/tMuK6vw5otj4d0Kx0jSoRDY2cQiiQeg7n1JOST3JJrh/heD4n1/W/HlwC0N4x07SM/w2UTEbx/10kDN9Atek0AcR8MgrXPjKd+buTX7hZieuESNYx9PLCY+ta02ixy3UGo399Na6xJEtuslvcFY1OMlY0bKtkgn5lJOAewxxvj681L4d63c+K9JtLe80bVHhi1WCeZoUtZRhEuyyo5CbcK+FJ4Q+tXPEWp+KtU8J3U0Wm+Hbe28g3K6hFqkl2iBfnWSJVhQuwIBHzLz3PcA9AsUuY7VEvpo5rgZDSRxlAwycfLk4OMZ5656dKzdN1O41TUpGs41XSIN0f2hwd1xIDg+X/sLyN38R6cDJXUvD+naw8VxqVp/pQjCF4pnjbGc7dyEErkng8VY0C1On6TbaeZEc2iCBSp/gXhM+h27c+/SgDD13Sb6GS413emq39kWlsrOYGOGJP4ggXJ80puAkOeuAFBYHS8Nahq2oxNPqmm2VlA6I8DW98bkyZyTn92oAxtwQTnJ6Y5j0fVGkn8QXN7cpHp9te+TC8hCqiJFGHJJ/6aGQc+lcX4h+IOkXNmNH8Ay6jrGrWpUQLocH2iGIrwqyyEiLyz0IL5x0wcGgD0O+tJJdS026g2gwO6yknkxMhyo/4GIj/wABrPvvEE1rq1zbw6VfX1rAiB5rRUby5SCxRgXBJ2mMjaD97ntWBa3vxJ1W0iB0jw94ekZAJJLi8kvnVu+2NFRfXrIe3Wktfh7eyKw1vxn4gvFkdpJYbV47GORmOTkxKJMdgPM4GB0AoAqa5rfhnRPB+qTaZCbzUNdknijsZQxur66bMflMj/PhT8pBGEVewArKm0WOfWPBXgTxTdh9Ls9DSR7fzCqapdRBI9jH+NUALlO+4EggVsXPh/S/COq6Tp/gjRdIstc1RpVOoXUDTNFCi7pGZtwkkJJUBd4zuyTxT9VjbUrq28M/EiwsLuC9ctp2p2QeFGmUE7MFi8E2AzKQ5BAOCCMEAm2weCPEcOn+G9O+0WWpgyPo+nrGjWrKuPPQMVRI2ChWBIG7aVyWbOh4qN3J4i8Nf2QsMerj7RIwuBlRa+WBIjFT3kNv07gHkDB5nThqHw31k2NxDPrtlrl4kdnqUkgN0sx4ENy55ZVQMyv1AUrjOM+lT2yLLJeQwI98ITGjHqR1C/TNAFCK0N9ZPL4o0vSlmjJOEf7Sm0D72541IPLcYOPXmvKbGTw5ouk6RZ+MtE0W+s9XgN3bwwab591bl8yeW8KqzOo3FRKoABABAyCdFbu+8S2mjeGNP1u/uLnVrOLVNa1Hcqva2jIuI4woVY2lPAwMhQ7cnBq3BZwjWb3wz8NbSz0iO22pq+tpEJHhOMrBGWz5k23ByxIQEZBJAoAZ4H1XTvBWk6lca9cN4e0O8ug+j6Xqc+biGLYoIEZJYbnDMIxkqD25Al8Qazo/jKARr8Pda8Rxj/VT3Onx2qjvlHuWjZfqBWrBp/gr4fTLPdyxf2zdcm6u2N1qF2e+ODI3fhRgdgK2NP8AFEuoXkMdp4b1/wCzSNg3c8EdukY/vMkrrJj6IT7UAeUXHgHVHffpnhPVtOQH5Y28SxzBT1JCTJMo59P/AK1Nh8NeKdNk33GneK0t15LaY+jTSg+zNDGxHTgCvXdb8SJp11DDAlpdM/BT7dFE4OcAbXIz+f4Uh8SzQfNqPh3XLSP/AJ6LDHcj/vmB3f8A8doA8pvbfwlrthd6R4m8R+KrbU7uF4YLfxNcTWcfmMpCsFURwyc84G72FQ6Lr1p4E8O6Touq+EYfDWpwmO0k1uWxEun5283HnoPmLbR8rFTlhk4BNezW95ofinT7iGN7LU7XOyeB1WQKcZ2yI33T7MAa4rVfDt54Ft5b/wAJxzX/AIcUH7d4clJlQQ8lntd2SrDk+V91hkAA4oA1/hdepNpmr2Ed7FftY6lPi9jZXW4WdvtCyZX5c4m2kDAypwAMVQ1uw1u31fQNa8T6pYXNhY36g2trZtFHGZUaFZWZpGLMryLzwFDMcZGRj6np+j+G7Cz8deA7eJNBmjU6taacuyK6s36zrGuAJY87sgA7dwPauu8BzWt9FryWV9JqWki9VbV5blrpTG1rA5AkcsWBZ2PJOM446UAUfH7eJ3MtvGkMPhiV0S6u9PaSTUI4Svz7YwuBk8blLMqnIUnpzvxOfQW0bwTZ+GWs21j+0rM6CLQhikayL5jDbz5QiD7u3TNb/wATdZ8Q2mpaDoXhmSzt7rX3ltVu51LG0KJ5jShejkRq+FOPm29s1i3Hhyw8ANpuneDLGC48Z67JJH/a2oAyyhQDJPcSt1IGR8gIBZlFAFrUZdR8BePdX1j+y77UvDGu+VNcNYQmaaxuUQRljGvzNG6qpJAOCPzhtPGV344t9ZsPCEGk6eJWltpJb+/aC+VtuzzPsyIXU8DaWdWwBwO0uu2Os+Dn0LUU8Wavqtzc6pbWNxaXgi8q6WaQI+xFQeWVBLjB4CEHPNdl4l8NeGdaCyeJNI0m8I+VZL23jcj2DMMj8KAINPWLxd4XtBqsbxzRXEZuoVOMXFvMCy+6eZH/AMCXHY1v3NxBC0Uc9xHC9w3lRBnCl3wThc9TgE4HYH0rhJPhD4ViLSaPHqeiXRORcaXqU8DD8NxU/iprMfwxrGgeIYbzSvGNtrOqiHyIrLxJsZ9hJOI5IgrIx7tsbdgZHyigDoLbTb2+8cNFqF1fXek6VDFPD9pSNUkunL8jYi7vLQA85AaTPUDG7Nomn3OkC0sx9lgD+bBJaEKYXzkPH2HOeMYOSCCCQedTx5eWB8vxR4S17TXH3prOH+0bfHqGhy+P95BWH4a+J/hLRfDN1BqWrR2k2ntctHa3atbTywrI7RBEmCszFNox3PFAHaaZrcsqvY3dtcXN/BL9mmktoSIX4B8wOTtAwQSu4spyOcZM2lz21vrNxoumWEcNtawrNNKmFUSSMdqYxyxClmJPdeu7jH0/4h+AktENv4s8OQxylptjalCrBnJdsjdwcsSfeuKbx14Lj8Ya89reXWsSXnk3CSaCs80jyBBEYC0HBAEasu44y79O4B3vxBu7Pw58PddmjiSNDbzJFDGuPNnlyFRQOrPI4H1atjwvYSaV4Z0jTpiGltLOG3cjoSiBT/KvP/CPhzVPEXieLxJ4ls73TtKsudK0a9vHuJBJ/wA/UwZ2VZACQqj7uT35r1OgDz+2H/CH/Ep7YYTRPFLNPHxhYdRRcuvt5salv96Nv71egVzXxF0KfxB4Uu7fT38rVYCt3p8v/PO5iO+M/QkYPsTV3whrsPiXwxpusW6mNbyFZGjJyY36Oh91YFT7igDyzx7eN4U+O+hahG18lrrunSRTw2YQm6ltjvUHd0G1gCcjjqQM1o/BTVDL4p8d2DXGnzCW7h1cCxmEsSNcIVdA/wDEVaHBIwMk8DOKz/2l5INJh8EeJLizF5HpmuRpJCUVt0UiNuGG4z8i4z3x061utPJD8Y/Cl7NZSadLq+iXlpJaysjOnkyRSIG2MVyAzdCepoAxfiWo0O7utXQBToGs2Wu5Uci1uB9nuFH1KzOfrXs4ORkdK4bx/pC6tqDac+0R6zo97prZ7yYRoz+A84/jV74U6s+ufDbw3qE5JuJbGJZievmqNr/+PK1AHV0UUUAFFFFABRRRQAUUUUAFFFFABRRRQBzU3j3wfC8qTeK/D8bwnbIrajCCh9D83H41YsZfD2nXmqXVve2aXF1cQm8ka6DHzXVEiU7mO3cuwKowDu4Hzc81Z/DWK3j0xft6MbK01K1J+ygeYbyRX3fe427SMc7s9RVD/hVt5E0MNr4ghjsGk0ye6iewLSSyWQjC7X80BFYRLkbWIPftQB2p8X+Gg98h8Q6OGsBuux9tizbjIXMnzfJyQOccms228e6NPrN7Cl9p50e206HUP7WF4hgYSTTRFd33Rgw9d3U4wMc84/ww1BriaSPxDDbwpcpeWdlFZytaxTLN5m94pLhwc8jEZiGWLYzjE/ib4bXniW5lvtU12JNTa3tI1ks7WWCNZLeeaVWwJ9+CJtpAkBBXcGGcAA9A0zUbLVbGK80u8tr2zlyY57eVZI3wcHDKSDyDVque8DeHP+EY0RrJ5op5pJ5LiWWMTYd3OSx86aV8nuS5yfSuhoAK8y/aAH2zwno+iEApreuWOnuD0KmXzD+GIzXpteZ/E3/SviV8L9OJGH1G6u8f9cbZiPf+L9aAOg8Ej7RrPi/UDz5+q+Qh9Ehhijx/32sh/GuW03U5L74seOpzYT3Gn2VrZaQ81tKwnj+WSVyiqAxAMwyVO4FQVB7dT8MPn8KG5Oc3d/fXWT3El3Kw/wDHSAPYCvLvC+siPWfiHPYnWo7iDxJM8U9pp81zCWjiRHjlCYVl68EgjhgQcGgDs/gfDE9p4t1G3aeSC91+58iWeR5JHiiCQrlnJYjMbYzyAcVofGXUrq18GnTNLfZquvXEekWjf3GmOHf/AIDGHbPtWR+zZqB1b4U2eoyJsmu728uJADkbnuJGOPbnFXb3/ie/HDT7bJa18NaY94+OgubkmNAfcRpIR/vUAdvommW2jaPY6ZYJ5dpZwJbxL6KqgD9BV2ub8beNNG8HWkD6rPm7un8qzsovmmupDwFRfqQMnAGRkiqA0nxTqtu9zrOtS6ZlSy6boqxZHHCPPKrFm91EYz7ckA7GWNJY3jlRXjcFWVhkMD1BHpXnOpfB/QnWX+wL/W/Dm+UT+VpV88cHmBtwbyWzHwQDgAVNpvw9s79Z5vEGrazqE5kI8lNcuhHb8DKfI6hj1JO0degAFYHiDwVbeHtTNzceJPFth4dnKRpLb67OVsJTxh1kZtyOcAHkhmwRgggA1v8AhB/HB/dt8UtRNuP4RpNqHx2+fbmoh8K9RkmkkufiL4wLyqqytBNDCzAZxgiPjBY1m2h8eWd5CPB+r33iDT2cKy+JNOFssa9288eXI3tiJwfpW1H8Rr/RLyKx8eeGb7TJZAxivNNDahbShR8x/dr5ifQp070ASaZ8GvBVpsa80yXV5wxdpdVuZLou5JJYq7FMkkkkKM5rn/GuseIbHxBL4f8ABul3S2tkIFWw0j7PbSOkgJMzSSoypECNgCqCWVssBgV6J4e8aeGvET+XouuafdzjrAkwEq/WM4YfiKta74c0fXjC2r6fBcyQZ8qRhh489QrjDAHuAeaAOY8D6xqy6lrWl6pLcXrWNpBdfvzE00Eknm7rZ3iARiBGjAgZxIM9ifF9V8f+K5b5ZbfRfE2utJDbXMlxpOovBFEZ4kkSOGKONgwUNt3PvLFWJxyB9LaLo+naHYiz0eyt7K1DF/LhQKCx6scdSe5PJrmE8DNpWpSXvhXUxphk35t57RLmKPe25xHkq8alvmKB9meQooA5zSH13xFDbWd/JNbeILCOPWNJvL62EUuG3xPBdRrgZ+8jFMBldWUAit++j8R+JZ9Ks7/Q49JtrW8gvbm6a8SYMYXDhIQvzHcygFmC/KTxk4ra8P8Ah5tLvrvVNS1KfU9UuY1ikuJlWNI41JISNF4VcsSepJPJOBjJ1D4iac93Lp/he2ufE2qRtseHTQGhhP8A01nOI0+hYt7UAXPiLpOoalpNjcaLHHPqWl30OoQ28j7Fn2Eho938JKs2D0zjPFY8198RNSvJvsWl6VoFkYVUzalcC5eJ8tukRIuG+Ujh2UZA98zpo/jbXcPrevweH7ZhzZaJEssoHo1xKp5/3Y19jUg+F/hqbadYi1DW5AcltW1Ca6U/8AZtn5LQBzOk32m+GtMl8L/DIR674mmbN1ejDxQyngz3MqjaNvaMc4AUADpswWs/hqx07wT4UmMms3Eb3V5qdwu8wqzHzLqQfxSO5YIp4yD/AAoRXeafY2mm2iWunWsFpbJwkMEYjRfoo4Fcp4UV5r/xrqcbRLfS37W0byfdRIIUVFP+zuLv/wADNAFbSbfTPDNxeSaXavMY3C6lq91ma5vJe0SMPmlfOBgYVSQqgkFVvzeFNPvtY8zVVjv45UaVrPUXa5OSf4UZzGijIHypzxz67elQW9pBa6fbxmSK3hV0nJVgxORuznO48knHOTyeajt1trGG91e9tvsUzhpLlnfzCqoAuQRnAKopwPyzmgCndeDtGlns5IbZrJLUllhsXNsjn5cbwmN2NvAPHJrK1TUmur2OSWbxN4edsRrJ9mjlt2OTjf8ALIqA55JKdhkGtYeL9Nb7tvrZB5B/sS9x/wCiqZJ4rSdRHo+lave3bcIktjNaxj3aSVFUAd8Zb0U9KAMLXbHVmEtxqGneZqlmge21rR8Ry+XuG5TE5JJHDGIl1cDj5sLXa6XLcNaxxag9u2oRoouPs4ITdjqoPIB645x0yetEsSf2lbPvDS+U8ZUvgspKncV6HBAHTjf2yc5eh3M+oyW11CpitLeS9sXiEhIPlz+Wj+5/dH6bzz6gHMT2978O9VvLzTrKe+8G3shnubS1QyS6bMxy8kcY5aFj8zIuSpyQMEiufS1tbq1v/wDhUXjnSLKK8Yu+kSMrRRyE/OY8fvLdjzkYIBOQoPNez1jaz4V8P64SdZ0PS79j/FdWkch/NgTQBzGheHvEereMbPxJ41/s62OmQyRadp9hI0qxvIAJJnkZVyxUbQAMAE9ya2PGXh6/1O+0jVtBvbez1nS3k8o3URkhmikUCSJwrAgEqjAg8FBwazm+Gek2f7zwveap4bnH3Tpt03k57ZgfdER/wH8ajOpeNvDWf7Y06HxRpy/8velKIbtR6tbs21+33GB/2aAM3xBpGsaXYan4z8Taha6nqukWU02m2dvA0VnZvsOZNpZmd8cFiRgZAAzXmnxB8F+P7e7n1Cyg8P3dov8AzE72BdRu7jJH31kRtisTxHAnHyqAfvV7toHjLw54mMtrYajBJdDKTWFwDFcJ2KvC4Dj05GK4nXX+F/h+V9O1LxN9hhQ7W0uPXZ1ij/2fJST5V/2MBfagCv8ABOLWBo2uWm2GylS0hQxW4H2a21A+d5qRAZVQqG23Kvyh94xnIrnbPQ7W2ubePVbXUmj8kJf6BJ4YN3Pez+WQ8n2/B3EvhhJvAGMEjt6HpHxL+G9jp0FppHiHRILSIbIra2YLtHosYGQOp6Vc/wCFp+Cv+hgtv++H/wDiaANnwPaajY+ENItdbdn1GK2RZt0nmMDj7pf+IgYBbuRnvWxPBFOgWeJJFBzh1DDP41wV18VNInm+y+FrDVfEuoFQwh0+1ZUUEkAvLJtRVJBGcnoeKxdX1P4i6hqWkWE76R4YTVJiiwWrfbLxY1G6VjIwES4XphX+YqO+QAd5q1h4W0u2kvNXtNEs7cHLz3UcUaj6swArlj8XfAGnWsq6fqXn29uCWGm2E00aAdTujQoAACevQGppPhN4fkv7fUp2u9R1WAEC51eY34fPqkuVXHbYEx2NW5rG71PxHBoOqT2j6Va263skFlC0KynftjSRSzYTKOcA/MVweFIYAZJ8S9Ngt2ubrRPFNvZIC73MuizhEQfxEBdwGOelXdJ+I/hLVLuK1t9bgiu5eI4LxHtZHPoqyhSfwFdFq15Dp+lXl5dKWgt4XlkUDJZQCSAO5NZtxo3h5tKt/D97Z6e9lIpWGwuArqVHJCK3YZ4x0HTAFAG7XB+Bv+JJ418V+GjhbdpV1qxX/plcZEqj2EyOcf8ATQVz1jfar8PbzWFj87UvA+m3awPC7NJdaZEYIpPNVjzJApkYFT8yhcgkAit/xbcRWnjLwN4jtJUktbuWTSZZYyGEkVxHviOe48yKPB/2/egDA/aqsnuvgxqk8XEllPb3KkdRiVVyPoHJrLnazfxX4F8R2txc6ndNrA0+bVJipFwJbObKRbQF8tCP4QBuz1YMa7z412/2r4R+L49u7GmTyYzj7iFs/pXm72NlaeF/hLdyaxq08t1eaZNbwXErNDyig4+XCkCTgE5PPXmgD1zxefJn8P3h+7bapHnPT96kkA/WYf54rnvgqPsui+INJACx6Vr9/axKOyNL5y/pKK6Lx3x4fV/+eV9ZTYzjOy6ibH6Vz/w//wBH+IfxIsl4j+32t2o/662seT+aH34oA9AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzXxd+++Onw9ToLey1ObPXduSJce3rXpVea+KTs+PHgUtwH07UVUn+IgREge+OaAOg+FX/JOvD7d3tVdj6s3JP5k15d4Lv4tF0L4qPdXe6G+8R6rHa2kcJaaWXaNxXBJIGOeMKFLEgdPUfhV/yTjw5/15R/yry34cwfZl+Lskmkgs2tasDqm6PCIVVxDyd/8AFu4GOaAN39k//kiWj/8AXa5/9HNVjwhrdppNn8SfHGqkrbnVZoww/jhtUWFAvqSyvj3aqX7LU6WvwI024lOI4nupG+glcmsPR7Q3Hwq+FOkXCgpresRXt2jcrKmZrtlPrlgtAE6aZLNp19qus21xqvj3UJLW7ure1iM39lWqTRyi2XsmEBO378jZwGr1qFrzWdS0zVtH123/AOEf8ss9rHah2uWIYcylvlAJHyhc5Xk9RWnqt9Dplk95dPHFbRkGaSR9qovQsT7UzT9ItNPvr66s0aJr1xJNGrHyzIM5cL0DNxuI64BPPNAHOX16nhrxnK32e5mt9ag80RWsDSt9ph2qSQo43xsg3HCjyuSMjPQa3p39s6ObYu9tIzRTI+AWikR1kQkZwcMoyM81SvtetBrUVjp1udS1ZGEcohAItEYqWMsnROADs+82BgHqK3ijxcujCeO3069upo3iiaVomjtomkKhS8xGNo3AsVDbR1FAHUVwmpNe+KfEl9orpJosuimDULa6AjmeYu0qxyL1CJmKVWU4ZlOMqCc9PollqFsJZdW1Nr24mwSiRLHDDjPEagbsc9WZj9OlOB0qPV766Etquox28aXTeYN6QguybxnhctIQT6mgDDXRNM8X2U0XjDw5YTX9rIYJWmtg6sQARJC5GdpBBGDlTlTyDXntl4H8MeHZ20XW7jxFBcIDJZtZ6lesL2EEDcscbE+YuVDqBjkMAAwA9h0/V7TUZSti0k0YXcJ1ibyWGf4ZCNrf8BJ6GvN9du9W8TfFi80PwzenT4NN0+OLVdSWMNJb+Y28RQZ4DuoUliCFAHcAUAc/408O+CtN0W3E154g/tW8eNbWwuNVvZboK0gVpFt1kLkhNzYx2xjPFTt4A0nVVxofgbWIv7l5rWuXVuiepVBM8ufYqmemRXqPhbwjovhiOT+ybMLczc3F5MxluLhv70krZZj9Tj0xW/QB5rofwntI9MhtPFOua14iiTJ+y3d5ILUZPQR7iWUdAJGevQ7CytdPtI7WwtoLW1iGEhgjCIo9Ao4FT1yuueOdJ0vVH0uKRbzU0UPLbxzRR+Sp6GR5GVV/3clscgEUAdVRWDo2p6rf3YFzaaVBagEt5OoGeX2yojCj67jW9QAVxF3eDwZ4nv72/BXw7rDpPLd9UsrkIsZMv92N1RPm6Bg2cbga7ekIDAggEHgg0AYen6YbTQLC28O6iiwQKBBJKizo8XO1DtKkqAQFIIPAyTzmY6hcWGZtduNLsrRQfnMxG48c5bAH05+tZ0nw/wDCjSvImh2duznc/wBmBgDH1IQgE+9S2PgbwtYzefbeHtLFx189rZHl/wC+2Bb9aAKt58QvB6xTRw+M/DENyFIUy6hCwRuxZfMBIz2yPqKj07V9Vvj/AMS3xB4V1X0Fujpn1HEsnp1/SuvSNI4xGiKqAYCgYAH0rH1Lwn4c1PP9paBpF5nr9os45PT1U+g/KgDPfSteubqW5afRtKnlQRS3Vpama5MYJICyPgDBJxuVwM9OaqeFr6KfxCml+GZ0fw3o9q0NzImJBNdMy7U8w5LMiq7OQclpFyc5q1/wrnwaRtPhnSmT+4bdSuPTHTHtXS2Vpb2NrFbWUEVvbRDbHFCgREHoAOAKAJqKKKACiub8Y+IbLSbXyn8TaFod8SGR9UZWTbnn5DLGTn13CvP7j4vR6UxaTW/C3iaNT88WjSvFckZxmOItIrn2Lr7GgD0zX/C+g+IlVde0bTtR2/dN1bpIV+hIyPwrhrT4VS+GLq4n+HevNoUczmRrG4s0vLfcf7u7EiD6Pj27V2Hg7xloPjGze48P6jFc+WdssJyksJ6YeM4ZT9RXQ0AeRai/xF0TXLDWb3w5o2vLbJLFNLokxgneJwpOY5c7jujQ4VieKsL8XrS8g1X+zoEh1OxtJLmXR9XElleR7FLHC7WEowCTtOQB3zXqtcj8S/AWjePdAmsNWgRblUP2W9VcS2z44ZW64z1XoaANjw9o50uKeS5uWvNRunEl1dMoXewGAFUfdRRwq84HUkkk89r3hppPDOvXmoQnU9ekilngaLIeJkDGCOA8FCpxgjBLEnvTvg94hvvFfwy0XV9QaP8AtCaKSKWRRlXeOR4i+OOGKbu3WtLUNfutEjQ61p7SLJIkEEtiwcSyu21EKttKFiQBklRnlhQBtTXCWGnNcX8oCQx7ppdvHA5bA7d6WxntLyFb2wlgnhnUFZ4WDLIo6YYdR1pb67hsbWS5uSwijwWKoznrjooJNcPaWM2qeI72+8LTXmhWflEzStaFYr65YghjDKoyqgfM67S+8Df8tAHRaxpN9eanZypfl9NEyPcWMiKFITJUq4G4YcIxBJBxjgZq9qwWCI3kWni9vUwsSqqhyScD5j91RnJPYZ4PSoNatNUmW3n0jUEt7uDOYpo90FwDjIcD5l6cMp4zyGHBo6L4mn1O6Fp/Yt9FcQyGG8YlDDbuBnhyR5gORjaCcEbgvIABDF4d1WO6uL+LWlW9vCpureS1WW0cAbQAvyuCFGM7+epB4A84122l0Pwj448NQBhH4ba38QaRnrHbCTzwi/7kkEyD/Z2ivQ7fxnpaatrMN3LPFLa3AtUiWOWUyhVBLIiqcnc7Ahc/dGfSuehK+LPiB4mWG0uobYeHo9PkNzEYmLSyTMBtPI+XnkA8jjmgDq/Hskdz8OfEUkZDwy6VcspxwymFq8QtdM1uz+CXhCS2uFvdIuJNInX7TKfO02b7RCN0fB3xsTjYSChJwSvyj0ix1EX37OSX87AF/DBaRmPG4WpDH8wa4fRbXd4F+Gq6hYWd9GLjTIbPUbO63oMSK7RyRkjDDa3I38qc7aAPY/H/AD4N1XPaHP45Fc/4S+T4w/EFAfla20uUj/aKTKf0Ra6Dx9z4R1BAPmlVYl+rOqj8MkVz/g7958XfiJITykemQ4HoIpG/P94f0oA9AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzT4gfufi/8Lrk8IZNStmOM8vbAj8cxj9a9LrzL434tH8Dav0Fj4ktBI/8AdikDRsf/AB5aAOi+F3y+DLeHvb3N3bHjHMdzLGf1WvL9EsrZviT8RtHh0c6tqS6lDd20F2Geyt2ngRmnkz8gOVz03nGF7ken+AP3E/inTzwbTWp2A9plS4z+cx/WvL/E2m2tp+0Fq7X2i6jqUGq6NDef8Sydo5ojE4iL4V0ZiBtHyEtjoDzQBT+BV5Lbfs1eJzMDBJYjUlKnpGRGXIA9ASeK6zX/AAte6r8EPCqaLHN/bGi2tjfWcUczRO7RxBWjDg5BaNnUHPUj615/8OB9n8D/AB18OWsN5FDbG8uLeK8VkmCT28gTfv5yVjXluT1PWvoTwbKs3hDQ5YzlHsYGU+xjWgDya7u4PFngu4sfDfjTWp5dUB046TdpBJPbyOpEiS74jIqou4sSScKdpyRXrOreHbDUxG0izQ3UMZiiured4ZkX03qQSM4O0kg9xWL4y+G/h/xVeR6jcRT6frcX+q1XTZfs90nGB84+99GBrEXwl8RNNwuk/EOK9gX7kWraUjt+MiMpP5UAdD8K2Q+ANHURJHPFGbe6C/xXMbGOZie5MiOSTyT1rVS5sfEml6rawkSwB5tPm3plSwyjjHcAkg/QivM9L8OfF3SYbqCx1nwb5U1zPdEvbT5DyyM7YHQfMxOOfxqx4f0X4s6Fo1rptnc+A2hgUjzJYbwvIxJLO53jLMxLE4GSTQB2HgzTF0vR9GlvrrUYb2e1ija1vb+SbEpjDMoDscsNrdPQ44qbxH4d/tHxL4e1WOG0kNjLItwJl5aJkOCpwcssgRgD79DXFa7o3xZ1rTZLO6ufAiKxDpLFFeLJC6nKujb+GUgEfrkZFJq+v/FPw5oV1fatpvg65gsoTLLcQ3dwm8KM8IUzuPp6nAoA9C1TxDpun6tZafc6pYW11MdxhnkCuyEMF288EsBjPUK2OnHCa9Y+JPBHjXVvE3hzSm1/RdZ8p9R06BglzBLGgQSw54cFQMp1z0qvoVl8SV0iaC40Hwl9ov3a4vZr++ml81n6qYxH0VcKF3YAUDNVpZ/HVh4l8M+DpdS8O6ZaahHOxbQ7FxNaQwpn5fOZ0ALMqA7Pp0oA27f42eCt/k6peX+j3oBL2uo6fPDIgHXPylf1qw/xb8P3AK+H7TXNfuB/yy03TJmx9XdVQfi1bXh7wppPhaW51OS7u7vUJUEc2papdGWUpnhNxwqLnHyqACccdK6igDzV7Tx94y+TUJY/Bmiv96G0lFxqMq9wZR8kWfVdxHrW7pPw38HaXYLaQ+HNMmTJLyXVus8srHqzu4LMT6k11tRieM3LW4cecqCQr/skkA/mDQByVz8MPA1woH/CJ6LCw6PbWiQOPo0YBB981llL74e6zpqi/vdQ8JahcJZNHeytNLpsznbEyytlmiZsIQxJUspBxkV6LXP/ABB0R/EXgrWdKgYpc3Fs32dwcbJl+aNvwcKfwoA6CisbwZraeJPCek6xGAv222SZk/uOR8y/UNkfhTPHV5ead4J8QXullRf22n3E1uWxgSLGxUnPHUDrQBi2PxR8JXPivVPDkurQWmrafKYnjuXEayEAE7GJwcZIIzkEHiuytriG5iEttLHNEc4eNgwOODyK+HPhz8NZb9577xL9quEufLMkMX+tuC5EiRDcM+ZKQpHTCbpCQoUv7Tb+E9DmlsjB4d0K+vJZZfJZbZTHe3JG18cZ+xW6kgk/fYLxuxvAPctQ1Sw06NpNQvrW0RRlmnmWMAe5Jrl774p+B7N5EfxNp0zR53i1k+0Fcdc+WGx/9Y+hrzS0+Gei6/f2dhovh7TF0K1Rln1mSyjV7yQ/LI8Zx0++qYwqklwPli3dxqehQWVhBodvHFdeINTlW4cIhS3hEeB5jRg4EEeRtjP3mxnJLNQB0Xhfx14c8UX09louo+dewIZJLeWGSCQKCAW2SKpIyQMgY5HrXS14/qrRaRrXh/U9Jkhj0zRNQXSJLidyZNQlu5kjuPmyAdjkSMxzl1fpsOfYKACuK8e3+oXmp6V4U0G7ksr7UxJPdXsWDJaWkeA7LngOzMqKT0yT/DXa1w3gzGrePfGOuHDRwSxaLbMeoWBd8uPrLMw/7ZigDW0DwR4a0GMDTdGskl5L3EkYknkJ6s8rZdifUk10KIsaKiKFVRgADAAp1UNe1a00LSLnUtRdktoFBbapZmJICqqjksSQAB1JAoA5jxh8M9A8S36aoEuNK16P/V6rpkpguAf9ojhx/vA1irb/ABV8N/Jb3Oh+MbJen2kGwu8dhuXMZ+pAJr09DuUNgjIzg9RS0AeYzeO/HUEL+d8LNQMyqX2xatbSKQBzgg5J4OBjJ49a53R9Q8U/GCyeF9a0fw5oEi4urLS7n7TqRXo0UjEAQ+h+XPYivV/+EitH8S/2Hax3F1dxpvuXhQGK0BBKiViRhmxwoy3IOAOa5D42eFtKvvA2vawNLtjrNlaPcxXsaeXcKIxuIWRcN90EYzQBs2l3baLaReG/BukPe/2aiW+xZfJt7YgAqskpyc4wSFV25BI5zWhZvZ+KbO3kvLaWGfT7wPLayNhobiPoGxww+YMD0IKsO1cNZ+AvC0fh9dY0q88Y6LYSr5rw2up3qucnBZk3Mx55yMjHzZI5rnv+EN0e0+JenWH/AAlHiK50rxFYG4j2a/MWmuI8EM5DAsrRfdOf+WRoA9iudYI8RW+kWcHny+X9ou5N2FtojuCE+rOykAeiucjAzaghFjLf3Fxdu0dxMJQJWwsI8tE2r6DKbvqx9a4tfg54GyWk0aWWRvvSS39y7t9WMmTUkXwe+H8bh/8AhFdOkcc7plaQn67ic/jQBueD9XN/bXlpd3MU2oafcPbzMpHzrw0b8ccxvGTjgNuHasvTPGHgrSLR1i8T6azXNxNc7JLpDO7u5cgIPmO3dtAxkKAKX/hVfgLbt/4RDQ8Zz/x5pn+VdRpmlafpNusGl2FpZQKNqx20KxqB6AKAKAOBg1DXNR8RX1z4H02SHT9QjBub3WIHt4VnUBVliiIEshKAKQQinYhDdc9l4X0GLQbKWMTy3V5cym4vLubG+4mIALEDgDAVQo4CqAOlbFFAHhOs3P2P9lLUxuwVtZ7NSB94m5aIcepyPzq9/Y2oDxl4Khl0f+xbZrzz54hfrN57wWsgV2iVcK2dgLh+RgNu+XGVqcMupfAjw7o9tD58ut6wkUcPmeWZEF3JcEbsHb8kROe1dl4Uj0+/8f6ZqWmSX8yjQpJpDe3MkzxmeaPapDsdhH2eQFVxghuvYA6rxz82jW0Q5MupWKbf7y/aoiw+m0NXP/DL/S/FXxF1LJxLra2gzxnyLaFP55H4VveKGEmt+GLYkbftkl1KD08uOCTnPbDvFWD8Ch5/gBdWYYk1q+vNUbjGfNncr/45toA9BooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArgfjzpsuqfCTxIltkXFtbi9iYdVaBhLke/yGu+qK6t4ru1mt7hA8MyGN1PRlIwR+VAHD+DtTjvPGEt5Dj7N4g0Wz1SHHQsu5JP/AB2S3rC+M8t54f8AF3gfxTpVvHPdLdS6M0UknlpJ9pQiLe3ZRIgOfeuf+G1xLpXh7w0t4xN14U1u48NXzE4/czNsjP03m156YBr0b4x6BN4k+G+tWVjuGoRxC7syoywniYSJj3JXb+NAHnOh+G5dA8feK/DpM8z634VWW4upSf8ATbuPdHJIp5PPnZI7Z4GBXpvwjvBf/C3wlcBgxbS7ZWIx95Y1VunuDXl9hqGhwyfCzxPo84Nxqd/K15HJNvmc3iGORnJOSqzJEmegIUCu7+Bn+jeB5NGP+s0XUrzTW+iTuU/DYyUAehUUVwXj7Vri78R6T4Q0/U/7La/hku729SQJNFboVXZCT0kdmwG5KhWI5wQAbXirxv4c8KhRrurW1tM3CW4Jknc/7MS5c/gKwV+J8Uo3W/g/xrNEfuyLo7KGHqAxBx+FGteEvBnhHw7LfpaxaRJZ5mj1C3YLeGXBAxK2Wkds7drbg2cEHpWxo114stIbBNdsLK/MqxrPNYSeU8DEDcWjc7WUHOWV8nsnagDJs/irok6zLLpviW2u4pPKa1fRLl5N/B2/u0ZckEHG7uKp6nY+IPiMBbXlveeGPDCOJMOyi/vHU7kOBkQorANzlm2gEAE1uXPgLTb7XNW1TUJrxrm9ljeJrW5ltGt1SJE2ho3BYkqWyfUDGFFTapMnhrS9O037fqAF/cGyj1GeRZpLeR0dkZi+QeVCjIPLLkHmgCn4D8/WdAs9d124OoXqeYsXlptiHluyCRIwT8zhd2TkjcQMDiqPg6703xP48u/EejRQmyj0uCH7QqKGkmnxK6sR1ZY1t85PG7Hata7l034beBJHRrqa1sYwkEMkhklmkOFjiT3ZsAADqal+Gnh+Xw34NsbG7Cf2hJvurwpjBuJWMkmPYMxA9gKAOivbS3v7SW1vYIri2mUpJFKgdHU9QQeCK5Hw3G/hnxU/hlZZJNJubRr7TVlYs1uI3RJYAx5KAyRsuTkBmHRRjtK5Ev8A2n8UYxD80Gi6bIk7DoJ7l4yq/UJCSR6SKe4oA66uZ1C5lf4jaJZwTSCNNOvLi4jViFP7yBY9w7nJfH+61buqX9rpWnXN/qM6W9nbRtLLK5wEUDJNc54FtLu6e+8SavA9vf6sU8q3kHz21omfJib0b5ndh2aQjtQB1lFFFAHB+B2/sDxf4i8KSfLA8h1nTRngwzN++Qf7k2449JFrt7u3hvLWa2uY1lgmRo5EboykYIP1BrlfiLo17dW1lrmgRh/EGiyG4tY92PtMZGJbcn0dRgHswQ9q2/DOuWXiTQ7TVdLkL21wuQGGGRhwyMOzKQQR2INAHkHw58uy8P6RZ2Wn3Mep+FopIdWdLQuYjGxLxwoRhprgBSWXJ8ts5BZc+i6pbW02mJNr1uNIuL+1S0uJ4Z1PkqZBttlbg7nMhXKLye+QlR65De+HPE0niKwtZ73Tb2JIdTtbdS8qMmfLuI0HLYBKuo+YgKQCVwcUeJ7Lxil3NY6hYw2UcZudNubiAt5IhYpPeEsNqFd5CK+OVLEYPABr+INWn0zULeGwtZotO03bGlvCuw39w6FYrWMdNig72bouF5wr45NbaC/Nxqeva6LCFpSTqETBftc8asXMW7pBCgkWM4+9vl5YKx6Pxp9hu720tjcvGLKzee91BpSDaWjjDEEdJZQjKGHzBRKQQcA+d/E/UF0LSrLWbiFor8xbdM0YRrstYFZBApTq0hYK3ljgsFzuWDkAxtU1CLxH8SPCHhW1sAiR3cU62+TjTbWA+Z5eO0rbFMjc4J8vOVYn6brw79nD4bal4fS78WeLhJ/wkWpxiOOGY5e2g4OH/wBtiAT3GOeS1e40AZPizXLfw34b1HWLsFobOFpdi9ZG/hQe7NhR7kVn/DbRbjQfBmnWmoEHUpA11et63MzGSXnv87sPoBWBdSjx741is7c+Z4Y8PXAmu5QfkvL5eUhH95YuHb/b2D+E16LQAVyPxNYW2g2eozAtZ6dqNreXQ9IUlG5z7JnzD7JXXU2aNJonimRZInUqyMMhgeoI7igBVYMoZSCpGQR0IrH8Z6tJoXhTVdSt4xJc29uzQo3R5cYQH2LECsHw08vhPWoPCt47yaXcKzaLcuclVUZa0c+qKMoT1QEdUJPQ+LNI/t7w1qWliUwPdQNHHKBny3x8r/g2D+FADPCOhReHdDgsY5GnnyZbm5cfPczscySt7s2T7cAcAVo6jZw6jp91ZXS7re5iaGQeqsCD+hrK8Ha8Nf0gSzRfZtSt3Nvf2hPNvOv3k9x3U91KnvW7QBwnwk1DUpNFl0XVoClzoATTJpW6zSxg/OOc7Wi8hxwPvnrjivpXh7w9qGseL9FaKDebyG8At5SksGY1KshU7oyJRMw24wzt6nN3xOJPC3iIeKoI3fS7iNbbWY413GNFJ8u6AHXZuZX77CD/AAYN678QWkt1Z3umxfa7ONitzqUMPmRxwlScK/8AEC4jzs3AAHdjGaAMOeTxPpSzwab4gl1OO3Dc3vh6S5lIHYSRywo54I4BPrVrQtL8U6xo1jqOpeLriyubmBZzBplnbCFCwBC5lSVmAzjO7nsRXbrLG0IlWRDEV3BwRtI65z6VmajodpqNpbWrS3MGnxLtFtaTGBJFwAoJTDbQB90EAg4IIoA5CTUfFljr6aXo+pad4lkTLXUd1bm2Nqu3K+ZPGSgZuAE8ssc7uFBNdL4b8Sx6vc3FheWc+l61bKHmsLgqW2E4EiMpIkjJyNw78EA8Vk+GLZdN8YavaeHLCzi8Pr5KXIifyxDdhGLbIwuGyn2cNyMH15xW8eSanY+JdA1v7DaJpWm3axT3guSZmhuB5TKY9mAgdonJ3/8ALMHHWgDv6r6jdJY6fdXcv+rt4mlb6KCT/KrFcd8YLqS3+GuvRwHFxeQf2fDjr5lwwhXH4yCgDz3womopbfDy202zS+v9H8NNrDW0kojEs84SNRuOQrbWueTxn0HNdn8LbaGTWPG+r20Cww3esvBEqgAFYFVHIx6zGdj7knvXL6hqV74fbxn4q0KSxuI9O8jQILOYEtIYVAQK4PyuZrhxtKkMAvK9a9M8EaEPDXhPS9I8wzSW0IE0p/5ayn5pH/4E5ZvxoA4j4uatLYWnia9tcmew0T7FbBerXF7KEUD3BiiOP9qvQPC+kx6D4a0nSISDHYWkVqpHfYgXP44rym4/4qfxd4ZsUYPHqWqTeJrraMj7JbBYrQ/7rkQt9c/j7TQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeL+INHjtfirr2gzP5GneO9KLwS/887+3XGV99hV/cqK9N8Faw+veF7C/uEEV2yGO6iH/LK4QlJU/wCAurD8K5j43aLd3/hFNX0VN2u+H7hNVssdXMfLx+4ZNwx3OKZ4G1u0fX47ixkB0XxZbjVrHn/V3Kqoni9iRsfHqJfQ0Acpd+F3t18e+B9BtrG0vL+SLWtOmZAD5bupbGMZMUyEqCeN6duD0ngKeXT/AIm+KNOuoHtP7ZtLXX4bZiCY3KCGdT7hkTP1+lanxPtLmzi03xZpcLTX2gSNNJCgy1xaMMTxj1O0BwP70YrnvGN5LZJ4E8fzz2cyWkwt7+4tNwgazuwE8wbudqv5Lc9OfxAPWa8u8EaLp3ijxN471jX7C01CQ6qdLhjuoVlWKC3RQAAwOMs7scdcivUa8Y8UaVY+FfGGqXniHTb248KavML5NQsRKJdLvNipIWMJEipIqId46EYPUUAeoauNIk+x6LqUMDpfLJFDbvFlGCodwHGB8hPpxnFW9Hs5NP0u2s5bmS7aBBH58v33A4Bb1OMZPc814XZeNfA5+ImkSR+N3n0zS4pLkS6jqLyI88iPEqIGHVUZyWYk/MoHVq67xx8TfDv9gLd+HPG+jR3UNxFvjju4JHkhZwkuI2OWKozOoHVkUcjIIB6BaNqEF3dyard6f9jeRUtI4oWjdATgB3ZyHY5GAFXHvms3XtB0a/ubm+8Syx3tjbRlvst6UNrbLtIZyhGCSN3zPnAzjGTnkrnxL8PPDs0N5d65Br2uf8sGEw1C8kb0ijTIjzjoiotM0LwlqXjHUL3W/G8M1lpl3Ok0HhwsCrKiqEa6I++3GfKztHGQT0AIfhz4bg1vVv8AhIWW+XwvazeZ4d0+6md1X5cNdBXyQG/5ZqThVJIA3cetUiqFUKoAUDAA6AVgeMtcn0i0trbS4o7jW9Rl+zWMMmdm/BLSPjnYigs30wOSKAKfi7xLcWt7DoPhyKO88S3ab0jfPlWkWcGecjog7L1c8DuRq+FtCg8P6X9lilluJ5JGnubqbHmXEzfekbHGTxwOAAAOAKj8J+HoPD1g8Yme7v7hvOvb6YDzbqXHLtjoOwUcKAAOBW3QBxeqw/8ACT+N49Lm+bRtFWO8uo88XF0xJhRvVUC+YR3Zoz2rtK5PwkRH4u8bwPjznv7e6X18prOCNf8Ax6GSusoAKKKKACvPdc07UfBuu3PiPw3aSXukXr+brOlQjL7sc3UC95MffQffxkfN19CooAo6Fq9hr2k2up6RdR3VjcpviljPDD+hB4IPIIINczr3w18P6td3N5Et5pd7csHmm064aETMCCDJFzFKcgZ3o2e+a5fx/PJ8M/EmneIfD9pLNYa7fLZ6npsZCxvM4OydMkKkpK7SSQrZGcHmvTNA1iy17S4r/TZC8D5UhlKvG4OGR1PKspBBU8gigDjE8Aa1HNqBj8b6iY76YTztJYWjysQqqvzGPaMBFAwoAxkDPNbPh7wFomjal/ajRz6nrhBB1TUpPPucdMKx4QY4wgUe1dVRQAV554g1nUfF2qT+GvB1y9taQsY9W1yLkW/rBAejTkdT0jB/vYAg13xBJ438Q3ng/wAIaoIIbMKdc1O2YF7dWJAt4T/z1ba2W6IAf4uB3mhaRYaDpNrpmkWsdrY2ybIooxwo/qSeSTySSTQAmg6RY6Do9rpek2629lbIEjjX09SepJOSSeSSSav0UUAFFFFAHPePdHl1rwxdQ2R2anBi7sJP+edzGd8Z+m4AEd1JHetHw7qkWueH9M1W3BEN9bR3KA9QHUMB+tXZpUgheWZgkcalmZjgADkk1zXwtRk+HHhrzFZGbT4X2twQGQEA++DQBF4p8PXw1RPEXhWSKHXYkEU0ExIg1CEHPlSYB2sMkpIBlSSDlSRWt4Z1618QWDT2yyQzxOYbm1mG2W2lHWN17EZBz0IIIJBBrXri/HNlLo8//CYaOjfbLGP/AE+CMcX1ovLKR3dBlkPXOV6MaAO0IyMHpXIWM6+DJhp1+4j8PySbdPum+7a5/wCXeQ9FUHiNumMIcELv6u2niureK4t5FkhlQOjqchlIyCPbFLNFHPE8U0aSROCrI4yGB6gjuKAMPTNVtr7wnpep6Tpc8+nX9tHcJbRrGrLFIgcZUsF6NyAT7ZqGw1zw7pkFrp+n+Xas8vlRadDbtHKrMSSfIwGVfvMSQAACc45rPttB17wxmHwnPZXmjDPl6VqLtF9mH92GdVYhB2RkbHQEAADMvYfHVx4ts9Yi8P6GFtrOW1hjm1iQBGkdGeQ7bc54jUADp83rQB0HjrWX0OLRmj+0pDc6kkVw1pavcS7AkkpCxorMdxjCnAJCsx7ZHGfFvxfdXXw18THTNAvxZfYJUkvtTU2KIWXauyNx5rPkjAKKCcfNWrr+lfEHXtLltZ38KWTErJE8ZuJnhlUhkkVjtGVYAjK4OORg4og8C6z4g1KyvviJrNtqENnIs9vpOnW7QWYlXpJJuZmlI6gEgD0NAHoVs7S28UkiGN2QMyHqpI6VxPjknVfGng3QE5Vbl9YugOcR264TP1mkiP8AwGu6rzk3TaDqvjPxv4jt5YYoFTT7CHGZJII+RsA6mWaRgB3wlAEN7pVhqHxF03QdLtkSy0l/7d1V1JJkuGZ/syO2clt7SS4J42L2IrrPHFzNHon2Gycpf6pILC3ZfvIzg7nHukYkk/4BVD4Y+HZtB0Ge41KKKPW9XuZNS1ERABVmkOfLGOoQYXPcgnua5L4mazdXE866MxOpXEjeH9GwTj7TLj7TcfSJFxu7MsgPWgC/8JbeHVtc8R+K4IwthLIuj6SAPlWytcplD/daXzD+Ar02uWH2LwB4U0PT7S3zp1vLa6bu3bfLDsIxI3Bzl2XPu2c0uj+N9M1XVYbKCG+jS5eVLS6lgxBdtHneI2zzjaxGQMhSRkc0AdRRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4RDpE3hzxPqXgWCRbWO5mbXvCNwwwkM6ktLa/7uS3H9yR+5Fe71x3xR8Iv4u8Oqmnziz12wlW80u87w3Ccrk/3T0I9D0OBQBt+Ftah8RaFb6hFG0TPmOe3f70EqkrJE3urAg/SuCttLs9Ev7/4fa3Fv8K66kp0klsCPcCZbTP8ACVyXj9iQPuVmeDfGYBfxJNb/AGKGWYWPijTzwdNvlwi3OP8AnmwAVj6bG/hevTfFvh6y8U6HNp18XRWKyQzxHElvKpykqN2ZTyD+HQmgDTsrdLOzgto2dkhjWNS7bmIAxknueOtTVxvgfxHezXc/hvxSqQ+JbFNxdV2x38OcLcRex43L/C3HQiuyoAZLGk0ZSVFdD1VhkH8Kz59A0a4Zmn0nT5WYYJe2RifzFadFAGdpehaRpLs2laVYWTN1NtbpGT9doFaNFFABXI6Yn9o/EvWryX5k0m0hsLcf3Hl/fTH8V+zj/gNddXJ+H2+zfEHxXZycPcJaahH/ALStGYTj6GDn/eHrQB1lFFFAHGeKJP8AhHfFen+JHwum3MY0zUnPSNS+beU/7Ku7oT2E2egNdnUN7awX1nPaXkMc9tOjRSxSLuV1YYKkHqCDXEWt/deAdljrry3PhhfltNWbLtaL2iuu+0dFl6YwHwfmYA72imwyJNEksLrJE6hldTkMD0IPcU6gAooooA4/4veH5vE3w31zTbMH7cYPPtdv3vOiYSR4PYlkA/GpfhnqGna/4Us/EumwRwy61Glzd7M4M4UI+R0yCm0nvtrq68r+GQ/4Rb4h+LvBTfLZyONd0sHtDMcSoPQLKMAf7VAHqlcf8Ur67g8OQadpc722oa1eRaXDcJ96ESE+ZIPdY1kYe4FdhWP4sNnbaNPq19BFKdIjkv4WkGfLdInG4e+1mH4mgDzj9n3RbG3l8Xazp1slvaz6m2nWSJ90WtqPLQj3ZjIxPUnk5Nev1wPwF046Z8H/AAtE+fMmtBdsT1JmJlyf++676gAooooAKKK5LWfFU1xfTaP4Qgi1LWEOyeZifstifWZx1b0jX5j32j5qAIfHty2rzQ+DtPY/atTTdfOn/LtY5xIxPZn5jTvksR9w12MUaRRpHEoSNAFVVGAAOgFY3hbw9DoNtMTNJealdv5t7fTAeZcyYxk44CgcKg4UcD326ACkZQylWAKkYIPQilqrqt/b6Vpd5qF6/l2tpC88reiKCxP5CgDnvhblPAmm22SVszLZIT/chleJf/HUFdXXOfDmyuLDwRpEV9H5d7JD9ouI/wC5LKTI6/gzkV0dABRRRQAUUUUAFedWDf8ACwfF0eo4D+E9CnYWZ6rf3q5UzD1ji5VT0L7j/CKd4kvrvxtqlx4X8PTvBpMLGLW9VhbBT1tYW7yEcO38AOPvEY7InTPDWgjAhsdK0+AAKowkUajAAA9hgAc0AU/Fup3FlZw2mmFf7Xv38i03DIjOMtKw/uouWPqQF6sK4L4XadBr3iOTxJb7m8P6RE+laCX5M3P+kXee5dwV3dwCe9ZviOXVPFWvHw/aGW11rWYAb9hgtoukk/6vPQTzdxz+IRWr1HRrjS9OvY/C+lQNENOsopPLjT93BESUjUt/eOxsDk4Uk9RkA4nUZtX8S6t4h0yLVbMSIBJa6Le2sclpf2TIuJC4G9gzbgWVsIcAqeM2Ph5oNte2miahbajqKabpUkottFuRGTp9wFkgeJpAu9hGHkQAk8HOSMV1F74M0O606xs1szbLYZNlLaytDLa56iORSGUHuucEcEEcVf8AD2i2ug6f9ksjM6tI80ks8hkklkY5ZmY8kkn8BgDAAoA0qKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDy34leF9Q0zWW8beELNby/8n7PrGk4+XVrXGMY/wCeqj7pxkjjn7pb8OfFun21hYR2t6114RvmEWk30hJazkJ/48rgk5VgSAhPUYUnO0t6pXkfjjwFeaPf6j4g8EWUF5FqAI1vw7McQaknd4x0Sbrz0OfXhgDvvF/hq38SWcIaaSz1G0fzrG/gx5trLjG5c9QejKeGHBrG8MeLrmHU4vDnjWKKw8QkYt5k4ttSUdXhY9G9Yz8w7ZHNct4A+IltBpxae7ubzw9C3lSXN0CLzR3HHk3qddowQJ+enz9N59L1zRtJ8U6MbPVLeG+0+cLIvPGequjA5BHUMpBHY0AatFcNpdr4t8MajbWIY+JvD0jrGtxNKsd9ZqTjMhOFnQDnIw/sxruaACiiigArjvHiS6Rd6d4stUeQaWHiv4kXLSWUmDIQO5jZUkHfCuBy1djQRkYPSgCO3niubeKe3kSWGVQ8ciNlXUjIII6gipK4H998O5ZSsUs/gyRjIfLBd9JJ64Uctb5545j5/h+73NpcwXltFc2k0U9vKoeOWJwyup6EEcEUAS0jKGUqwBUjBB6EUtFAHHP4Nm0mZrjwVqTaPuYs+nyJ51jIepxFkGIn1jZR3INOXxTquljb4n8N3kKr1vNKzfwH32qBMPp5ZA9TXX0UAU9J1K01ewjvdOmE1tJkK4BHIJBBBwQQQRg1coooAK8w+K6nR/Gnw/8AFMIx5Wp/2TdEd4bpSoLH0V1U/U16fXmn7RY2/Cu9uRgta3llMoI6kXUQ/rQB6XXnvx/vpbL4R+IEts/aL2NLCJQcbjO6xY/JzXoVeafHH97b+CLQ/cuvFWnxuM9VUvIR/wCOUAeg6TZR6ZpVlYQ/6q1hSBOMcKoUfyq1RRQAVzF74qmN5PZ6LoGsalcxOY2cwfZbdWBwf3su0MPeMP7Zrp6KAOMfw/r3iAg+KdVFlYkc6Xo0jxhvaS5OJHHsgjHrmuo0nTbLSNPhsdLtILOzhGI4YECKo9gKt0UAFFFFABXE+KpD4m8Q2/hW2w9jbmO81l+oEYO6K3/3pGAYj+4pz98Zk1PxTcardzaR4JEV5fIdlxqLqWs7H13MOJJB/wA81OQfvFRW54Y0G18PaYLS1aSWR3aa4uZjmW5lY5aRz3Yn8AMAYAAoA1qKKKACiiigBs0iQxPLM6xxIpZnY4CgdST2Fec3Wsal8RJJdP8ACk01h4XyY7rXk+V7ns0dnnt2M3Qc7cnkdZ4o8L6f4nFpFrJnmsYHLvZCQrBcHjHmqPvgEZCk49Qav397YaJpjXF5LDZ2UChcn5VUdFUD16AAck4AoAj0vT9N8N6HFZ2MUNjplnGcDO1UUclmJ/Elj15JNeY+MfF017eaedPs2vry5bdoGjsCpupB0vrgZG2BOqhsdN3Xbtg8XeLbzXdYj0aw0xr+/YCW20FmwFHBW41Fh/q4xwVhzuPG7khV6TSdAk8CaBrfia+WXxF4qlhNzfXAwjzKoz5MIP3EUA7VHUj6YAK8elz/AA48EXV5DcQXviHULuFtR1a8U7GllkWMyuBgiKMNwuQAB1HJrFurXW9UluNatHk1LVdA1ZLC9GnubUavaRhJdu3djfG8rYG4Bijr0fFW9T8QX3inVvD2s6No97d+DTIbK6aXcovorkKnmC32ktEh2ku2OC2ARk103gD4f6T4PhQ21nY/boka2S9hgEUssGRsEpH33ACgt3Izxk0AdmDkA4I+tFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHBeOfhvaa9qA1zQ7yXQfFUS7U1K1UfvR/cnTpKnA4PoO3FeaW/iPxF8M70W+vWEOk2zuRlN76NdEnrHIAXs3b+6QYycnavWvoio7iCK5gkhuIklhkUq8cihlYHqCD1FAHLeF/H+ieIJIbZZjZahMC0drclQZgOpidSUmX3jZvfFdbXkvib4GeHr5Zn8OXNz4dllbe8Nsqy2buOjNbPlMjtt24rqfh14b1vw34di0/WNb/tKeK4ZhKQ7BocABPnZmGME8NgZ7igDsaKKKACiiigArkZvCM2l3Ut54NvhpUkhLy2EieZYzMTkt5YIMbH+8hHqVauuooA49fFep6bhPEvhjUYMdbrS1OoQH3AQecPxj/E1o6R4w8P6vfLZWOqQNfMCRayZimIHX924Dcd+OK36KACiiigAooooAK4D4+2Lah8HPFcUed0dmbkY7eUwlz+GzNd/VXVbKPUtLvLGf/VXULwPxn5WUg/zoAZol+mq6NYahF/q7u3jnX6OoYfzrgvjV/x8/Dv/ALG2z/8ARc1WP2f72W9+EXh5bnIuLOJ7GRT/AAmGRogPyQVX+NX/AB8/Dv8A7G2z/wDRc1AHpVFFFABRRRQAVX1G7Wxsprl4p5liXd5dvEZJG9lUck1YooA5Ftc8T6iMaP4YFmh6XGs3aRceoji8xj9GKU0+ELzVju8Xa7c6hETk2Fmps7Qj0ZVYySD2dyp/u12FFAENlaW1haRWtjbw21tEu2OGFAiIPQKOAKmoooAKKKKACq2o31pptnJd6jdQWlrHgvNPIERcnAyx4HJA/GrNFAHlfin406Fpt0NP0ZZdS1RztSIRyDn2QKZHz22ptPTcOtY+n6D458bXyX2rSzeHrQfcuZ0Q3qqeot4QWS1yCQXYvL74wB67p2jaZplxdz6dp9paz3cjTXEkMKo0zk5LOQMsSe5q/QBh+EfCuj+EtNNlodoIUdt80rEvLO/d5HPLMfU/hgVtuqurK6hlYYIIyCKWigDE8FeHofCnhiy0S1uJri3sw6xPNjcELsyrx/dBCj2ArboooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKQkKCSQAOSTS1xPiZpPFPiA+FraR00u3RZ9ZlQ4Lq3+rtQe28As/ogA/jyADJ/Z7YXHgO5v4hi1v8AVr66tjjGYmnbB/Q1yGv6ncXvj/QfD+ozyTX1l4ya5SKRv+XY2zyxMP8AZAZlHujD2r2DwZon/CO+H4tMBi2xTTugiXaqq8zuqgdsBgPwrmvij4eHn6Z400qwW48QeHXM6Kq5e5tirLNCPU7GYp1ww4xuNAHoFFVNJ1G11fS7TUdOmWezuolmhkXoyMMg/kat0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcl8NkDabrN253XN1reoGZj1Pl3LwoPwjijH0Arra5i88EaVcXl1cxTatZtdOZJ0stSuLeORz1YqjgBj3IwTQBQ+IPxG0nwbazb4p9T1GIB3srIBniQnHmSnpEn+0xArW8E+ILrxJpBvrrSZNMBfEQN1DcpMmAQ6PEzKRzjr2q9oehaXoVibTSLGC0t2JZ1jXmRj1Zj1Zj3JJJrnZ/htoC3ctzpJ1HQ5ZmLSjSL2S1jkPq0anZn325oAj+FaCyh8T6PDgWela3Pb2yj+CN0juNg9lM7KPYCu4rI8MeHrDw1pz2emLPtklaeWW4meaWaRsbnd3JZmOByT2Fa9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Creating plane behind the isthmus, anterior to trachea. A cross-section diagram with the Kelly clamp in this plane.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_13_10455=[""].join("\n");
var outline_f10_13_10455=null;
var title_f10_13_10456="Principles of burn reconstruction: The female breast";
var content_f10_13_10456=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Principles of burn reconstruction: The female breast",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/13/10456/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/13/10456/contributors\">",
"     Jorge Leon-Villapalos, MD, FRCS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/13/10456/contributors\">",
"     Peter Dziewulski, MD, FRCS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/13/10456/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/13/10456/contributors\">",
"     Marc G Jeschke, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/13/10456/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/13/10456/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/13/10456/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H23140722\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The breast and the nipple-areolar complex are frequently injured in burns involving the anterior chest wall. Burns to the breast can potentially impair",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    destroy both function and esthetics. Damage to the breast is particularly important to the prepubescent young girl. Absence of a nipple is a noticeable and striking concern to both women and men burn patients, even when more extensive burns and scarring are present elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The principles of burn reconstruction for the female breast are discussed here. An overview of reconstruction techniques, the local management of burns with topical antimicrobials and dressings, and the acute management of a burn patient are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23140729\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most burns to the breast occur in children and in the domestic environment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The most common causes of burns to the female breasts include scalds (range 66 to 89 percent), flame (range 8 to 34 percent), cooking oil (range 2 to 5 percent), and other trauma (&lt;5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. The epidemiology of the global burden of burns is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23865?source=see_link\">",
"     \"Epidemiology of burn injuries globally\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6174528\">",
"    <span class=\"h1\">",
"     ANATOMIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mammary gland in children is located four to eight millimeters deep into the subcutaneous tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/3\">",
"     3",
"    </a>",
"    ]. Familiarity of the location of the breast tissue in children is mandatory before beginning a debridement procedure to the anterior chest wall (",
"    <a class=\"graphic graphic_figure graphicRef63944 \" href=\"UTD.htm?1/5/1104\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67072 \" href=\"UTD.htm?35/63/36863\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23140847\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT AND EARLY MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burns to the breast are initially gently washed and debrided of loose burned skin and debris and dressed with topical antimicrobials and dressings. The burn eschar should not be excised from the nipple-areolar complex, but should be allowed to separate spontaneously as healing proceeds from the deep glandular structures [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. The relative avascular adipose tissue and connective tissue of the nonlactating breast requires a careful excision of all nonviable tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/1\">",
"     1",
"    </a>",
"    ]. In prepubertal girls, care should be taken not to excise the breast bud from the anterior chest wall during the debridement of the burned skin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/5\">",
"     5",
"    </a>",
"    ]. In adult females, the breast mound should not be excised, if at all possible.",
"   </p>",
"   <p>",
"    The depth of the burn helps determine the next phase of the treatment plan. Minor and superficial partial thickness burns to the breast continue to be treated with local antimicrobial agents and dressings until healed. Deeper burns are treated with tissue coverage. Two treatment options for deep burns include spontaneous eschar separation and skin grafting or tangential excision of the eschar and skin grafting after burn demarcation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/6\">",
"     6",
"    </a>",
"    ]. Surgical experience, the overall condition of the patient, and the extensiveness of the burn will help determine the best approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link&amp;anchor=H21593914#H21593914\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\", section on 'Local treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=see_link\">",
"     \"Classification of burns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37479?source=see_link\">",
"     \"Treatment of minor thermal burns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4938156\">",
"    <span class=\"h1\">",
"     PREPUBESCENT FEMALES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest wall burns in the prepubescent female can be devastating to both the child and the parents as normal breast growth and development may be compromised [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/7\">",
"     7",
"    </a>",
"    ]. Attention to detail and avoidance of excision of the breast bud is required to preserve the development of the breast. Young girls with burns to the anterior chest wall must have long-term follow-up to help ensure proper development and esthetic appearance of the breasts during and after puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The subcutaneous breast tissue may remain viable and the breast bud preserved if the burn is from a scalding injury [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/8\">",
"     8",
"    </a>",
"    ]. During puberty, the breast parenchyma can develop under the scar, resulting in breast contracture and disfigurement [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/9\">",
"     9",
"    </a>",
"    ]. The breast mound and the nipple-areolar complex are displaced, the contours are unclear, and the inframammary fold is effaced. This is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single institution study, 193 prepubescent girls were treated for anterior chest wall burns over 20 years; 52 (27 percent) were treated with surgical debridement and split-thickness skin grafts, but only 11 with documented burns to the breast and nipple-areolar complex were available for long-term follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/2\">",
"       2",
"      </a>",
"      ]. The mean time from burn to followup was 26.5 years (range 19 to 32 years).",
"      <br/>",
"      <br/>",
"      All 11 women required reconstructive procedures after the onset of breast development to improve breast appearance. Complications of the burns included breast asymmetry, distortion, banding, and unpleasant skin texture. A variety of reconstructive techniques to improve breast development and appearance were used.",
"     </li>",
"     <li>",
"      In a longitudinal assessment of 28 prepubescent girls with severe burns to the anterior chest wall, 17 (61 percent) lost the nipple-areolar complex, but all developed breast tissue at puberty [",
"      <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/10\">",
"       10",
"      </a>",
"      ]. However, 20 (71 percent) of these young patients experienced entrapment of the breast and required surgical intervention and incisional releases of the anterior chest wall to allow for proper breast development.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39735043\">",
"    <span class=\"h1\">",
"     RECONSTRUCTION PRINCIPLES FOR THE DEVELOPING BREAST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on observational data and the specifics of the burn, the ideal time to reconstruct the burned prepubescent breast is once breast maturity is attained [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/5\">",
"     5",
"    </a>",
"    ]. Growth, development, and patient cooperation must be considered when planning reconstructive procedures. It is generally best to allow the scar to mature prior to reconstruction and to perform the procedures during early adulthood. If the release of the contracture is ill timed, the post-pubertal development and growth of the breast parenchyma acquires a splayed, hypoplastic, and flattened form [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23140629\">",
"     'Reconstruction of the adult burned breast'",
"    </a>",
"    below.) In severe cases, however, staged procedures throughout puberty may be required to optimize the esthetic result.",
"   </p>",
"   <p>",
"    The following principles are used to reconstruct the prepubescent burned breast [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Expansion of skin surface",
"      </strong>",
"      &mdash; Expansion of the breast skin surface can be accomplished by releasing contractures and applying split-thickness or full-thickness skin grafts at the inframammary fold, periareolar area, sternal area, and anterior axillary line. Dermal regeneration templates can be used in conjunction with skin grafts. Additional options for augmentation include the use of tissue expansion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a breast prosthesis and free flap tissue. An adequate tissue envelope, such as a submuscular insertion, must be used to protect the implant. Expanded skin flaps allow a near-normal mammary gland development [",
"      <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Resurfacing",
"      </strong>",
"      &mdash; The shape and volume of the breast can be improved by completely resurfacing a severely scarred chest and breast with thick split-thickness or full-thickness skin grafts, with or without a dermal regeneration template.",
"     </li>",
"     <li>",
"      <strong>",
"       Amastia",
"      </strong>",
"      &mdash; Amastia (absence of a breast) is corrected by performing total breast reconstruction. This is necessary when the breast bud and nipple-areolar complex are destroyed by the burn and the breast fails to develop. Reconstruction options include submuscular tissue expansion and implant placement, pedicled (latissimus dorsi) or free flap options such as the transverse rectus abdominis myocutaneous (TRAM) flap, superior or inferior gluteal artery perforator fasciocutaneous flap, or the deep inferior epigastric perforator flap (DIEP). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=see_link\">",
"       \"Breast reconstruction in women with breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Asymmetry",
"      </strong>",
"      &mdash; Asymmetry is best addressed by performing a breast reduction of the larger breast. In cases of a unilateral burn and impaired breast development, a unilateral breast reduction of the unburned breast may provide for a balanced cosmetic appearance. Burned breasts are less likely to develop a natural ptosis.",
"     </li>",
"     <li>",
"      <strong>",
"       Absent or disfigured nipple papilla",
"      </strong>",
"      &mdash; Volume and shape should be corrected, followed by a second staged procedure to reconstruct the nipple papilla. Local tissue is typically used to form the papilla, but there is a risk of flap failure when using burned skin or skin grafts. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=see_link&amp;anchor=H40#H40\">",
"       \"Breast reconstruction in women with breast cancer\", section on 'Reconstruction of the nipple/areolar complex'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Absent or disfigured nipple-areolar complex",
"      </strong>",
"      &mdash; Once the scar is mature, tattooing provides an excellent option to enhance the appearance of the nipple-areolar complex and can match the color of skin tone or contralateral unburned nipple-areolar complex.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23140629\">",
"    <span class=\"h1\">",
"     RECONSTRUCTION OF THE ADULT BURNED BREAST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concepts for the reconstruction of the burned prepubescent breast can be applied to the adult breast. (See",
"    <a class=\"local\" href=\"#H39735043\">",
"     'Reconstruction principles for the developing breast'",
"    </a>",
"    above.) Reconstruction is performed when the burned breast envelope is insufficient to allow unrestricted breast growth and further development [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/12\">",
"     12",
"    </a>",
"    ]. The goal of reconstructive surgery is to restore the four components of the post-burn deformity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Changes in the shape and volume of the breast mound",
"     </li>",
"     <li>",
"      Damage to the skin",
"     </li>",
"     <li>",
"      Loss of definition of the inframammary crease",
"     </li>",
"     <li>",
"      Displacement or loss of the nipple areolar complex",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4938273\">",
"    <span class=\"h2\">",
"     Restoration of the shape, volume, and skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The shape, volume, and skin of the burned breast can be reconstructed using skin grafts, with or without dermal regeneration templates,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tissue flaps. Contracture release with full-thickness skin grafts",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    autologous tissue reconstruction are the traditional techniques for reconstruction of the burned breast [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/3,12-16\">",
"     3,12-16",
"    </a>",
"    ]. Resurfacing of the post-burn skin can be performed using the abdominal skin as a full-thickness skin graft [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reconstruction with a pedicled or free latissimus dorsi or transverse rectus myocutaneous flap provides adequate tissue coverage to reconstruct the shape and volume of a burned breast [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/18\">",
"     18",
"    </a>",
"    ]. The decision to use either a free or pedicled flap depends on the availability of unburned skin, the reliability of the pedicle vessels (eg, thoracodorsal artery for a latissimus dorsi free flap, deep inferior epigastric artery perforators for a transabdominal rectus flap, and superior and inferior gluteal artery perforators for the gluteal flaps), and the skill of the surgeon.",
"   </p>",
"   <p>",
"    Free and pedicled flaps can provide a fully autologous option of reconstruction. When more volume is needed than can be provided by a flap alone, or when there is a limited availability of tissue for reconstruction, a flap can be used in combination with a tissue expander or prosthesis, such as a latissimus dorsi flap and a tissue expander or permanent prosthesis. This follows the principles of standard breast reconstruction following oncoplastic procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=see_link&amp;anchor=H20#H20\">",
"     \"Breast reconstruction in women with breast cancer\", section on 'Autogenous tissue reconstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The advantages of using a local free or pedicled flap for reconstruction of a burned breast include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coverage with well vascularized skin with superior pliability, elasticity, and durability compared with skin grafts",
"     </li>",
"     <li>",
"      Coverage with tissue of similar texture and color",
"     </li>",
"     <li>",
"      Reconstruction of breast anatomical landmarks, such as using the reverse abdominoplasty to recreate the inframammary fold [",
"      <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/19\">",
"       19",
"      </a>",
"      ]. This procedure depends on the presence of healthy pliable skin in the immediate vicinity of the defect to reconstruct.",
"     </li>",
"     <li>",
"      An improved cosmetic result since flap reconstruction can be tailored to the patient&rsquo;s defect and provides a more natural appearance of the shape and volume of the breast",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The disadvantages of flap reconstruction include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Technically more difficult than skin grafts",
"     </li>",
"     <li>",
"      Longer operative times",
"     </li>",
"     <li>",
"      Failure of autologous reconstruction deprives the patient of healthy tissue at another site",
"     </li>",
"     <li>",
"      Unsightly donor site scarring",
"     </li>",
"     <li>",
"      Implant infection or extrusion compromises the result of flap reconstruction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is generally believed that scar tissue lacks elasticity and pliability, cannot be expanded with tissue expanders, and serves as a serious limitation to achieving adequate volume reconstruction of the breast mound [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]. However, a retrospective review of 15 women with burns to the breasts reconstructed with contracture release and tissue expanders found no significant differences in major complications, operative time, and amount of time to expansion, compared to the same reconstruction procedures in 20 women with congenital breast anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/13\">",
"     13",
"    </a>",
"    ]. In another study, burn patients who underwent endoscopically assisted placement of tissue expanders had significantly fewer major complications, required less operative time, and required less time to expand compared to expanders placed by the traditional open method [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of dermal regeneration templates in breast reconstruction following burns reduces the recurrence of scar contracture and provides pliability to the reconstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/21\">",
"     21",
"    </a>",
"    ]. Prevention of infection of the template is fundamental, and close monitoring of the burn wounds is necessary. The use of negative pressure therapy helps keep the template in place. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link&amp;anchor=H8044936#H8044936\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\", section on 'Dermal regeneration templates'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link&amp;anchor=H21594043#H21594043\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\", section on 'Biosynthetic dressings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link&amp;anchor=H13#H13\">",
"     \"Negative pressure wound therapy\", section on 'Clinical applications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Expansion of a dermal regeneration template (Integra) as a staged procedure appears to be reliable and safe [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Patient satisfaction and short-term evaluation of this technique is promising [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/23\">",
"     23",
"    </a>",
"    ], but no long-term studies or clinical trials are available. The stages of reconstruction using the template, skin grafts, tissue expander, and permanent prosthesis are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first stage includes release and excision of contractures and scars, submuscular insertion of anatomical tissue expander, and coverage of the anterior chest wall with Integra.",
"     </li>",
"     <li>",
"      The second stage is performed one month later and involves removal of the outer silicone layer of Integra, applying a split-thickness skin graft to the burned areas, and partially inflating and expander.",
"     </li>",
"     <li>",
"      The third stage includes overinflating the expander. The expander is subsequently removed, and replaced with a permanent silicone prosthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women who experienced a unilateral breast burn may develop asymmetry as the burned breast may be limited in growth and development. A combination of augmentation mammaplasty and reconstruction of the burned breast with contracture release offers both functional and esthetic benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatives to reconstruction of the burned breast are limited. There are no high quality data from randomized trials or large reviews for the optimal reconstruction of the burned breast. The techniques applied to reconstruction of the breast for other conditions (eg, congenital abnormalities, cancer, esthetics, and trauma) could in theory be applied to the burned breast. These techniques include injection of non-autologous fillers or lipomodelling, a technique that transfers autologous adipose tissue to remodel the breast [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/11,25,26\">",
"     11,25,26",
"    </a>",
"    ]. Concerns have been raised that injection of mature adipocytes and adipocyte-derived stem cells into the hormonally active environment of the breast may potentiate breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/27\">",
"     27",
"    </a>",
"    ]. Long-term outcome has not been studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4938281\">",
"    <span class=\"h2\">",
"     Restoration of the inframammary fold",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distortion of the inframammary fold is functionally disabling and esthetically disfiguring [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/19\">",
"     19",
"    </a>",
"    ]. The reconstruction and redefinition of the inframammary fold can be performed by simple scar debridement and grafting of the area. Replacement of the burned skin and subdermal tissue with a normal skin advancement flap provides a natural and esthetic solution. The expanded reverse abdominoplasty can recreate the inframammary crease in a multistaged process [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/19,28\">",
"     19,28",
"    </a>",
"    ]. This technique provides an optimal esthetic result, but its use is limited if burn scars involve the abdomen. Infection, hematoma, seroma, fat necrosis, flap loss, and abnormally shaped umbilicus and breast are complications of this procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4938289\">",
"    <span class=\"h2\">",
"     Restoration of the nipple-areolar complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reconstruction of burned nipple-areola complex is a challenge due to excessive nipple flattening and the thin dermis secondary to a tight scar. Split-thickness skin grafts and pressure therapy have been described to release the contracture, but have not provided satisfactory results [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/29\">",
"     29",
"    </a>",
"    ]. A modification of the star flap has produced promising results in terms of maintenance of nipple projection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standard techniques applicable to nipple reconstruction are limited in burn patients. The lack of pliability of burned skin results in loss of projection of the nipple. Most nipple reconstruction techniques use local flaps to reproduce the anatomy of the nipple, nipple sharing, or the insertion of composite grafts subcutaneously as alternative options. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=see_link&amp;anchor=H40#H40\">",
"     \"Breast reconstruction in women with breast cancer\", section on 'Reconstruction of the nipple/areolar complex'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23141265\">",
"    <span class=\"h1\">",
"     SPECIAL CIRCUMSTANCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reconstruction of a burned breast is particularly challenging in women who are lactating, pregnant, have large breasts, or who may have had previous breast reconstructive procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23141308\">",
"    <span class=\"h2\">",
"     Burns during pregnancy and lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In initial and early management of these patients, combination antibiotic ointments provide the best local care until wounds are treated by tissue coverage.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"     Silver sulfadiazine",
"    </a>",
"    , cerium nitrate, and povidone-iodine should",
"    <strong>",
"     not",
"    </strong>",
"    be used during pregnancy or during lactation (",
"    <a class=\"graphic graphic_table graphicRef81801 \" href=\"UTD.htm?14/8/14477\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/31\">",
"     31",
"    </a>",
"    ]. Early treatment by tangential excision and split-thickness skin grafts facilitates healing of the wounds and minimizes septic complications, thus improving maternal and fetal outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/32-35\">",
"     32-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After burns to the breast in pregnancy, breastfeeding has been successful if residual breast tissue is preserved [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/29,36,37\">",
"     29,36,37",
"    </a>",
"    ]. Absence of a nipple-areolar complex precludes breastfeeding; distortion of the complex does not [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/29\">",
"     29",
"    </a>",
"    ]. Split-thickness skin grafts and customized pressure therapy is used to correct a contracture deformity. (See",
"    <a class=\"local\" href=\"#H4938289\">",
"     'Restoration of the nipple-areolar complex'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For burns that are minor, or only involve a portion of the breast, it is not critical that the women disrupt breastfeeding. Combination antibiotic ointments provide the best local care if the woman chooses to continue breastfeeding, and should be continued until wounds are treated by tissue coverage. In circumstances of major burns to the breast or extensive burns to the body, cessation of lactation may be the optimal approach. Prophylactic management of burned lactating breasts with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    stops lactation and induces breast involution [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/38\">",
"     38",
"    </a>",
"    ]. Once engorgement has dissipated, surgical excision of the burn and tissue coverage can proceed. Burns in women who are no longer lactating may be treated with a variety of topical antimicrobial agents. &nbsp;(See",
"    <a class=\"local\" href=\"#H23140629\">",
"     'Reconstruction of the adult burned breast'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2224515\">",
"    <span class=\"h2\">",
"     Burns to large breasts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postburn deformities of the large breast include nipple areolar complex displacement, burn scar contracture, and scarring. In a retrospective review of 11 women with deep thermal burns to ptotic and hypertrophied breasts with postburn deformities, reconstruction with the inferior pedicle dermal flap [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/39-42\">",
"     39-42",
"    </a>",
"    ] resulted in reduction of the large breast size, elimination or reduction of burn scars, and relocation of the nipple areolar complex to a normal position [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/43\">",
"     43",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23140757\">",
"    <span class=\"h2\">",
"     Burns to the reconstructed breast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breasts reconstructed with myocutaneous flaps following cancer, esthetic related procedures, or previous burns develop cutaneous anesthesia and dysesthesias, which increases the risk of severe burns from thermal exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/44-48\">",
"     44-48",
"    </a>",
"    ]. Interruption of the afferent and efferent neural pathways resulting in deranged proprioception to thermal injury plays an important role in the pathogenesis of these injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/45,46,48\">",
"     45,46,48",
"    </a>",
"    ]. Patients undergoing reconstructive procedures of the breast must be advised of the risk of injury from exposure to the sun and contact hazards. Some recovery of sensation and temperature occurs, although this is variable in both time and degree [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Burns to the reconstructed breast are treated as described in the previous section (See",
"    <a class=\"local\" href=\"#H23140629\">",
"     'Reconstruction of the adult burned breast'",
"    </a>",
"    above.). These options include debridement, local therapy, full-thickness and split-thickness skin grafts,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tissue transfer procedures, depending on the extensiveness of the injury [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23141252\">",
"    <span class=\"h2\">",
"     Postburn mammary hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mammary hyperplasia can occur in patients with previous full-thickness burns of their breasts. Reduction mammoplasty has been generally avoided due to concern of devascularization of the skin graft or the nipple-areola complex. However, reduction mammaplasty in this group of patients may be safe and carry minimal risk. A retrospective review of six patients with full-thickness burns of the breasts and subsequent skin graft coverage observed no nipple loss, hematoma, infection, or major loss of skin flaps [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10456/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23140645\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burns to the breast can potentially impair",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    destroy both function and esthetics. The later effects of burns to the breast, which are related to loss of normal tissue and scarring, include limitation of movement, pain, disfigurement, and social embarrassment. Damage to the breast is particularly important to the prepubescent young girl, but absence of a nipple is a noticeable and striking concern to both female and male burn patients. Reconstruction depends on the depth and extensiveness of the burns and the availability of viable, unburned tissue.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial management of burns to the breast includes gentle debridement of loose burned skin, cleansing, and local topical dressings. The nipple and areolar complex should not be excised (See",
"      <a class=\"local\" href=\"#H23140847\">",
"       'Initial treatment and early management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For prepubescent girls with burns to the anterior chest wall, the breast bud should be preserved during the debridement procedures. We suggest using split-thickness skin grafts to reconstruct the burned anterior chest wall in young girls and prefer to delay reconstruction with flaps until after breast development (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The release of contractures and more extensive reconstructive procedures, such as pedicled or free tissue transfer, are performed as the breast tissue develops. (See",
"      <a class=\"local\" href=\"#H4938156\">",
"       'Prepubescent females'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For burns to the adult woman&rsquo;s breast, the breast mound should be preserved if tissue is viable. The reconstruction in the fully developed breast needs to take into consideration the restoration of nipple height, the adequate definition of the inframammary fold and the symmetry in volume, size, and shape of both breasts. We suggest using autologous tissue, either as a free or pedicled flap (with or without prosthesis insertion) to provide the optimal cosmetic result for restoring volume and shape (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A tissue expander or implant can be used to enhance the results if the autologous tissue is insufficient. (See",
"      <a class=\"local\" href=\"#H4938273\">",
"       'Restoration of the shape, volume, and skin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For burns to the breast during pregnancy and lactation, we recommend the use of combination antibiotic ointments as the initial treatment and avoid the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"       silver sulfadiazine",
"      </a>",
"      , cerium nitrate, and povidone-iodine (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23141308\">",
"       'Burns during pregnancy and lactation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For major burns to the breast during lactation, we recommend using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      for cessation of lactation (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). For minor or limited burns to the breast, the option to continue to breastfeed is at the discretion of the woman. (See",
"      <a class=\"local\" href=\"#H23141308\">",
"       'Burns during pregnancy and lactation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Muller M, Gahankari D, Herndon DN. Chapter 13: Operative wound management. In: Total Burn Care, 3rd ed, 2007. p.193.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/2\">",
"      Foley P, Jeeves A, Davey RB, Sparnon AL. Breast burns are not benign: long-term outcomes of burns to the breast in pre-pubertal girls. Burns 2008; 34:412.",
"     </a>",
"    </li>",
"    <li>",
"     McCauley RL. Chapter 57: Reconstruction of the burned breast. In: Total Burn Care, 3rd ed, 2007. p.741.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/4\">",
"      Burvin R, Robinpour M, Milo Y, et al. Female breast burns: conservative treatment with a reconstructive aim. Isr J Med Sci 1996; 32:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/5\">",
"      Armour AD, Billmire DA. Pediatric thermal injury: acute care and reconstruction update. Plast Reconstr Surg 2009; 124:117e.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/6\">",
"      al-Qattan MM, Zuker RM. Management of acute burns of the female pediatric breast: delayed tangential excision versus spontaneous eschar separation. Ann Plast Surg 1994; 33:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/7\">",
"      Ogilvie MP, Panthaki ZJ. Burns of the developing breast. J Craniofac Surg 2008; 19:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/8\">",
"      Versaci AD, Balkovich ME, Goldstein SA. Breast reconstruction by tissue expansion for congenital and burn deformities. Ann Plast Surg 1986; 16:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/9\">",
"      Grishkevich VM. Restoration of the shape, location and skin of the severe burn-damaged breast. Burns 2009; 35:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/10\">",
"      McCauley RL, Beraja V, Rutan RL, et al. Longitudinal assessment of breast development in adolescent female patients with burns involving the nipple-areolar complex. Plast Reconstr Surg 1989; 83:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/11\">",
"      Ho Quoc C, Bouguila J, Brun A, et al. [Surgical treatment of sequelae of deep breast burns: a 25-year experience]. Ann Chir Plast Esthet 2012; 57:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/12\">",
"      MacLennan SE, Wells MD, Neale HW. Reconstruction of the burned breast. Clin Plast Surg 2000; 27:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/13\">",
"      Levi B, Brown DL, Cederna PS. A comparative analysis of tissue expander reconstruction of burned and unburned chest and breasts using endoscopic and open techniques. Plast Reconstr Surg 2010; 125:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/14\">",
"      Kunert P, Schneider W, Flory J. Principles and procedures in female breast reconstruction in the young child's burn injury. Aesthetic Plast Surg 1988; 12:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/15\">",
"      Kalender V, Aydm H, Karabulut AB, et al. Breast reconstruction with the internal mammary artery pedicled fasciocutaneous island flap: description of a new flap. Plast Reconstr Surg 2000; 106:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/16\">",
"      Slator RC, Wilson GR, Sharpe DT. Postburn breast reconstruction: tissue expansion prior to contracture release. Plast Reconstr Surg 1992; 90:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/17\">",
"      Mueller M, Boorman JG. Post-burn breast resurfacing using an abdominal full-thickness skin graft. Br J Plast Surg 2002; 55:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/18\">",
"      Loss M, Infanger M, K&uuml;nzi W, Meyer VE. The burned female breast: a report on four cases. Burns 2002; 28:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/19\">",
"      Haik J, Grabov-Nardini G, Goldan O, et al. Expanded reverse abdominoplasty for reconstruction of burns in the epigastric region and the inframammary fold in female patients. J Burn Care Res 2007; 28:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/20\">",
"      Toranto JD, Yu D, Cederna PS. Endoscopic versus open tissue-expander placement: is less invasive better? Plast Reconstr Surg 2007; 119:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/21\">",
"      Tsoutsos D, Stratigos A, Gravvanis A, et al. Burned breast reconstruction by expanded artificial dermal substitute. J Burn Care Res 2007; 28:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/22\">",
"      Shariff Z, Rawlins JM, Austin O. Burned breast reconstruction by expanded artificial dermal substitute. J Burn Care Res 2007; 28:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/23\">",
"      Palao R, G&oacute;mez P, Huguet P. Burned breast reconstructive surgery with Integra dermal regeneration template. Br J Plast Surg 2003; 56:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/24\">",
"      Hsiao YC, Yang JY, Chuang SS, et al. Are augmentation mammaplasty and reconstruction of the burned breast collateral lines? Experience in performing simultaneous reconstructive and aesthetic surgery. Burns 2009; 35:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/25\">",
"      Sinna R, Delay E, Garson S, et al. Breast fat grafting (lipomodelling) after extended latissimus dorsi flap breast reconstruction: a preliminary report of 200 consecutive cases. J Plast Reconstr Aesthet Surg 2010; 63:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/26\">",
"      ELFadl D, Garimella V, Mahapatra TK, et al. Lipomodelling of the breast: a review. Breast 2010; 19:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/27\">",
"      Parrish JN, Metzinger SE. Autogenous fat grafting and breast augmentation: a review of the literature. Aesthet Surg J 2010; 30:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/28\">",
"      Akbas H, Guneren E, Eroglu L, et al. The combined use of classic and reverse abdominoplasty on the same patient. Plast Reconstr Surg 2002; 109:2595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/29\">",
"      Matthews RN. Old burns and pregnancy. Br J Obstet Gynaecol 1982; 89:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/30\">",
"      Motamed S, Davami B. Postburn reconstruction of nipple-areola complex. Burns 2005; 31:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/31\">",
"      El-Gallal ARS, Yousef SM. Burns in pregnancy: A ten-year review of admitted patients. Ann Burns Fire Disasters 2002; 15:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/32\">",
"      Mabrouk AR, el-Feky AE. Burns during pregnancy: a gloomy outcome. Burns 1997; 23:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/33\">",
"      Prasanna M, Singh K. Early burn wound excision in \"major' burns with \"pregnancy': a preliminary report. Burns 1996; 22:234.",
"     </a>",
"    </li>",
"    <li>",
"     Napoli B, D'Arpa N, Masellis M, Graziano R. Burns in pregnancy. Annals of Burns and Fire Disasters 2000; 13:18.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/35\">",
"      Bartle EJ, Sun JH, Wang XW. Burns in pregnancy. J Burn Care Rehabil 1988; 9:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/36\">",
"      Faridi MM, Dewan P. Successful breastfeeding with breast malformations. J Hum Lact 2008; 24:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/37\">",
"      Polko LE, McMahon MJ. Burns in pregnancy. Obstet Gynecol Surv 1998; 53:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/38\">",
"      Giele HP, Nguyen H, Wood F, Crocker AD. Management of full thickness burns to lactating breasts. Burns 1994; 20:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/39\">",
"      Ribeiro L. A new technique for reduction mammaplasty. Plast Reconstr Surg 1975; 55:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/40\">",
"      Courtiss EH, Goldwyn RM. Reduction mammaplasty by the inferior pedicle technique. An alternative to free nipple and areola grafting for severe macromastia or extreme ptosis. Plast Reconstr Surg 1977; 59:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/41\">",
"      Robbins TH. A reduction mammaplasty with the areola-nipple based on an inferior dermal pedicle. Plast Reconstr Surg 1977; 59:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/42\">",
"      Georgiade NG, Serafin D, Morris R, Georgiade G. Reduction mammaplasty utilizing an inferior pedicle nipple-areolar flap. Ann Plast Surg 1979; 3:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/43\">",
"      El-Khatib HA. Reliability of inferior pedicle reduction mammaplasty in burned oversized breasts. Plast Reconstr Surg 1999; 103:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/44\">",
"      Alexandrides IJ, Shestak KC, Noone RB. Thermal injuries following TRAM flap breast reconstruction. Ann Plast Surg 1997; 38:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/45\">",
"      Davison JA. Burns to reconstructed breasts. Ann R Coll Surg Engl 1999; 81:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/46\">",
"      Nahabedian MY, McGibbon BM. Thermal injuries in autogenous tissue breast reconstruction. Br J Plast Surg 1998; 51:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/47\">",
"      Liew S, Hunt J, Pennington D. Sensory recovery following free TRAM flap breast reconstruction. Br J Plast Surg 1996; 49:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/48\">",
"      Delfino S, Brunetti B, Toto V, Persichetti P. Burn after breast reconstruction. Burns 2008; 34:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10456/abstract/49\">",
"      Thai KN, Mertens D, Warden GD, Neale HW. Reduction mammaplasty in postburn breasts. Plast Reconstr Surg 1999; 103:1882.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15397 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-C55D250E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_13_10456=[""].join("\n");
var outline_f10_13_10456=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23140645\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23140722\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23140729\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6174528\">",
"      ANATOMIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23140847\">",
"      INITIAL TREATMENT AND EARLY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4938156\">",
"      PREPUBESCENT FEMALES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39735043\">",
"      RECONSTRUCTION PRINCIPLES FOR THE DEVELOPING BREAST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23140629\">",
"      RECONSTRUCTION OF THE ADULT BURNED BREAST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4938273\">",
"      Restoration of the shape, volume, and skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4938281\">",
"      Restoration of the inframammary fold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4938289\">",
"      Restoration of the nipple-areolar complex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23141265\">",
"      SPECIAL CIRCUMSTANCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23141308\">",
"      Burns during pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2224515\">",
"      Burns to large breasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23140757\">",
"      Burns to the reconstructed breast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23141252\">",
"      Postburn mammary hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23140645\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15397\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15397|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/5/1104\" title=\"figure 1\">",
"      Breast development and milk lines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/63/36863\" title=\"figure 2\">",
"      Tanner staging breasts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15397|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/8/14477\" title=\"table 1\">",
"      Antimicrobial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=related_link\">",
"      Breast reconstruction in women with breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=related_link\">",
"      Classification of burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23865?source=related_link\">",
"      Epidemiology of burn injuries globally",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=related_link\">",
"      Local treatment of burns: Topical antimicrobial agents and dressings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=related_link\">",
"      Principles of burn reconstruction: Overview of surgical procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37479?source=related_link\">",
"      Treatment of minor thermal burns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_13_10457="Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy";
var content_f10_13_10457=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/13/10457/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/13/10457/contributors\">",
"     Michael R Rudnick, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/13/10457/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/13/10457/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/13/10457/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/13/10457/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/13/10457/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast nephropathy is a generally reversible form of acute kidney injury that occurs soon after the administration of radiocontrast media [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/1-11\">",
"     1-11",
"    </a>",
"    ]. Important issues that remain unresolved include its pathogenesis, relative efficacies of various prophylactic strategies, and the relative nephrotoxicity of different iodinated radiocontrast agents.",
"   </p>",
"   <p>",
"    A review of the pathogenesis, clinical characteristics, and diagnosis of iodinated radiocontrast media-induced nephropathy is presented here. Preventive strategies for reducing the risk of contrast nephrotoxicity, and a discussion of acute tubular necrosis, the most common cause of acute kidney injury developing in hospitalized patients, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1865687499\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best data related to the pathogenesis of contrast nephropathy come from animal models. Studies show evidence of acute tubular necrosis (ATN) but the mechanism by which ATN occurs is not well understood [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. The two major theories are that ATN is caused by renal vasoconstriction resulting in medullary hypoxia, possibly mediated by alterations in nitric oxide, endothelin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adenosine, and that ATN is a direct result of the cytotoxic effects of the contrast agents [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/12-20\">",
"     12-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, unlike other types of ATN, contrast nephropathy is usually characterized by relatively rapid recovery of renal function. If ATN contributes to contrast nephropathy, it is not clear why recovery occurs relatively quickly (ie, within a few days), compared with a longer duration (ie, one to three weeks) as with ATN due to other causes. There are at least two possibilities to explain the short duration of ATN:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The degree of tubular necrosis is much less severe than seen in other settings.",
"     </li>",
"     <li>",
"      The decline in GFR is due to functional changes in tubule epithelial cells rather than necrosis per se. This phenomenon, which is similar to postischemic dysfunction in the \"stunned\" myocardium, may be at least in part due to redistribution of membrane transport proteins from the basolateral to the luminal membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, it is possible that prerenal factors or intratubular obstruction contribute to the pathogenesis. This possibility is suggested by the observation that the FENa may be below 1 percent in patients with contrast nephropathy by contrast with that in patients with ischemic or toxin-induced ATN [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/22\">",
"     22",
"    </a>",
"    ]. Since contrast nephropathy is almost always non-oliguric however, the significance of a FENa &lt;1 is unclear. (See",
"    <a class=\"local\" href=\"#H1865688711\">",
"     'Other laboratory manifestations'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link&amp;anchor=H3#H3\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\", section on 'FENa in acute kidney injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individual mechanisms are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Renal vasoconstriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal vasoconstriction is a common finding in contrast nephropathy and is mediated in part by vasoactive mediators such as endothelin and adenosine and possibly by direct contact with high osmolal contrast agent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. However much of our understanding of the role of vasoactive mediators is derived from animal models. As a result, the magnitude of the contribution of individual mediators to human contrast nephropathy is not clear. Endothelin receptor antagonists failed to prevent contrast media induced kidney injury in human studies but the significance of this is not clear given the fact that non-selective antagonists were used [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link&amp;anchor=H25#H25\">",
"     \"Prevention of contrast-induced nephropathy\", section on 'Inhibition of renal vasoconstriction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although overall renal vasoconstriction (and reduced renal blood flow) do not appear to correlate well with a rise in the serum creatinine concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/16\">",
"     16",
"    </a>",
"    ], reductions in medullary blood flow may be important [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/14\">",
"     14",
"    </a>",
"    ]. In a rat model, for example, the combined administration of iothalamate and inhibitors of endogenous vasodilators such as nitric oxide and prostaglandins, causes marked ischemia and tubular necrosis in the medullary thick ascending limb of the loop of Henle [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, reductions in renal blood flow of variable duration have been demonstrated following contrast administration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal blood flow determined by para-aminohippurate (PAH) clearance remained 30 percent below baseline up to two hours after the administration of contrast [",
"      <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/19\">",
"       19",
"      </a>",
"      ]. This effect was most pronounced following the administration of high osmolal agents, but the low osmolal agent,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/45/36565?source=see_link\">",
"       iopamidol",
"      </a>",
"      , also significantly reduced blood flow [",
"      <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Renal blood flow remained 45 percent below baseline levels for at least four hours following contrast administration [",
"      <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further reduction in medullary blood flow may occur due to effects of viscosity. The renal medullary vascular bed, the vasa recta, is composed of long vessels of small diameter. Blood flow is facilitated by maintenance of low viscosity, which can be markedly altered by contrast media, especially iso-osmolal preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/13\">",
"     13",
"    </a>",
"    ]. Increased viscosity may also enhance tubular interstitial pressure, which further reduces medullary blood flow.",
"   </p>",
"   <p>",
"    The outer medulla appears particularly susceptible to injury due to reductions in renal blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/14\">",
"     14",
"    </a>",
"    ]. This increased susceptibility results from baseline borderline hypoxic conditions in the outer medulla, which are due in part to the high oxygen requirements for active sodium transport and countercurrent flow [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As will be described below, diabetes mellitus and heart failure increase the risk of contrast-induced kidney injury in humans. There is evidence that these disorders are associated with impaired nitric oxide generation, which could contribute to the susceptibility to contrast agents [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Epidemiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tubular injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubular injury, due to direct cytotoxic effects or in association with the generation of oxygen free radicals, contributes to contrast nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/12,13,26\">",
"     12,13,26",
"    </a>",
"    ]. Some animal models suggest that decreased activity of protective antioxidant enzymes may explain the enhanced risk with hypovolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Antioxidant activity may explain the apparent protective effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link&amp;anchor=H16#H16\">",
"     \"Prevention of contrast-induced nephropathy\", section on 'Acetylcysteine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tubular injury may also be exacerbated by and act in concert with renal vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In one study, for example, administration of a nonionic, low-osmolality contrast agent led to an 18 percent reduction in creatinine clearance and increased adenosine excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/18\">",
"     18",
"    </a>",
"    ]. Concurrent use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , an adenosine receptor antagonist, prevented the fall in creatinine clearance. In comparison, an ionic high-osmolality contrast agent produced a greater reduction in creatinine clearance (42 percent) that was only partially corrected by theophylline and that was associated with a more prolonged increase in adenosine excretion, suggesting concurrent tubular injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of radiocontrast-induced nephropathy varies widely depending on the presence or absence of risk factors, (primary chronic kidney disease), the amount and type of agent administered and the exact radiologic procedure.",
"   </p>",
"   <p>",
"    Adding to this uncertainty is the fact that reductions in renal function occur in hospitalized patients who do not receive iodinated contrast and most studies do not reliably exclude other causes of acute kidney injury unrelated to contrast media (eg, atheroemboli during angiography, or changes in diuretic or RAS inhibition in the immediate period post contrast exposure). As an example, in one retrospective review of 32,161 patients who had serum creatinine measured on five consecutive days, and who underwent a CT scan but did not receive contrast material during the previous 10 days, more than half showed a change in creatinine of at least 25 percent and more than two fifths showed a change of at least 0.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/29\">",
"     29",
"    </a>",
"    ]. This is an important point to remember when evaluating published reports, especially those that include patients of low risk for contrast nephropathy.",
"   </p>",
"   <p>",
"    According to virtually all reports, among patients who have no risk factors, the risk of contrast nephropathy is negligible (ie, &le;1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Among high risk patients (especially those with diabetes and CKD), the reported risk following percutaneous angiography with or without intervention is 10 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/30-34\">",
"     30-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for contrast nephropathy include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/1-6,9,35-38\">",
"     1-6,9,35-38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic kidney disease",
"     </li>",
"     <li>",
"      Diabetic nephropathy with renal insufficiency",
"     </li>",
"     <li>",
"      Advanced heart failure or other cause of reduced renal perfusion (such as hypovolemia or hemodynamic instability)",
"     </li>",
"     <li>",
"      High total dose of contrast agent",
"     </li>",
"     <li>",
"      First generation hyperosmolal ionic contrast agents",
"     </li>",
"     <li>",
"      Percutaneous coronary interventions, which also promote the development of atheroemboli",
"     </li>",
"     <li>",
"      Multiple myeloma (especially with older contrast agents)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The contribution of individual factors to overall risk is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18304276\">",
"    <span class=\"h2\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of contrast nephropathy is higher among patients with chronic kidney disease (CKD) and the magnitude of the risk is directly associated with the severity of renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/1,2,4,6,35,39,40\">",
"     1,2,4,6,35,39,40",
"    </a>",
"    ]. In one study of 7586 patients undergoing percutaneous interventions, the overall incidence of AKI (defined as a greater than 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    increase in the baseline serum creatinine) was 3.3 percent but the incidence increased to 22 percent among patients with a serum creatinine of 2.0 to 2.9 [177 to 256",
"    <span class=\"nowrap\">",
"     mmol/L],",
"    </span>",
"    and to 31 percent for those with a baseline creatinine &ge;3.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [265",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Statistically, the increase in risk is likely continuous with the decline in GFR. However, the GFR at which a clinical significantly risk is incurred is not well defined. It is likely that non-diabetic patients with estimated GFR &gt;45",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    have only a modest risk of contrast nephropathy, especially if contrast is administered intravenously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18304283\">",
"    <span class=\"h2\">",
"     Diabetic nephropathy with renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with CKD, diabetic patients are at higher risk for contrast nephropathy compared with nondiabetic patients. In one prospective study that directly compared diabetic and nondiabetic patients who had a baseline serum creatinine greater than 1.69",
"    <span class=\"nowrap\">",
"     mg/dl",
"    </span>",
"    (150",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and were undergoing CT scan with contrast, diabetic patients had a higher incidence of contrast nephropathy compared with nondiabetic patients (8.8 versus 4.0 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/1\">",
"     1",
"    </a>",
"    ]. Similarly, in an analysis of data from a randomized trial that included 250 patients with serum creatinine &gt;1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30949?source=see_link\">",
"     iohexol",
"    </a>",
"    during percutaneous coronary interventions, a much higher incidence was observed among diabetic patients compared with nondiabetic patients (33 versus 12 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with normal kidney function, diabetes does not increase the risk of contrast nephropathy. As an example, in a randomized trial that included 341 patients with serum creatinine &le;1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30949?source=see_link\">",
"     iohexol",
"    </a>",
"    during percutaneous interventions, there was no difference in the negligible incidence of contrast nephropathy between diabetic and non-diabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18304491\">",
"    <span class=\"h2\">",
"     Dose and type of contrast agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have demonstrated a dose-dependent risk of renal dysfunction, with lower doses of contrast being safer, but not free of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/2,5,6,36,40\">",
"     2,5,6,36,40",
"    </a>",
"    ]. Low dose has been variably defined in different studies, generally ranging from less than 30 to less than 125 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/5,6,36,40\">",
"     5,6,36,40",
"    </a>",
"    ]. As an example, in one study, low dose was defined by a formula as less than 5",
"    <span class=\"nowrap\">",
"     ml/kg",
"    </span>",
"    (to a maximum of 300 ml) divided by the serum creatinine concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/40\">",
"     40",
"    </a>",
"    ]. However, diabetic patients with a serum creatinine concentration above 5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (440",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    may be at risk from as little as 20 to 30 mL of contrast [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The type of administered contrast agent alters the risk. The use of first generation hyperosmolal ionic contrast agents is associated with an enhanced risk of nephropathy (versus that observed with nonionic low osmolal or iso-osmolal agents) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/2\">",
"     2",
"    </a>",
"    ]. This is particularly true if such agents are administered to high risk patients without adequate additional preventive measures. The risk associated with specific agents is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link&amp;anchor=H5#H5\">",
"     \"Prevention of contrast-induced nephropathy\", section on 'Type of contrast agent'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18306140\">",
"    <span class=\"h2\">",
"     Specific radiologic procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the studies identifying risk factors for contrast nephropathy included patients undergoing percutaneous angiography, particularly coronary angiography. By contrast to that associated with angiography, the risk of contrast nephropathy associated with contrast CT scans is quite low, even among patients with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/41\">",
"     41",
"    </a>",
"    ]. As an example, in a study of 421 patients with estimated GFR less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, only 3.5 percent had an increase in serum creatinine of greater than 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    within 48 to 96 hours post-procedure. Despite the absence of pre- and post-procedure intravenous fluid administration, fewer than one percent of outpatients who had a baseline estimated GFR between 45 and 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 had an increase in serum creatinine greater than 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Patients undergoing emergent CT (for diagnosis of ruptured aortic aneurysm or acute pulmonary embolus) were excluded from the study.",
"   </p>",
"   <p>",
"    The incidence of AKI may be higher for patients who receive contrast for a non-elective contrast enhanced CT. This was suggested by a prospective study of 633 outpatients who received intravenous contrast for contrast enhanced CT in the emergency department of a single tertiary care center (2.4 percent of whom had a baseline estimated GFR less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/42\">",
"     42",
"    </a>",
"    ]. Seventy patients (11 percent) had an increase in serum creatinine greater than 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or greater than 25 percent within two to seven days after contrast administration. Six patients (one percent) developed severe kidney injury (defined as an increase in serum creatinine greater than or equal to 3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or the need for dialysis at 45 days); five required hemodialysis or died. A possible reason for the higher incidence of acute kidney injury in this study may be that patients identified through emergency department visits are more likely to have comorbidities that were not adjusted for, such as hypotension, hyperglycemia, or volume depletion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18304572\">",
"    <span class=\"h2\">",
"     Multiple myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multiple myeloma are at increased risk from a contrast study, although the incidence of acute kidney injury appears to be less than 1.5 percent with the use of modern contrast agents, at least among patients who have no other risk factors. As an example, in a review of seven retrospective studies of myeloma patients receiving contrast media, 476 patients who had undergone 568 contrast media studies, the prevalence of AKI was 0.6 to 1.25 percent, which is low but likely higher than that among individuals who do not have multiple myeloma and have no other risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/43\">",
"     43",
"    </a>",
"    ]. Volume depletion, which promotes the intratubular precipitation of filtered light chains, is usually present in those patients who develop contrast nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/43\">",
"     43",
"    </a>",
"    ]. In addition, a possible interaction between light chains and the contrast agent may play a contributory role, although this was more likely with older contrast agents no longer in use [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18305754\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other risk factors that have been suggested by a few studies include hyperglycemia and the use of either angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperglycemia may increase the risk for contrast nephropathy independent of a pre-existing diagnosis of diabetes mellitus. In a study of 6358 patients undergoing angiography following myocardial infarction, the adjusted risk of contrast nephropathy incrementally increased with higher glucose levels among patients without diabetes mellitus, with odds ratios of 1.31, 1.51, 1.58, and 2.14 for glucose groups of 110 to &lt;140, 140 to &lt;170, 170 to &lt;200, and &gt;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/45\">",
"     45",
"    </a>",
"    ]. Although there was no increase in glucose-associated risk among patients with established diabetes mellitus, the unadjusted risk for contrast nephropathy in patients with diabetes mellitus and a glucose of &lt;140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    was approximately double that of nondiabetic patients in the same blood glucose categories. The presence or absence of CKD among individuals who developed contrast nephropathy was not reported in this study.",
"   </p>",
"   <p>",
"    The effect of ACE inhibitors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ARBS on the incidence of contrast nephropathy is not clear. In a retrospective study of 5299 patients undergoing percutaneous interventions, compared with a propensity-matched cohort, ACE inhibitor or ARB users were more likely to develop AKI (odds ratio 1.43, 95% CI 1.06-1.94) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However in a randomized trial of 220 patients with estimated GFR of 15 to 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, there was no difference in the incidence of contrast nephropathy between patients who were on ACE inhibitors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ARBs prior to angiography, and patients who had a similarly reduced estimated GFR but were not on ACE inhibitors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ARBS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/47\">",
"     47",
"    </a>",
"    ]. In addition, it is not clear whether holding or withdrawing an ACE inhibitor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ARB prior to angiography provides any benefit. Studies that have examined this issue and our approach to the use of ACE inhibitors and ARBs prior to contrast procedures are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18300532\">",
"    <span class=\"h2\">",
"     Creatinine increase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of kidney injury is probably within minutes of exposure to contrast agents. However clinical manifestations such as oliguria or an increase in the serum creatinine are generally observed within 24 to 48 hours after contrast exposure. Most patients are nonoliguric [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/4,48\">",
"     4,48",
"    </a>",
"    ]. As an example, in a prospective study that compared nonionic and ionic contrast agents, among approximately 40 patients who developed contrast nephropathy, none were oliguric [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus injury is usually manifested only by an increase in the serum creatinine.",
"   </p>",
"   <p>",
"    In almost all cases, the increase in creatinine reflecting a decline in GFR occurs within 24 to 48 hours of contrast administration and is mild. The creatinine usually starts to decline within three to seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/8,48\">",
"     8,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1865688711\">",
"    <span class=\"h2\">",
"     Other laboratory manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted, the major laboratory manifestation is an increased serum creatinine. Other manifestations of AKI may be present, including hyperkalemia, acidosis and hyperphosphatemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The urinary sediment may show classic findings of ATN including muddy brown granular and epithelial cell casts and free renal tubular epithelial cells. However, the absence of these urinary findings does not exclude the diagnosis and their presence does not always establish the diagnosis of ATN. The sediment does not show evidence of glomerular disease (such as dysmorphic red blood cells or red blood casts) or interstitial nephritis (such as white cells or white cell casts). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H13#H13\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Urine sediment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link&amp;anchor=H26746321#H26746321\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\", section on 'Urinalysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Protein excretion on presentation is absent or mild. However, many of the commonly used iodinated radiocontrast agents induce false positive results when either a dipstick or sulfosalicylic acid is used to detect proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/49\">",
"     49",
"    </a>",
"    ]. How this occurs is not clear, but protein excretion may be overestimated by as much as 1.5 to 2",
"    <span class=\"nowrap\">",
"     g/L.",
"    </span>",
"    Thus, the urine should not be tested for protein for at least 24 hours after a contrast study. If urine is tested and proteinuria is detected, the test should be repeated at least 48 hours after contrast exposure to exclude a false positive result.",
"   </p>",
"   <p>",
"    The fractional sodium excretion (FENa) is often below 1 percent in patients with contrast nephropathy. In one study, among 12 patients with transient oliguric AKI, all 12 patients had FENa less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/22\">",
"     22",
"    </a>",
"    ]. In a larger prospective study of 443 patients, despite the administration of sodium chloride prior to angiography, the mean FENa was 0.3 to 0.7 among patients who developed AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/4\">",
"     4",
"    </a>",
"    ]. The low FENa among such patients is in contrast to that in patients who develop AKI due to ischemic or toxin-induced ATN, which is usually greater than 1 percent, but this may be explained by the fact that contrast nephropathy is usually non-oliguric and ischemic ATN is usually oliguric. The use of the FENa in other forms of AKI is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link&amp;anchor=H3#H3\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\", section on 'FENa in acute kidney injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calculators for the FENa are available using either standard units (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or SI units (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1865688745\">",
"    <span class=\"h2\">",
"     Radiographic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no characteristic radiographic features of contrast nephropathy. A prolonged nephrogram may be seen among patients with established contrast nephropathy who undergo an intravenous pyelogram (which is generally no longer performed in this setting), or a contrast enhanced CT scan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of radiocontrast-induced nephropathy is based upon the clinical presentation including the characteristic rise in serum creatinine concentration beginning with the first 24 to 48 hours after contrast exposure, and the exclusion of other causes of AKI. This typically requires a urinalysis and, occasionally, a renal ultrasound or biopsy.",
"   </p>",
"   <p>",
"    The urinalysis provides important diagnostic information, usually by excluding other causes of AKI rather than by providing a conclusive positive diagnosis of contrast nephropathy. As noted above, the presence of classic findings of contrast nephropathy include muddy brown granular and epithelial cell casts and free renal tubular epithelial cells. In the appropriate clinical setting, these findings strongly support the diagnosis of contrast nephropathy, although the absence of these urinary findings does not exclude the diagnosis. However, the absence of other findings such as white blood cells (wbc) or wbc casts or dysmorphic red blood cells (rbc) or rbc casts generally excludes interstitial nephritis and glomerular diseases as causes of AKI. Conversely, the presence of wbc, wbc casts, dysmorphic rbc or rbc casts suggests causes of AKI other than ATN such as interstitial nephritis or glomerular lesions.",
"   </p>",
"   <p>",
"    Although an ultrasound is usually obtained among all patients who present with an elevated creatinine, we generally do not obtain an ultrasound, at least initially, among patients who have a characteristic presentation of contrast nephropathy following contrast exposure. However, we do obtain an ultrasound to exclude other causes of AKI among patients who do not follow a classic clinical course of contrast nephropathy, or in whom the diagnosis of contrast nephropathy is questionable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A renal biopsy is generally not helpful for the diagnosis of contrast nephropathy since the lesions of ATN are focal and non-specific, and because AKI due to contrast nephropathy is generally short-lived.",
"   </p>",
"   <p>",
"    However, as with the ultrasound, a biopsy may rarely be required to exclude other causes of AKI among patients who do not follow a classic clinical course, or in whom the diagnosis of contrast nephropathy is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H454598616\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis includes, but is not limited to, ischemic acute tubular necrosis, acute interstitial nephritis, and renal atheroemboli. The former two require additional insults such as sepsis or hypotension, or medication exposure, which can be deduced by history. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute interstitial nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients who develop AKI after angiography, contrast nephropathy must be distinguished from renal atheroemboli. The latter has one or more of the following distinguishing characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presence of other embolic lesions (such as digital ischemia of the toes) or livedo reticularis",
"     </li>",
"     <li>",
"      Transient eosinophilia and hypocomplementemia",
"     </li>",
"     <li>",
"      Onset of kidney injury that may be delayed for days to weeks after the procedure",
"     </li>",
"     <li>",
"      Protracted course with frequently little or no recovery of renal function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A full discussion of this condition is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13528?source=see_link\">",
"     \"Clinical presentation, evaluation, and treatment of renal atheroemboli\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18300539\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the increase in creatinine reflecting a decline in GFR is usually mild. In most cases, the creatinine usually starts to decline within three to seven days and the patient returns to or close to baseline renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/8,48\">",
"     8,48",
"    </a>",
"    ]. As an example, among 21 patients with contrast nephropathy, 12 (57 percent) regained baseline renal function and four additional patients (19 percent) had a partial recovery within five to seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/48\">",
"     48",
"    </a>",
"    ]. Only five patients had persistent renal dysfunction at the time of discharge.",
"   </p>",
"   <p>",
"    Dialysis is rarely required for AKI following contrast administration. In one study of over 1800 consecutive patients who underwent percutaneous interventions, the incidence of AKI that was severe enough to require dialysis was &lt;1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/31\">",
"     31",
"    </a>",
"    ]. The risk is higher among patients with severe underlying CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/13/10457/abstract/2,8,34\">",
"     2,8,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it is increasingly appreciated that residual renal dysfunction may persist even among patients in whom the creatinine returns to baseline. This is especially noted among patients with underlying CKD among whom an episode of AKI results in a persistent increase in the risk of progression of CKD. This issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4553?source=see_link&amp;anchor=H7#H7\">",
"     \"Renal and patient outcomes after acute tubular necrosis\", section on 'Degree of recovery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally patients will require dialysis in the acute setting. The indications for dialysis are the same as in other forms of AKI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109658431\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contrast nephropathy is a generally reversible type of acute kidney injury that occurs soon after the administration of radiocontrast media. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis is not completely understood. Based upon animal studies, contrast nephropathy is most likely due to acute tubular necrosis (ATN) related to vasoconstriction and cytotoxic effects from contrast, possibly with contributions from prerenal factors or intratubular obstruction. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The reported incidence of contrast-induced nephropathy varies widely, largely depending upon the presence or absence of risk factors, primarily including underlying chronic kidney disease. The risk is very small among patients with baseline normal renal function, even among diabetic patients. The risk increases with the severity of underlying renal dysfunction, especially among diabetic patients. The risk is also higher among patients with heart failure or hemodynamic instability. The risk increases as the volume of contrast agent increases but there is no &ldquo;safe&rdquo; dose below which acute kidney injury does not occur. The risk various with various types of contrast agents, particularly hyperosmolal ionic contrast agents. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link&amp;anchor=H5#H5\">",
"       \"Prevention of contrast-induced nephropathy\", section on 'Type of contrast agent'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinical manifestations of contrast nephropathy are observed within the first 24 to 48 hours after the contrast study. Most patients are nonoliguric and the only perceived abnormality is a mild increase in the serum creatinine which starts to decline within three to seven days. The urinary sediment may show classic findings of ATN. Protein excretion is absent or mild. The FENa is often below 1 percent which is in contrast to patients who develop AKI due to ischemic or toxin-induced ATN, but this may in part be explained by the fact that contrast nephropathy is usually non-oliguric and ischemic ATN is usually oliguric. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis is based upon the clinical presentation and the exclusion of other causes of AKI. A characteristic urinalysis supports the diagnosis but does not provide a conclusive diagnosis of contrast nephropathy. The absence of other findings on urinalysis such as white blood cells (wbc) or wbc casts or dysmorphic red blood cells (rbc) or rbc casts generally excludes other causes of AKI such as interstitial nephritis and glomerular diseases. Conversely, the presence of wbc, wbc casts, dysmorphic rbc or rbc casts suggests other causes of AKI.",
"     </li>",
"     <li>",
"      We generally do not obtain an ultrasound, at least initially, among patients who have a characteristic presentation of contrast nephropathy following contrast exposure. However, we do obtain an ultrasound to exclude other causes of AKI among patients who do not follow a classic clinical course of contrast nephropathy, or in whom the diagnosis of contrast nephropathy is uncertain. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A renal biopsy is generally not helpful for the diagnosis of contrast nephropathy since the lesions of ATN are focal and non-specific, and because AKI due to contrast nephropathy is generally short-lived. However, as with the ultrasound, a biopsy may rarely be required to exclude other causes of AKI among patients who do not follow a classic clinical course, or in whom the diagnosis of contrast nephropathy is uncertain. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes ischemic acute tubular necrosis, acute interstitial nephritis, and renal atheroemboli. The former two require additional insults such as sepsis or hypotension, or medication exposure, which may be excluded by history. Renal atheroemboli may be distinguished by the presence of other embolic lesions (as on the toes) or livedo reticularis, and transient eosinophilia and hypocomplementemia. In addition, the onset of kidney injury due to atheroemboli may be delayed for days to weeks after the procedure and has a protracted course with frequently little or no recovery of renal function. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/1\">",
"      Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989; 320:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/2\">",
"      Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995; 47:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/3\">",
"      Davidson CJ, Hlatky M, Morris KG, et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial. Ann Intern Med 1989; 110:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/4\">",
"      Schwab SJ, Hlatky MA, Pieper KS, et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 1989; 320:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/5\">",
"      Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989; 86:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/6\">",
"      Lautin EM, Freeman NJ, Schoenfeld AH, et al. Radiocontrast-associated renal dysfunction: incidence and risk factors. AJR Am J Roentgenol 1991; 157:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/7\">",
"      Lautin, EM, Freeman, NJ, Schoenfeld, AH, et al. Radiocontrast-associated renal dysfunction: a comparison of lower-osmolality and conventional high-osmolality contrast media. AJR Am J Roentgenol 1991; 157:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/8\">",
"      Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism--a critical review. Am J Kidney Dis 1994; 24:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/9\">",
"      Barrett BJ. Contrast nephrotoxicity. J Am Soc Nephrol 1994; 5:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/10\">",
"      Solomon R. Contrast-medium-induced acute renal failure. Kidney Int 1998; 53:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/11\">",
"      Weisbord SD, Palevsky PM. Radiocontrast-induced acute renal failure. J Intensive Care Med 2005; 20:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/12\">",
"      Detrenis S, Meschi M, Musini S, Savazzi G. Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant 2005; 20:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/13\">",
"      Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005; 68:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/14\">",
"      Heyman SN, Rosenberger C, Rosen S. Regional alterations in renal haemodynamics and oxygenation: a role in contrast medium-induced nephropathy. Nephrol Dial Transplant 2005; 20 Suppl 1:i6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/15\">",
"      Agmon Y, Peleg H, Greenfeld Z, et al. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 1994; 94:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/16\">",
"      Weisberg LS, Kurnik PB, Kurnik BR. Radiocontrast-induced nephropathy in humans: role of renal vasoconstriction. Kidney Int 1992; 41:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/17\">",
"      Cantley LG, Spokes K, Clark B, et al. Role of endothelin and prostaglandins in radiocontrast-induced renal artery constriction. Kidney Int 1993; 44:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/18\">",
"      Katholi RE, Taylor GJ, McCann WP, et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995; 195:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/19\">",
"      Russo D, Minutolo R, Cianciaruso B, et al. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995; 6:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/20\">",
"      Pflueger A, Larson TS, Nath KA, et al. Role of adenosine in contrast media-induced acute renal failure in diabetes mellitus. Mayo Clin Proc 2000; 75:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/21\">",
"      Molitoris BA, Dahl R, Geerdes A. Cytoskeleton disruption and apical redistribution of proximal tubule Na(+)-K(+)-ATPase during ischemia. Am J Physiol 1992; 263:F488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/22\">",
"      Fang LS, Sirota RA, Ebert TH, Lichtenstein NS. Low fractional excretion of sodium with contrast media-induced acute renal failure. Arch Intern Med 1980; 140:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/23\">",
"      Wang A, Holcslaw T, Bashore TM, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 2000; 57:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/24\">",
"      Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002; 143:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/25\">",
"      Heyman SN, Rosen S, Rosenberger C. Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy. Clin J Am Soc Nephrol 2008; 3:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/26\">",
"      Heinrich MC, Kuhlmann MK, Grgic A, et al. Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology 2005; 235:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/27\">",
"      Yoshioka T, Fogo A, Beckman JK. Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 1992; 41:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/28\">",
"      Goodman AI, Olszanecki R, Yang LM, et al. Heme oxygenase-1 protects against radiocontrast-induced acute kidney injury by regulating anti-apoptotic proteins. Kidney Int 2007; 72:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/29\">",
"      Newhouse JH, Kho D, Rao QA, Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR Am J Roentgenol 2008; 191:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/30\">",
"      Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/31\">",
"      Brar SS, Shen AY, Jorgensen MB, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008; 300:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/32\">",
"      Heinrich MC, H&auml;berle L, M&uuml;ller V, et al. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology 2009; 250:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/33\">",
"      Rudnick MR, Davidson C, Laskey W, et al. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. Am Heart J 2008; 156:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/34\">",
"      Solomon RJ, Mehran R, Natarajan MK, et al. Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol 2009; 4:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/35\">",
"      Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105:2259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/36\">",
"      McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/37\">",
"      Nikolsky E, Mehran R, Lasic Z, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int 2005; 67:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/38\">",
"      Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/39\">",
"      Barrett BJ, Parfrey PS, Vavasour HM, et al. Contrast nephropathy in patients with impaired renal function: high versus low osmolar media. Kidney Int 1992; 41:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/40\">",
"      Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990; 89:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/41\">",
"      Weisbord SD, Mor MK, Resnick AL, et al. Incidence and outcomes of contrast-induced AKI following computed tomography. Clin J Am Soc Nephrol 2008; 3:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/42\">",
"      Mitchell AM, Jones AE, Tumlin JA, Kline JA. Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting. Clin J Am Soc Nephrol 2010; 5:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/43\">",
"      McCarthy CS, Becker JA. Multiple myeloma and contrast media. Radiology 1992; 183:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/44\">",
"      Holland MD, Galla JH, Sanders PW, Luke RG. Effect of urinary pH and diatrizoate on Bence Jones protein nephrotoxicity in the rat. Kidney Int 1985; 27:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/45\">",
"      Stolker JM, McCullough PA, Rao S, et al. Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients undergoing coronary angiography. J Am Coll Cardiol 2010; 55:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/46\">",
"      Rim MY, Ro H, Kang WC, et al. The effect of renin-angiotensin-aldosterone system blockade on contrast-induced acute kidney injury: a propensity-matched study. Am J Kidney Dis 2012; 60:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/47\">",
"      Rosenstock JL, Bruno R, Kim JK, et al. The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol 2008; 40:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/48\">",
"      Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 1990; 150:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/13/10457/abstract/49\">",
"      Morcos SK, el-Nahas AM, Brown P, Haylor J. Effect of iodinated water soluble contrast media on urinary protein assays. BMJ 1992; 305:29.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7241 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_13_10457=[""].join("\n");
var outline_f10_13_10457=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H109658431\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1865687499\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Renal vasoconstriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tubular injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18304276\">",
"      Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18304283\">",
"      Diabetic nephropathy with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18304491\">",
"      Dose and type of contrast agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18306140\">",
"      Specific radiologic procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18304572\">",
"      Multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18305754\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18300532\">",
"      Creatinine increase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1865688711\">",
"      Other laboratory manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1865688745\">",
"      Radiographic manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H454598616\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18300539\">",
"      PROGNOSIS AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109658431\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=related_link\" title=\"calculator 1\">",
"      Calculator: Fractional excretion of sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=related_link\" title=\"calculator 2\">",
"      Calculator: Fractional excretion of sodium (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13528?source=related_link\">",
"      Clinical presentation, evaluation, and treatment of renal atheroemboli",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=related_link\">",
"      Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=related_link\">",
"      Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4553?source=related_link\">",
"      Renal and patient outcomes after acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_13_10458="Liposomal doxorubicin: Drug information";
var content_f10_13_10458=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Liposomal doxorubicin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/20/28997?source=see_link\">",
"    see \"Liposomal doxorubicin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15125198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Doxil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F163252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Caelyx&reg;;",
"     </li>",
"     <li>",
"      Myocet&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F163273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Anthracycline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F163255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"     <b>",
"      Liposomal formulations of doxorubicin should NOT be substituted for conventional doxorubicin hydrochloride on a mg-per-mg basis.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      AIDS-related Kaposi's sarcoma:",
"     </b>",
"     I.V.: 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once every 3 weeks; continue as long as responding and tolerating",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Multiple myeloma:",
"     </b>",
"     I.V.: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 4 every 3 weeks (in combination with bortezomib) for up to 8 cycles until disease progression or unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Ovarian cancer, progressive or recurrent:",
"     </b>",
"     I.V.: 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once every 4 weeks (minimum of 4 cycles is recommended)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      AIDS-related Kaposi's sarcoma (Caelyx&reg;):",
"     </b>",
"     I.V.: 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once every 2-3 weeks; continue as long as responding and tolerating",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Breast cancer, metastatic:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Caelyx&reg;: 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once every 4 weeks until disease progression or unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Myocet&trade;: 60-75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once every 3 weeks (in combination with cyclophosphamide)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Ovarian cancer, advanced (Caelyx&reg;):",
"     </b>",
"     I.V.: 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once every 4 weeks until disease progression or unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Unlabeled uses/doses:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Breast cancer, metastatic (unlabeled use in U.S.):",
"     </b>",
"     I.V.: 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 4 weeks (Keller, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Cutaneous T-cell lymphomas (unlabeled use):",
"     </b>",
"     I.V.: 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 and 15 every 4 weeks for 6 cycles (Dummer, 2012)",
"     <b>",
"      or",
"     </b>",
"     20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 4 weeks (Wollina, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hodgkin lymphoma, salvage treatment (unlabeled use):",
"     </b>",
"     I.V.: GVD regimen: 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (post-transplant patients) or 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (transplant-naive patients) days 1 and 8 every 3 weeks (in combination with gemcitabine and vinorelbine) for 2-6 cycles (Bartlett, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Multiple myeloma (unlabeled dosing):",
"     </b>",
"     I.V.: 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 4 weeks (in combination with vincristine and dexamethasone) for at least 4 cycles (Rifkin, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Soft tissue sarcoma, advanced (unlabeled use):",
"     </b>",
"     I.V.: 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 4 weeks for 6 cycles (Judson, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Uterine sarcoma, advanced or recurrent (unlabeled use):",
"     </b>",
"     I.V.: 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 4 weeks until disease progression or unacceptable toxicity (Sutton, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F163256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15581682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F163257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Ovarian cancer and AIDS-related Kaposi's sarcoma:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bilirubin 1.2-3 mg/dL: Administer 50% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bilirubin &gt;3 mg/dL: Administer 25% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Multiple myeloma:",
"     </i>",
"     Dosage adjustment information is not available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      AIDS-related Kaposi's sarcoma (Caelyx&reg;):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Bilirubin 1.2-3 mg/dL: Administer 50% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Bilirubin &gt;3 mg/dL: Administer 25% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Breast cancer:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Caelyx&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Bilirubin 1.2-3 mg/dL: Initial dose: Administer 75% of normal dose; if tolerated and no change in bilirubin/hepatic enzymes, may increase to full dose with cycle 2",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Bilirubin &gt;3 mg/dL: Initial dose: Administer 50% of normal dose; if tolerated and no change in bilirubin/hepatic enzymes, may increase dose to 75% of normal dose for cycle 2; if cycle 2 dose tolerated, may increase to full dose for subsequent cycles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Myocet&trade;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Bilirubin 1.2-3 mg/dL: Administer 50% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Bilirubin &gt;3 mg/dL: Administer 25% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Ovarian cancer (Caelyx&reg;):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Bilirubin 1.2-3 mg/dL: Initial dose: Administer 75% of normal dose; if tolerated and no change in bilirubin/hepatic enzymes, may increase to full dose with cycle 2",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Bilirubin &gt;3 mg/dL: Initial dose: Administer 50% of normal dose; if tolerated and no change in bilirubin/hepatic enzymes, may increase dose to 75% of normal dose for cycle 2; if cycle 2 dose tolerated, may increase to full dose for subsequent cycles.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F163274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Recommended Dose Modification Guidelines",
"     </caption>",
"     <col align=\"center\" width=\"180\">",
"     </col>",
"     <col align=\"left\" width=\"320\">",
"     </col>",
"     <thead valign=\"top\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Toxicity Grade",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose Adjustment",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          HAND FOOT SYNDROME (HFS)",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Mild erythema, swelling, or desquamation not interfering with daily activities)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Redose unless patient has experienced previous Grade 3 or 4 HFS toxicity. If so, delay up to 2 weeks and decrease dose by 25%; return to original dosing interval.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Erythema, desquamation, or swelling interfering with, but not precluding, normal physical activities; small blisters or ulcerations &lt;2 cm in diameter)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Delay dosing up to 2 weeks or until resolved to Grade 0-1. If after 2 weeks there is no resolution, discontinue liposomal doxorubicin.  Otherwise, if no prior Grade 3-4 HFS, continue treatment at previous dose and dosage interval.  If a prior Grade 3-4 HFS has occurred, continue prior dosage interval, but decrease dose by 25%.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Blistering, ulceration, or swelling interfering with walking or normal daily activities; cannot wear regular clothing)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Delay dosing up to 2 weeks or until resolved to Grade 0-1. Decrease dose by 25% and return to original dosing interval; if after 2 weeks there is no resolution, discontinue liposomal doxorubicin.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Diffuse or local process causing infectious complications, or a bedridden state or hospitalization)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Delay dosing up to 2 weeks or until resolved to Grade 0-1. Decrease dose by 25% and return to original dosing interval. If after 2 weeks there is no resolution, discontinue liposomal doxorubicin.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          STOMATITIS",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Painless ulcers, erythema, or mild soreness)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Redose unless patient has experienced previous Grade 3 or 4 toxicity. If so, delay up to 2 weeks and decrease by 25%. Return to original dosing interval.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Painful erythema, edema, or ulcers, but can eat)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Delay dosing up to 2 weeks or until resolved to Grade 0-1. If after 2 weeks there is no resolution, discontinue liposomal doxorubicin.  Otherwise, if not prior Grade 3-4 stomatitis, continue treatment at previous dose and dosage interval. If prior Grade 3-4 toxicity, continue treatment with previous dosage interval, but decrease dose by 25%.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Painful erythema, edema, or ulcers, and cannot eat)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Delay dosing up to 2 weeks or until resolved to Grade 0-1. Decrease dose by 25% and return to original dosing interval. If after 2 weeks there is no resolution, discontinue liposomal doxorubicin.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Requires parenteral or enteral support)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Delay dosing up to 2 weeks or until resolved to Grade 0-1. Decrease dose by 25% and return to original dosing interval. If after 2 weeks there is no resolution, discontinue liposomal doxorubicin.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Hematologic Toxicity (see below for multiple myeloma)",
"     </caption>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"85\">",
"     </col>",
"     <col align=\"center\" width=\"105\">",
"     </col>",
"     <col align=\"left\" width=\"260\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Grade",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         ANC",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Platelets",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Modification",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1500-1900",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75,000-150,000",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Resume treatment with no dose reduction.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1000-&lt;1500",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50,000-&lt;75,000",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Wait until ANC &ge;1500 and platelets &ge;75,000; redose with no dose reduction.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500-999",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25,000-&lt;50,000",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Wait until ANC &ge;1500 and platelets &ge;75,000; redose with no dose reduction.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;500",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;25,000",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Wait until ANC &ge;1500 and platelets &ge;75,000; redose at 25% dose reduction or continue full dose with cytokine support.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing Adjustment for Toxicity in Treatment with Bortezomib (for Multiple Myeloma)",
"     </b>",
"     (see Bortezomib monograph for bortezomib dosage reduction with toxicity guidelines):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Fever &ge;38&deg;C and ANC &lt;1000/mm",
"      <sup>",
"       3",
"      </sup>",
"      :",
"     </i>",
"     If prior to doxorubicin liposomal treatment (day 4), do not administer; if after doxorubicin liposomal administered, reduce dose by 25% in next cycle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      ANC &lt;500/mm",
"      <sup>",
"       3",
"      </sup>",
"      , platelets &lt;25,000/mm",
"      <sup>",
"       3",
"      </sup>",
"      , hemoglobin &lt;8 g/dL:",
"     </i>",
"     If prior to doxorubicin liposomal treatment (day 4); do not administer; if after doxorubicin liposomal administered, reduce dose by 25% in next cycle if bortezomib dose reduction occurred for hematologic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Grade 3 or 4 nonhematologic toxicity:",
"     </i>",
"     Delay dose until resolved to grade &lt;2; reduce dose by 25% for all subsequent doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Neuropathic pain or peripheral neuropathy:",
"     </i>",
"     No dose reductions needed for doxorubicin liposomal, refer to Bortezomib monograph for bortezomib dosing adjustment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Caelyx&reg;: Nonhematologic toxicity: Breast cancer, ovarian cancer:",
"     </b>",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Caelyx&reg;: Recommended Dose Modification Guidelines",
"     </caption>",
"     <col align=\"center\" width=\"160\">",
"     </col>",
"     <col align=\"left\" width=\"160\">",
"     </col>",
"     <col align=\"left\" width=\"160\">",
"     </col>",
"     <thead valign=\"top\">",
"      <tr>",
"       <th align=\"center\">",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Week After Prior Caelyx&reg; Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Breast Cancer or Ovarian Cancer)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         Toxicity Grade",
"        </p>",
"       </th>",
"       <th align=\"left\">",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         Weeks 4 and 5",
"        </p>",
"       </th>",
"       <th align=\"left\">",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         Week 6",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          HAND FOOT SYNDROME (HFS)",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Mild erythema, swelling, or desquamation not interfering with daily activities)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Redose unless patient has experienced previous Grade 3 or 4 HFS toxicity. If so, wait an additional week",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Decrease dose by 25%; return to 4-week interval",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Erythema, desquamation, or swelling interfering with, but not precluding, normal physical activities; small blisters or ulcerations &lt;2 cm in diameter)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Wait an additional week",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Decrease dose by 25%; return to 4-week interval",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Blistering, ulceration, or swelling interfering with walking or normal daily activities; cannot wear regular clothing)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Wait an additional week",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Discontinue therapy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Diffuse or local process causing infectious complications, or a bedridden state or hospitalization)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Wait an additional week",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Discontinue therapy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          STOMATITIS",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Painless ulcers, erythema, or mild soreness)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Redose unless patient has experienced previous Grade 3 or 4 stomatitis. If so, wait an additional week.",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Decrease dose by 25%; return to 4-week interval or if warranted, discontinue therapy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Painful erythema, edema, or ulcers, but can eat)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Wait an additional week",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Decrease dose by 25%; return to 4-week interval or if warranted, discontinue therapy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Painful erythema, edema, or ulcers, and cannot eat)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Wait an additional week",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Discontinue therapy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Requires parenteral or enteral support)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Wait an additional week",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Discontinue therapy",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Caelyx&reg;: Hematologic toxicity: Breast cancer, ovarian cancer: Refer to U.S. dosage adjustment for hematologic toxicity section.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Caelyx&reg;: Nonhematologic toxicity: AIDS-related Kaposi&rsquo;s sarcoma:",
"     </b>",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Caelyx&reg;: Recommended Dose Modification Guidelines: Hand-Foot Syndrome (HFS) (AIDS-related Kaposi&rsquo;s Sarcoma)",
"     </caption>",
"     <col align=\"center\" width=\"160\">",
"     </col>",
"     <col align=\"left\" width=\"160\">",
"     </col>",
"     <col align=\"left\" width=\"160\">",
"     </col>",
"     <thead valign=\"top\">",
"      <tr>",
"       <th align=\"center\">",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Weeks Since Last Caelyx&reg; Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (AIDS-related Kaposi&rsquo;s Sarcoma)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         Toxicity Grade",
"        </p>",
"       </th>",
"       <th align=\"left\">",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         3 Weeks",
"        </p>",
"       </th>",
"       <th align=\"left\">",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         4 Weeks",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          HAND-FOOT SYNDROME (HFS)",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Mild erythema, swelling, or desquamation not interfering with daily activities)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Redose unless patient has experienced previous Grade 3 or 4 skin toxicity. If so, wait an additional week",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Decrease dose by 25%; return to 3-week interval",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Erythema, desquamation, or swelling interfering with, but not precluding, normal physical activities; small blisters or ulcerations &lt;2 cm in diameter)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Wait an additional week",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Decrease dose by 50%; return to 3-week interval",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Blistering, ulceration, or swelling interfering with walking or normal daily activities; cannot wear regular clothing)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Wait an additional week",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Discontinue therapy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Diffuse or local process causing infectious complications, or a bedridden state or hospitalization)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Wait an additional week",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Discontinue therapy",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Caelyx&reg;: Recommended Dose Modification Guidelines: Stomatitis (AIDS-related Kaposi&rsquo;s Sarcoma)",
"     </caption>",
"     <col align=\"center\" width=\"160\">",
"     </col>",
"     <col align=\"left\" width=\"160\">",
"     </col>",
"     <col align=\"left\" width=\"160\">",
"     </col>",
"     <thead valign=\"top\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         STOMATITIS",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Toxicity grade:",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Caelyx&reg; Dosage Adjustment",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (AIDS-related Kaposi&rsquo;s Sarcoma)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Painless ulcers, erythema, or mild soreness)",
"        </p>",
"       </td>",
"       <td align=\"left\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         No dosage adjustment",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Painful erythema, edema, or ulcers, but can eat)",
"        </p>",
"       </td>",
"       <td align=\"left\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Wait 1 week and if symptoms improve, redose at 100% dose",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Painful erythema, edema, or ulcers, and cannot eat)",
"        </p>",
"       </td>",
"       <td align=\"left\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Wait 1 week and if symptoms improve, redose with a 25% dose reduction",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Requires parenteral or enteral support)",
"        </p>",
"       </td>",
"       <td align=\"left\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Wait 1 week and if symptoms improve, redose with a 50% dose reduction",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Caelyx&reg;: Hematologic toxicity: AIDS-related Kaposi's sarcoma:",
"     </b>",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Caelyx&reg;: Hematologic Toxicity (AIDS-related Kaposi's Sarcoma)",
"     </caption>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"85\">",
"     </col>",
"     <col align=\"center\" width=\"105\">",
"     </col>",
"     <col align=\"left\" width=\"260\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Grade",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         ANC",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Platelets",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Modification",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1500-1900",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75,000-150,000",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         None",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1000-&lt;1500",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50,000-&lt;75,000",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         None",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500-999",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25,000-&lt;50,000",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Wait until ANC &ge;1000 and/or platelets &ge;50,000; redose with a 25% dose reduction.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;500",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;25,000",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Wait until ANC &ge;1000 and/or platelets &ge;50,000; redose with a 50% dose reduction.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Myocet&trade;: Hematologic or gastrointestinal toxicity:",
"     </b>",
"     Dosage reduction: If initial dose was 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , reduce dose to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; if initial dose was 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , reduce dose to 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . If toxicity persists with subsequent cycles, consider reducing dose further (from 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     or from 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Neutropenia:",
"     </i>",
"     If grade 4 neutropenia (ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) without fever lasting &ge;7 days or grade 4 neutropenia of any duration with concurrent fever (&ge;38.5&deg;C) occurs, consider reducing dose with subsequent cycles.",
"     <b>",
"      Note:",
"     </b>",
"     Prior to dose reductions, prophylactic cytokine therapy may be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Thrombocytopenia or anemia:",
"     </i>",
"     If grade 4 thrombocytopenia or anemia occurs, hold therapy until recovery to &le; grade 2. Reduce dose with subsequent cycles or consider discontinuing treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Gastrointestinal toxicity or mucositis:",
"     </i>",
"     Grade 3 mucositis persisting &ge;3 days, or grade 4 mucositis of any duration, or grade 3 or 4 gastrointestinal toxicity not responsive to interventions and/or prophylaxis: Consider dose reduction with subsequent cycles.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F163229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Doxil&reg;: 2 mg/mL (10 mL, 25 mL) [contains soy, sucrose]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F15577820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride, pegylated:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Caelyx&reg;: 2 mg/mL (10 mL, 25 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, encapsulated liposomes:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myocet&trade;: 3-vial kit (doxorubicin HCl for injection 50 mg/vial, liposomes for injection, and buffer for injection)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F163214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F163232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer as a bolus injection or I.M. or SubQ. Avoid extravasation (irritant); monitor infusion site; extravasation may occur without stinging or burning. Monitor for infusion reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxil&reg;, Caelyx&reg;: Administer IVPB over 60 minutes; manufacturer recommends administering at initial rate of 1 mg/minute to minimize risk of infusion reactions until the absence of a reaction has been established, then increase the infusion rate for completion over 1 hour. Do",
"     <b>",
"      NOT",
"     </b>",
"     administer undiluted. Do",
"     <b>",
"      NOT",
"     </b>",
"     infuse with in-line filters. Incompatible with heparin flushes; flush with 5-10 mL of D",
"     <sub>",
"      5",
"     </sub>",
"     W solution before and after drug administration (do not rapidly flush through the I.V. line). Monitor for local erythematous streaking along vein and/or facial flushing (may indicate rapid infusion rate).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Myocet&trade;: Infuse over 1 hour.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F163280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, aminophylline, ampicillin, aztreonam, bleomycin, butorphanol, calcium gluconate, carboplatin, cefazolin, cefepime, cefoxitin, chlorpromazine, cimetidine, ciprofloxacin, cisplatin, clindamycin, cyclophosphamide, cytarabine, dacarbazine, dexamethasone sodium phosphate, diphenhydramine, dobutamine, dopamine, droperidol, enalaprilat, etoposide, famotidine, fluconazole, fluorouracil, furosemide, ganciclovir, gentamicin, granisetron, haloperidol lactate, heparin, hydrocortisone sodium succinate, hydromorphone, ifosfamide, leucovorin calcium, lorazepam, magnesium sulfate, mesna, methotrexate, methylprednisolone sodium succinate, metronidazole, ondansetron, piperacillin, potassium chloride, prochlorperazine edisylate, ranitidine, sulfamethoxazole/trimethoprim, ticarcillin/clavulanate, tobramycin, vancomycin, vinblastine, vincristine, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, amphotericin B cholesteryl sulfate complex, buprenorphine, ceftazidime, docetaxel, gallium nitrate, hydroxyzine, mannitol, meperidine, metoclopramide, mitoxantrone, morphine, paclitaxel, piperacillin/tazobactam, promethazine, sodium bicarbonate.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F163230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. labeling: Treatment of ovarian cancer (progressive or recurrent after platinum-based treatment); multiple myeloma (in combination with bortezomib in patients who are bortezomib na&iuml;ve and after failure of at least 1 prior therapy); AIDS-related Kaposi's sarcoma (after failure of or intolerance to prior systemic therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Canadian labeling: Treatment of metastatic breast cancer (as monotherapy [Caelyx&reg;] or in combination with cyclophosphamide [Myocet&trade;]); advanced ovarian cancer (after failure of first-line treatment [Caelyx&reg;]); AIDS-related Kaposi's sarcoma (after failure of or intolerance to prior systemic therapy [Caelyx&reg;])",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5045755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic breast cancer, Hodgkin lymphoma (salvage treatment), cutaneous T-cell lymphomas (mycosis fungoides and S&eacute;zary syndrome), advanced soft tissue sarcomas; advanced or recurrent uterine sarcoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F163282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       DOXOrubicin liposomal may be confused with DACTINomycin, DAUNOrubicin, DAUNOrubicin liposomal, doxapram, doxazosin, DOXOrubicin, epirubicin, IDArubicin, valrubicin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       DOXOrubicin liposomal may be confused with DAUNOrubicin liposomal",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxil&reg; may be confused with Doxy 100&trade;, Paxil&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Liposomal formulation (Doxil&reg;) may be confused with the conventional formulation (Adriamycin PFS&reg;, Adriamycin RDF&reg;)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Use caution when selecting product for preparation and dispensing; indications, dosages and adverse event profiles differ between conventional DOXOrubicin hydrochloride solution and DOXOrubicin liposomal. Both formulations are the same concentration. As a result, serious errors have occurred. Liposomal formulation of doxorubicin should NOT be substituted for doxorubicin hydrochloride on a mg-per-mg basis.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Caelyx&reg; [Canada] may be confused with Myocet&trade; [Canada]; product formulations and indications differ",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Doxil [U.S., Israel] may be confused with Doxal brand name for doxepin [Finland] and pyridoxine/thiamine [Brazil]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F163271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (8% to 21%), headache (&le;11%), pain (&le;21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Palmar-plantar erythrodysesthesia/hand-foot syndrome (&le;51% in ovarian cancer [grades 3/4: 24%]; 3% in Kaposi's sarcoma), rash (&le;29% in ovarian cancer, &le;5% in Kaposi's sarcoma), alopecia (9% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (17% to 46%), stomatitis (5% to 41%), vomiting (8% to 33%), constipation (&le;30%), diarrhea (5% to 21%), anorexia (&le;20%), mucositis (&le;14%), dyspepsia (&le;12%), intestinal obstruction (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Myelosuppression (onset: 7 days; nadir: 10-14 days; recovery: 21-28 days), thrombocytopenia (13% to 65%; grades 3/4: 1%), neutropenia (12% to 62%; grade 4: 4%), leukopenia (36%), anemia (6% to 74%; grade 4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (7% to 40%), back pain (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (&le;16%), dyspnea (&le;15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest, chest pain, deep thrombophlebitis, edema, hypotension, pallor, tachycardia, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, chills, confusion, depression, dizziness, emotional lability, insomnia, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne, bruising, dry skin (6%), exfoliative dermatitis, fungal dermatitis, furunculosis, maculopapular rash, pruritus, skin discoloration, vesiculobullous rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration, hypercalcemia, hyperglycemia, hypokalemia, hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdomen enlarged, anorexia, ascites, cachexia, dyspepsia, dysphagia, esophagitis, flatulence, gingivitis, glossitis, ileus, mouth ulceration, oral moniliasis, rectal bleeding, taste perversion, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Cystitis, dysuria, leukorrhea, pelvic pain, polyuria, urinary incontinence, urinary tract infection, urinary urgency, vaginal bleeding, vaginal moniliasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemolysis, prothrombin time increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased, alkaline phosphatase increased, hyperbilirubinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, hypertonia, myalgia, neuralgia, neuritis (peripheral), neuropathy, paresthesia (&le;10%), pathological fracture",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis, dry eyes, retinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ear pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Albuminuria, hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Apnea, cough (&le;10%), epistaxis, pleural effusion, pneumonia, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction; infusion-related reactions (7%; includes bronchospasm, chest tightness, chills, dyspnea, facial edema, flushing, headache, herpes simplex/zoster, hypotension, pruritus); moniliasis, diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abscess, acute brain syndrome, abnormal vision, acute myeloid leukemia (secondary), alkaline phosphatase increased, anaphylactic or anaphylactoid reaction, asthma, balanitis, blindness, bronchitis, BUN increased, bundle branch block, cardiomegaly, cardiomyopathy, cellulitis, CHF, colitis, creatinine increased, cryptococcosis, diabetes mellitus, erythema multiforme, erythema nodosum, eosinophilia, fecal impaction, flu-like syndrome, gastritis, glucosuria, hemiplegia, hemorrhage, hepatic failure, hepatitis, hepatosplenomegaly, hyperkalemia, hypernatremia, hyperuricemia, hyperventilation, hypoglycemia, hypolipidemia, hypomagnesemia, hypophosphatemia, hypoproteinemia, hypothermia, injection site hemorrhage, injection site pain, jaundice, ketosis, lactic dehydrogenase increased, lymphadenopathy, lymphangitis, migraine, myositis, optic neuritis, oral cancers (squamous cell; long-term use), palpitation, pancreatitis, pericardial effusion, petechia, pneumonitis, pneumothorax, pulmonary embolism, radiation injury, reddish/orange discoloration of urine/body fluids, renal failure, sclerosing cholangitis, seizure, sepsis, skin necrosis, skin ulcer, syncope, Stevens-Johnson syndrome, tenesmus, thromboplastin decreased, thrombosis, tinnitus, toxic epidermal necrolysis, urticaria, visual field defect, ventricular arrhythmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F163235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to doxorubicin liposomal, conventional doxorubicin, or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Canadian labeling (Caelyx&reg;): Additional contraindications (not in U.S. labeling): Breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F163218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Severe myelosuppression may occur.",
"     </b>",
"     Monitor blood counts. Treatment delay, dosage modification, or discontinuation may be required. Leukopenia is usually transient, although persistent or severe neutropenia may result in superinfection or neutropenic fever; sepsis due to neutropenia has resulted in discontinuation (may rarely be fatal). Hemorrhage due to thrombocytopenia may occur. Hematologic toxicity may be more severe with combination chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Acute infusion reactions may occur, some may be serious/life-threatening (eg, allergic or anaphylactoid reactions). Reactions may include flushing, dyspnea, facial swelling, headache, chills, back pain, hypotension, and/or chest/throat tightness. Infusion reactions typically occur with the first dose and usually resolve with within several hours to a day after terminating the infusion; some have resolved with slowing the infusion rate. To minimize the risk of infusion reactions, infuse at an initial rate of 1 mg/minute. Medications for the treatment of reactions should be readily available in the event of severe reaction.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Doxorubicin may cause cumulative, dose-related myocardial toxicity may lead to congestive heart failure as the cumulative (lifetime) dose of pegylated doxorubicin liposomal approaches 550 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      . When calculating cumulative doses, also include prior dose of other anthracyclines and anthracenediones. Cardiotoxicity may occur at lower cumulative doses (400 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      ) in patients who have received prior mediastinal irradiation or are receiving concurrent cyclophosphamide treatment.",
"     </b>",
"     For Myocet&trade; (Canadian availability), cardiotoxicity may occur as the cumulative (lifetime) dose approaches 750 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Anthracycline-induced cardiotoxicity may be delayed (after discontinuation of anthracycline treatment). Use only if potential benefits outweigh cardiovascular risk in patients with a history of cardiovascular disease. Monitor cardiac function with biopsy, echocardiography, or MUGA scan; evaluate left ventricular ejection fraction (LVEF) prior to treatment and periodically during treatment; if results indicate possible heart failure, carefully evaluate the potential effects of continued treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Palmar-plantar erythrodysesthesia (hand-foot syndrome): Hand-foot syndrome has been reported, more commonly in patients with ovarian cancer and multiple myeloma, and less commonly in patients with Kaposi's sarcoma. May occur early in treatment, but is usually seen after 2-3 treatment cycles. Dosage modification may be required; mild cases resolve within 1-2 weeks. In severe cases, treatment discontinuation may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Radiation therapy: Radiation recall reaction has been reported with doxorubicin liposomal treatment after radiation therapy. Radiation-induced toxicity (to the myocardium, mucosa, skin, and liver) may be increased by doxorubicin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Use with caution in patients with hepatic impairment; dosage reduction is recommended.",
"     </b>",
"     Use in patients with hepatic impairment has not been adequately studied; no dosing adjustment recommendations are available for multiple myeloma patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Splenectomized patients: Use of Caelyx&reg; (Canadian availability) in splenectomized patients with AIDS-related Kaposi&rsquo;s sarcoma is not recommended; (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Toxicity potentiation: Doxorubicin may potentiate the toxicity of cyclophosphamide (hemorrhagic cystitis) and mercaptopurine (hepatotoxicity).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Liposomal vs conventional formulation dosing:",
"     <b>",
"      [U.S. Boxed Warning]: Liposomal formulations of doxorubicin should NOT be substituted for conventional doxorubicin hydrochloride on a mg-per-mg basis.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F163268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2B6 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F163223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bevacizumab: May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: May diminish the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic). Antineoplastic Agents (Anthracycline, Systemic) may decrease the serum concentration of Cardiac Glycosides. The effects of liposomal formulations may be unique from those of the free drug, as liposomal formulation have unique drug disposition and toxicity profiles, and liposomes themselves may alter digoxin absorption/distribution.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inhibitors (Moderate) may decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stavudine: DOXOrubicin (Liposomal) may diminish the therapeutic effect of Stavudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Taxane Derivatives: May enhance the adverse/toxic effect of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may increase the serum concentration of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: DOXOrubicin (Liposomal) may enhance the adverse/toxic effect of Zidovudine. DOXOrubicin (Liposomal) may diminish the therapeutic effect of Zidovudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F163247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (due to GI irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease doxorubicin levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F163225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F163237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies at doses less than the equivalent human dose (based on BSA). May cause fetal harm if administered during pregnancy. Women of childbearing potential should avoid becoming pregnant during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F163263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5045756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding should be discontinued during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (Doxil Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (10 mL): $1293.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (Lipodox 50 Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (25 mL): $2878.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (Lipodox Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (10 mL): $1151.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F163227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, liver function tests (ALT/AST, bilirubin, alkaline phosphatase); monitor for infusion reactions, hand-foot syndrome, and stomatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiac function (left ventricular ejection fraction [LVEF]; baseline and periodic); echocardiography, or MUGA scan may be used. Endomyocardial biopsy is the most definitive test for anthracycline myocardial injury.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F163238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      A.D.Mycin (KP);",
"     </li>",
"     <li>",
"      Adriablastin (AT, CH, HN);",
"     </li>",
"     <li>",
"      Adriablastina (CZ, GR, PT);",
"     </li>",
"     <li>",
"      Adriablastina R.D. (TH);",
"     </li>",
"     <li>",
"      Adriacin (JP);",
"     </li>",
"     <li>",
"      Adriamicine (RU);",
"     </li>",
"     <li>",
"      Adriamycin (AU, CZ, DK, FI, GB, HK, NO, SE, TH);",
"     </li>",
"     <li>",
"      Adriamycin P.F.S. (KP);",
"     </li>",
"     <li>",
"      Adriamycin R.D.F. (KP);",
"     </li>",
"     <li>",
"      Adriblastin (RU);",
"     </li>",
"     <li>",
"      Adriblastina (AE, AR, BE, BF, BG, BH, BJ, CI, CR, CY, DO, EG, ET, GH, GM, GN, GT, HN, IL, IQ, IR, IT, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NI, NL, OM, PA, PE, PH, QA, SA, SC, SD, SL, SN, SV, SY, TN, TR, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Adriblastina CS (CO);",
"     </li>",
"     <li>",
"      Adriblastina PFS (IL);",
"     </li>",
"     <li>",
"      Adriblastina RD (BR);",
"     </li>",
"     <li>",
"      Adriblastina RTU (CN);",
"     </li>",
"     <li>",
"      Adriblastine (FR);",
"     </li>",
"     <li>",
"      Adrim (IN, PH);",
"     </li>",
"     <li>",
"      Adrimedac (DE);",
"     </li>",
"     <li>",
"      Adrubicin (KP);",
"     </li>",
"     <li>",
"      Amminac (TH);",
"     </li>",
"     <li>",
"      Caelyx (AR, AT, AU, BE, BG, CH, CN, CR, CZ, DE, DK, DO, EC, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IT, MX, MY, NI, NL, NO, PA, PE, PH, PT, RU, SE, SG, SV, TH, TR, TW, UY, VE);",
"     </li>",
"     <li>",
"      Carcinocin (ID);",
"     </li>",
"     <li>",
"      Dicladox (PE);",
"     </li>",
"     <li>",
"      Doxolem (CR, DO, GT, HN, MX, NI, PA, SV, TH);",
"     </li>",
"     <li>",
"      Doxor Lyo (TW);",
"     </li>",
"     <li>",
"      Doxorubicin (IN);",
"     </li>",
"     <li>",
"      Doxorubicin Meiji (IN);",
"     </li>",
"     <li>",
"      Doxorubin (NZ, TH);",
"     </li>",
"     <li>",
"      Lipo-Dox (TH);",
"     </li>",
"     <li>",
"      Myocet (AT, BE, BG, CH, CZ, DE, DK, ES, FI, FR, GB, GR, HN, IE, IT, NL, NO, PT, RU, SE, TR);",
"     </li>",
"     <li>",
"      Rubidox (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F163217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doxorubicin inhibits DNA and RNA synthesis by intercalating between DNA base pairs causing steric obstruction and inhibits topoisomerase-II at the point of DNA cleavage. Doxorubicin is also a powerful iron chelator. The iron-doxorubicin complex can bind DNA and cell membranes, producing free hydroxyl (OH) radicals that cleave DNA and cell membranes. Active throughout entire cell cycle. Doxorubicin liposomal is a pegylated formulation which protects the liposomes, and thereby increases blood circulation time.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F163234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 2.7-2.8 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: Unknown; nonliposomal (conventional) doxorubicin: 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: Distribution: 4.7-5.2 hours, Elimination: 44-55 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and in plasma to doxorubicinol and the sulfate and glucuronide conjugates of 4-demethyl,7-deoxyaglycones",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (5% as doxorubicin or doxorubicinol)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alba E, Ruiz-Borrego M, Margel&iacute; M, et al, &ldquo;Maintenance Treatment With Pegylated Liposomal Doxorubicin versus Observation Following Induction Chemotherapy for Metastatic Breast Cancer: GEICAM 2001-01 Study,&rdquo;",
"      <i>",
"       Breast Cancer Res Treat",
"      </i>",
"      , 2010, 122(1):169-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/20361253/pubmed\" id=\"20361253\" target=\"_blank\">",
"        20361253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartlett NL, Niedzwiecki D, Johnson JL, et al, &ldquo;Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin (GVD), A Salvage Regimen in Relapsed Hodgkin&rsquo;s Lymphoma: CALGB 59804,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2007, 18(6):1071-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/17426059/pubmed\" id=\"17426059\" target=\"_blank\">",
"        17426059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Biehn SE, Moore DT, Voorhees PM, et al, &ldquo;Extended Follow-Up of Outcome Measures in Multiple Myeloma Patients Treated on a Phase I Study With Bortezomib and Pegylated Liposomal Doxorubicin,&rdquo;",
"      <i>",
"       Ann Hematol",
"      </i>",
"      , 2007, 86(3):211-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/17146676/pubmed\" id=\"17146676\" target=\"_blank\">",
"        17146676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cannon TL, Muggia F, Hirsch D, et al, &ldquo;Multiple Cases of Squamous Cell Carcinoma of the Tongue and Oral Cavity in Patients Treated With Long-Term Pegylated Liposomal Doxorubicin (PLD) for Ovarian Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(15s):5557 [abstract 5557 from 2011 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dummer R, Quaglino P, Becker JC, Hasan B, et al, &ldquo;Prospective International Multicenter Phase II Trial of Intravenous Pegylated Liposomal Doxorubicin Monochemotherapy in Patients With Stage IIB, IVA, or IVB Advanced Mycosis Fungoides: Final Results from EORTC 21012,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(33):4091-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/23045580/pubmed\" id=\"23045580\" target=\"_blank\">",
"        23045580",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forbes C, Wilby J, Richardson G, et al, &ldquo;A Systematic Review and Economic Evaluation of Pegylated Liposomal Doxorubicin Hydrochloride for Ovarian Cancer,&rdquo;",
"      <i>",
"       Health Technol Assess",
"      </i>",
"      , 2002, 6(23):1-119.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gabizon A, Shmeeda H, and Barenholz Y, &ldquo;Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2003, 42(5):419-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/12739982/pubmed\" id=\"12739982\" target=\"_blank\">",
"        12739982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gordon AN, Fleagle JT, Guthrie D, et al, &ldquo;Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(14):3312-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/11454878/pubmed\" id=\"11454878\" target=\"_blank\">",
"        11454878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gordon AN, Granai CO, Rose PG, et al, &ldquo;Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(17):3093-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/10963637/pubmed\" id=\"10963637\" target=\"_blank\">",
"        10963637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hussein MA, Wood L, Hsi E, et al, &ldquo;A Phase II Trial of Pegylated Liposomal Doxorubicin, Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2002, 95(10):2160-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/12412170/pubmed\" id=\"12412170\" target=\"_blank\">",
"        12412170",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Judson I, Radford JA, Harris M, et al, &ldquo;Randomised Phase II Trial of Pegylated Liposomal Doxorubicin (DOXIL/CAELYX) versus Doxorubicin in the Treatment of Advanced or Metastatic Soft Tissue Sarcoma: a Study by the EORTC Soft Tissue and Bone Sarcoma Group,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2001, 37(7):870-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/11313175/pubmed\" id=\"11313175\" target=\"_blank\">",
"        11313175",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keller AM, Mennel RG, Georgoulias VA, et al, &ldquo;Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(19):3893-901.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/15459210/pubmed\" id=\"15459210\" target=\"_blank\">",
"        15459210",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      King PD and Perry MC, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo;",
"      <i>",
"       Oncologist",
"      </i>",
"      , 2001, 6(2):162-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/11306728/pubmed\" id=\"11306728\" target=\"_blank\">",
"        11306728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mark M and Th&uuml;rlimann B, &ldquo;Fatal Pneumonitis After Treatment With Pegylated Liposomal Doxorubicin in a Patient With Metastatic Breast Cancer in Complete Remission,&rdquo;",
"      <i>",
"       Med Oncol",
"      </i>",
"      , 2012, 29(3):1477-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/21667322/pubmed\" id=\"21667322\" target=\"_blank\">",
"        21667322",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Northfelt DW, Dezebe BJ, Thommes JA, et al, &ldquo;Pegylated-Liposomal Doxorubicin versus Doxorubicin, Bleomycin, and Vincristine in the Treatment of AIDS-Related Kaposi&rsquo;s Sarcoma: Results of a Randomized Phase III Clinical Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(7):2445-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/9667262/pubmed\" id=\"9667262\" target=\"_blank\">",
"        9667262",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O&rsquo;Brien ME, Wigler N, Inbar M, et al, &ldquo;Reduced Cardiotoxicity and Comparable Efficacy in a Phase III Trial of Pegylated Liposomal Doxorubicin HCl (CAELYX&trade;/Doxil&reg;) versus Conventional Doxorubicin for First-Line Treatment of Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2004, 15(3):440-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/4998846/pubmed\" id=\"4998846\" target=\"_blank\">",
"        4998846",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orditura M, Quaglia F, Morgillo F, et al, &ldquo;Pegylated Liposomal Doxorubicin: Pharmacologic and Clinical Evidence of Potent Antitumor Activity With Reduced Anthracycline-induced Cardiotoxicity (Review),&rdquo;",
"      <i>",
"       Oncol Rep",
"      </i>",
"      , 2004, 12(3):549-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/15289836/pubmed\" id=\"15289836\" target=\"_blank\">",
"        15289836",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orlowski RZ, Voorhees PM, Garcia RA, et al, &ldquo;Phase I Trial of the Proteasome Inhibitor Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Advanced Hematologic Malignancies,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2005, 105(8):3058-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/15626743/pubmed\" id=\"15626743\" target=\"_blank\">",
"        15626743",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Shaughnessy JA, &ldquo;Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer,&rdquo;",
"      <i>",
"       Clin Breast Cancer",
"      </i>",
"      , 2003, 4(5):318-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/14715106/pubmed\" id=\"14715106\" target=\"_blank\">",
"        14715106",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2012, 23(Suppl 7):167-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/22997449/pubmed\" id=\"22997449\" target=\"_blank\">",
"        22997449",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al, \"Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(20):3323-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/20498395/pubmed\" id=\"20498395\" target=\"_blank\">",
"        20498395",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rifkin RM, Gregory SA, Mohrbacher A, et al, &ldquo;Pegylated Liposomal Doxorubicin, Vincristine, and Dexamethasone Provide Significant Reduction in Toxicity Compared With Doxorubicin, Vincristine, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 106(4):848-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/16404741/pubmed\" id=\"16404741\" target=\"_blank\">",
"        16404741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sharpe M, Easthope SE, Keating GM, et al, &ldquo;Polyethylene Glycol-Liposomal Doxorubicin: A Review of Its Use in the Management of Solid and Haematological Malignancies and AIDS-Related Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2002, 62(14):2089-126.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/12269857/pubmed\" id=\"12269857\" target=\"_blank\">",
"        12269857",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sparano JA, Makhson AN, Semiglazov VF, et al, \"Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(27):4522-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/19687336/pubmed\" id=\"19687336\" target=\"_blank\">",
"        19687336",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stebbing J and Gaya A, &ldquo;Pegylated Liposomal Doxorubicin (Caelyx) in Recurrent Ovarian Cancer,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 2002, 28(2):121-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/12297120/pubmed\" id=\"12297120\" target=\"_blank\">",
"        12297120",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sutton G, Blessing J, Hanjani P, et al, &ldquo;Phase II Evaluation of Liposomal Doxorubicin (Doxil) in Recurrent or Advanced Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group Study,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2005, 96(3):749-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/15721421/pubmed\" id=\"15721421\" target=\"_blank\">",
"        15721421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Theodoulou M and Hudis C, &ldquo;Cardiac Profiles of Liposomal Anthracyclines: Greater Cardiac Safety Versus Conventional Doxorubicin?&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2004, 100(10):2052-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/15139046/pubmed\" id=\"15139046\" target=\"_blank\">",
"        15139046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vorbiof DA, Rapoport BL, Chasen C, et al, &ldquo;First Line Therapy With Paclitaxel (Taxol) and Pegylated Liposomal Doxorubicin (Caelyx) in Patients With Metastatic Breast Cancer: A Multicentre Phase II Study,&rdquo;",
"      <i>",
"       Breast",
"      </i>",
"      , 2004, 13(3):219-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/15177425/pubmed\" id=\"15177425\" target=\"_blank\">",
"        15177425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waterhouse DN, Tardi PG, Mayer LD, et al, &ldquo;A Comparison of Liposomal Formulations of Doxorubicin With Drug Administered in Free Form: Changing Toxicity Profiles,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2001, 24(12):903-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/11735647/pubmed\" id=\"11735647\" target=\"_blank\">",
"        11735647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wollina U, Dummer R, Brockmeyer NH, &ldquo;Multicenter Study of Pegylated Liposomal Doxorubicin in Patients With Cutaneous T-Cell Lymphoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2003, 98(5):993-1001.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/13/10458/abstract-text/12942567/pubmed\" id=\"12942567\" target=\"_blank\">",
"        12942567",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10135 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-0DF129FE3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_13_10458=[""].join("\n");
var outline_f10_13_10458=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708687\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125198\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163252\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163273\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163255\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163256\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15581682\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163257\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163274\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163229\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15577820\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163214\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163232\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163280\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163230\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5045755\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163282\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163271\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163235\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163218\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163268\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163223\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163247\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163225\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163237\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163263\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5045756\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323123\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163227\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163238\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163217\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163234\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10135\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10135|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/20/28997?source=related_link\">",
"      Liposomal doxorubicin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_13_10459="Incidence childhood arthritis";
var content_f10_13_10459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F78901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F78901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of juvenile rheumatoid arthritis in different countries",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Country",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incidence",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Finland",
"       </td>",
"       <td>",
"        9.2/100,000",
"       </td>",
"       <td>",
"        Laaksonen, 1966",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Finland",
"       </td>",
"       <td>",
"        19.6/100,000",
"       </td>",
"       <td>",
"        Kunnamo, 1986",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sweden",
"       </td>",
"       <td>",
"        10.9/100,000",
"       </td>",
"       <td>",
"        Gare, 1992",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Canada",
"       </td>",
"       <td>",
"        5.3/100,000",
"       </td>",
"       <td>",
"        Oen, 1995",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        UK",
"       </td>",
"       <td>",
"        10.0/100,000",
"       </td>",
"       <td>",
"        Symmons, 1996",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_13_10459=[""].join("\n");
var outline_f10_13_10459=null;
var title_f10_13_10460="Tests for diagnosing HIV II";
var content_f10_13_10460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Spectrum of available tests for the diagnosis of HIV-1 (II)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Assay",
"       </td>",
"       <td class=\"subtitle1\">",
"        CD4 counts",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent positive, sensitivity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DNA PCR assay",
"       </td>",
"       <td>",
"        All stages",
"       </td>",
"       <td>",
"        &gt;99",
"       </td>",
"       <td>",
"        Qualitative DNA PCR is used to detect cell-associated",
"proviral DNA; primers are commercially available from Roche",
"Laboratories. Sensitivity (&gt;99 percent) and specificity (98 percent) are reduced",
"compared to routine serology. This is not considered sufficiently",
"accurate for diagnosis without confimation (Ann Intern Med 1996;",
"124:803). Main use is viral detection in: neonatal HIV and challenged",
"or indeterminant serologic tests.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Quantitative HIV RNA",
"       </td>",
"       <td>",
"        &gt;200/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Quantitation",
"of plasma RNA using reverse transcription and then amplification by",
"PCR. Results are in copies/mL. A 3-fold change is considered",
"significant. This is the preferred test for staging and therapeutic",
"monitoring. There are three techniques and suppliers of reagents: HIV RNA PCR (Roche), bDNA (Chiron), and NASBA (Organon).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;200/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        98-100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salivary test (OraSure Test System)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &gt;99",
"       </td>",
"       <td>",
"        Salivary collection device to collect IgG for EIA and Western blot. Advantage is avoidance of phlebotomy. Sensitivity and specificity comparable to standard serology (JAMA 1997; 227:254).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine test (Calypte 1)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &gt;99",
"       </td>",
"       <td>",
"        Used for EIA test only, so positive results must be verified by serology. Must be administered by a physician. Cost is low - about $4/test.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Barlett, JG. Medical Management of HIV Infection. Port City Press, Baltimore, MD 1998.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_13_10460=[""].join("\n");
var outline_f10_13_10460=null;
var title_f10_13_10461="Postop complication predictors";
var content_f10_13_10461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Canet risk index: Independent predictors of postoperative complications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Factor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adjusted odds ratio (95% CI)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Age, years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &le;50",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        51-80",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.4 (0.6-3.3)",
"       </td>",
"       <td class=\"sublist_other\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &gt;80",
"       </td>",
"       <td class=\"sublist_other\">",
"        5.1 (1.9-13.3)",
"       </td>",
"       <td class=\"sublist_other\">",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Preoperative O",
"        <sub>",
"         2",
"        </sub>",
"        saturation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &ge;96 percent",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        91-95 percent",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.2 (1.2-4.2)",
"       </td>",
"       <td class=\"sublist_other\">",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &le;90 percent",
"       </td>",
"       <td class=\"sublist_other\">",
"        10.7 (4.1-28.1)",
"       </td>",
"       <td class=\"sublist_other\">",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory infection in the last month",
"       </td>",
"       <td>",
"        5.5 (2.6-11.5)",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preoperative anemia - hemoglobin &le;10 g/dL",
"       </td>",
"       <td>",
"        3.0 (1.4-6.5)",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Surgical incision",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Upper abdominal",
"       </td>",
"       <td class=\"sublist_other\">",
"        4.4 (2.3-8.5)",
"       </td>",
"       <td class=\"sublist_other\">",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Intrathoracic",
"       </td>",
"       <td class=\"sublist_other\">",
"        11.4 (1.9-26.0)",
"       </td>",
"       <td class=\"sublist_other\">",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Duration of surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &le;2 hours",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2-3 hours",
"       </td>",
"       <td class=\"sublist_other\">",
"        4.9 (2.4-10.1)",
"       </td>",
"       <td class=\"sublist_other\">",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &gt;3 hours",
"       </td>",
"       <td class=\"sublist_other\">",
"        9.7 (2.4-19.9)",
"       </td>",
"       <td class=\"sublist_other\">",
"        23",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Emergency surgery",
"       </td>",
"       <td>",
"        2.2 (1.0-4.5)",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of points in risk score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pulmonary complication rate",
"        <br/>",
"        (validation sample)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        &lt;26 points",
"       </td>",
"       <td>",
"        1.6 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        26-44 points",
"       </td>",
"       <td>",
"        13.3 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High risk",
"       </td>",
"       <td>",
"        &ge;45 points",
"       </td>",
"       <td>",
"        42.1 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Canet J, Gallart L, Gomar C, et al. Prediction of postoperative pulmonary complications in a population-based surgical cohort. Anesthesiology 2010; 113:1338.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_13_10461=[""].join("\n");
var outline_f10_13_10461=null;
var title_f10_13_10462="ACC AHA choice imaging CHD diagnosis able to exercise";
var content_f10_13_10462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52995%7ECARD%2F61603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52995%7ECARD%2F61603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for cardiac stress imaging as the initial test for diagnosis of coronary heart disease (CHD) in patients with chronic stable angina who are able to exercise",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Class I",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       1. Exercise myocardial perfusion imaging or exercise echocardiography in patients with an intermediate pretest probability of CAD who have one of the following baseline ECG abnormalities:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Pre-excitation (Wolff-Parkinson-White) syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. More than 1 mm of ST depression at rest",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2. Exercise myocardial perfusion imaging or exercise echocardiography in patients with prior revascularization (either PTCA or CABG).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       3. Adenosine or dipyridamole myocardial perfusion imaging in patients with an intermediate pretest probability of CAD and one of the following baseline ECG abnormalities:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Electronically paced ventricular rhythm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. Left bundle-branch block",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       4. Dobutamine stress echocardiography in patients with an intermediate pretest probability of CAD and left bundle branch block.*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Class IIb",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       1. Exercise myocardial perfusion imaging and exercise echocardiography in patients with a low or high probability of CAD who have one of the following baseline ECG abnormalities:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Pre-excitation (Wolff-Parkinson-White) syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. More than 1 mm of ST depression",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       2. Adenosine or dipyridamole myocardial perfusion imaging in patients with a low or high probability of CAD and one of the following baseline ECG abnormalities:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Electronically paced ventricular rhythm b. Left bundle-branch block",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       3. Exercise myocardial perfusion imaging or exercise echocardiography in patients with an intermediate probability of CAD who have one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Digoxin use with &lt;1 mm ST depression on the baseline ECG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. LVH with &lt;1 mm ST depression on the baseline ECG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       4. Exercise myocardial perfusion imaging, exercise echocardiography, adenosine or dipyridamole myocardial perfusion imaging or dobutamine echocardiography as the initial stress test in a patient with a normal rest ECG who is not taking digoxin.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       5. Exercise in patients with left bundle-branch block.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       ACC/AHA classification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Class I:",
"       </strong>",
"       Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       <strong>",
"        Class II:",
"       </strong>",
"       Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <strong>",
"        Class IIa:",
"       </strong>",
"       Weight of evidence/opinion is in favor of usefulness/efficacy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <strong>",
"        Class IIb:",
"       </strong>",
"       Usefulness/efficacy less well established by evidence/opinion.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Class III:",
"       </strong>",
"       Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Modified from: Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116:e418.",
"    </div>",
"    <div class=\"reference\">",
"     Data modified from: Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for cardiac stress imaging as the initial test for diagnosis of coronary heart disease (CHD) in patients with chronic stable angina who are unable to exercise",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Class I",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1. Adenosine or dipyridamole myocardial perfusion imaging or dobutamine echocardiography in patients with an intermediate pretest probability of CAD.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2. Adenosine or dipyridamole stress myocardial perfusion imaging or dobutamine echocardiography in patients with prior revascularization (either PTCA or CABG).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Class IIb",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1. Adenosine or dipyridamole stress myocardial perfusion imaging or dobutamine echocardiography in patients with a low or high probability of CAD in the absence of electronically paced ventricular rhythm or left bundle-branch block.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       2. Adenosine or dipyridamole myocardial perfusion imaging in patients with a low or a high probability of CAD and one of the following baseline ECG abnormalities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Electronically paced ventricular rhythm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. Left bundle-branch block",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       ACC/AHA classification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Class I:",
"       </strong>",
"       Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       <strong>",
"        Class II:",
"       </strong>",
"       Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <strong>",
"        Class IIa:",
"       </strong>",
"       Weight of evidence/opinion is in favor of usefulness/efficacy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <strong>",
"        Class IIb:",
"       </strong>",
"       Usefulness/efficacy less well established by evidence/opinion.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Class III:",
"       </strong>",
"       Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data modified from: Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_13_10462=[""].join("\n");
var outline_f10_13_10462=null;
var title_f10_13_10463="ZAP-70 and Vh genes in CLL";
var content_f10_13_10463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Expression of ZAP-70 in chronic lymphocytic leukemia and immunoglobulin mutational status",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 351px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This scatter plot shows the levels of ZAP-70 expression, as measured by flow cytometry, in lymphocytes from 56 patients with chronic lymphocytic leukemia (CLL). Also shown for each patient is the mutational status of the variable region of the immunoglobulin heavy chain. Open circles represent subjects with mutated Vh genes, while the closed circles are from patients with unmutated Vh genes. In this study, the two groups were almost completely separable when the threshold for categorizing ZAP-70 positivity was set at 20 percent (dashed line).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Crespo, M, et al. N. Engl J Med 2003; 348:1764.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_13_10463=[""].join("\n");
var outline_f10_13_10463=null;
